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ABSTRACT
Direct investigation of the intestinal immune system is difficult since tissues
are relatively inaccessible. Faeces is a readily available source of intestinal contents
which may contain proteins and other substances secreted from the mucosa.
However, protein recovery is affected by gut proteases and differences in whole gut
transit time, limiting the value of any conclusions.
The potential ofwhole gut lavage fluid (WGLF) as a source of intestinal
proteins has been evaluated. The clear effluent obtained following routine bowel
cleansing with a polyethylene glycol based isotonic solution can be rapidly processed
with the addition ofprotease inhibitors, preventing further proteolytic digestion. The
gut lavage procedure reduces and standardizes the transit time, allowing comparison
ofprotein secretion.
Detection of antigen specific antibodies by capture enzyme linked
iuimunosorbant assay (ELISA) requires an intact antigen binding site to be associated
with heavy chain. As protein degradation in WGLF is less than for faeces, antibody
detection should be possible. Proteolysis ofWGLF immunoglobulins, especially those
lost from more proximal regions of the gut, could lead to underestimation of
intestinal humoral immunity. The first aim of this thesis was to validate WGLF as a
source of intact intestinal antibodies.
Up to 85% ofWGLF immunoglobulins had bound to a thiophilic ligand
(T-Gel) which has been shown to specifically absorb intact immunoglobulins from
biological fluids. Subsequent to SDS-PAGE and western blotting, anti heavy chain
staining of the 55 Kd heavy chahi band was more intense with T-Gel binding as
opposed to unfractionated immunoglobulins. There was also greater recovery of
antigen specific antibodies in the T-Gel binding fr action. These findings may indicate
that WGLF immunoglobulins are largely intact and that estimation by ELISA was
likely to be quantitative.
j*
Loss of IgG to the gut in patients with inflammatory bowel disease (IBD) can
arise from plasma or by local production from cells in the lamina propria.
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The source of IgG in WGLF was shown to be predominantly plasma since the
relative coefficient of excretion for IgG in WGLF was similar to albumin for all IBD
patients. To limit the effect of greater susceptibitity to proteolysis of albumin
compared to otherWGLF proteins, the study was restricted to patients with colonic
disease. Secondly, onlyWGLF without high protease activity was used. It has been
assumed that protein loss occurs lfom the site diagnosed as diseased by clinical
assessment.
To confirm that plasma leakage was the major source ofWGLF IgG in
patients with colonic IBD, loss of another plasma protein, complement C3, was
investigated. A competitive ELISA was developed to quantify C3 in WGLF. This
required binding of a single antibody enabling detection ofboth immune complexes
and free C3. WGLF C3 was raised in patients with active IBD. This loss mirrored
that of IgG and albumin, showing no diagnostic specificity, hi patients with ulcerative
colitis, the relative loss ofC3 was similar to that for albumin. In contrast, patients
with colonic Crohn's disease (CD) had twofold loss of C3 relative to albumin,
indicating that mucosal production was a major contributor to WGLF C3. As patients
with inactive CD had slightly raised WGLF C3, this may be an indicator of early
clinical relapse.
The relationship between WGLF C3 and relapse ofCD was investigated by
follow up of 43 patients for one year after gut lavage. Of 10 who relapsed, 8 bad
normal WGLF C3 whereas of 15 patients who remained in steroid free remission, 8
had raised WGLF C3. There was a risk factor of4.4 for relapse in patients with
inactive CD who had normal WGLF C3. This suggested either complement
deposition or a protective role of complement e.g., in dealing apoptotic cells. These
hypotheses could be further investigated using intestinal biopsies.




Direct investigation of immune activity within the intestinal mucosa is difficult
because of the inaccessibility of the tissue. Indirect means of study include collection
of substances secreted hito the gut lumen e.g., by use of a perfusion system. Research
at the G.I unit, Edinburgh has shown that routine bowel preparation by whole gut
lavage can be easily adapted to give reproducible bowel perfusion. Collection of the
effluent perfusion fluid per rectum and subsequent addition ofprotease inhibitors has
provided a useful medium in which to quantify substances secreted from the intestinal
wall (O'Mahoney et al, 1991).
Previous work from the department has shown that some proteins e.g., IgA
are detectable in WGLF from all subjects. This is likely to reflect physiological
secretion. Only low concentrations of other proteins such as IgG, albumin, EL-1 and
IL-8 were detected in WGLF from most subjects but concentrations were increased
in patients with active inflammatory bowel disease (IBD). Clinical studies have
demonstrated selectivity of intestinal loss of these proteins (Arnott et al, 1997).
Values ofWGLF IgG above the upper 95th percentile of that observed hi a
non-inflammatory population have been shown to correlate with clinical indices of
disease activity disease (the Powell-Tuck index for ulcerative colitis and the Crohn's
disease activity index) hi patients with IBD (Choudari et al, 1993). Subjects with IBD
showing intestinal symptoms may undergo the WGLF procedure in preparation for
further intestinal examination. This made it relatively easy to collect spechnens and
quantify IgG as a guide of the severity of intestinal inflammation.
In contrast, calculation of clinical indices has been relatively complicated,
requiring clinical assessment over seven days in the case of the CDAI. Consequently,
it has been tempting to use biochemical markers of inflammation to reflect disease
activity. Before adapting this approach, one should understand that this is an isolated
measure of one component of disease activity i.e. loss of a particular protein across
the gut wall. With a damaged mucosa, that protein may come from plasma or local
production as part of the local inflammatory event.
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The WGLF concentration of that protein might therefore overestimate the mucosal
inflammation component of disease activity.
The inactive phase of IBD is a state of stable chronic inflammation
characterized by greater numbers ofB and T-cells in the intestinal mucosa than seen
in healthy individuals (Rosekrans et al, 1980). These cells may be in a quiescent state
and produce low concentrations of inflammatory mediators. These may be
undetectable in WGLF, either because of the limitations of assay sensitivity or
because the intestinal epithelium is impermeable to them. Changes in the permeability
of the intestinal epithelium might allow movement ofproteins from the mucosa to the
gut lumen and visa-versa. Movement of antigenic proteins from the gut lumen to the
intestinal mucosa may provide the stimulus for activation of the mucosal immune
compartment (Gardiner et al, 1995).
The active phase of disease is an acute inflammatory reaction exacerbated by
a hyper-reactivity of the mucosal immune system. The early phase is characterized by
increased migration ofneutrophils into the intestinal mucosa.This has been
demonstrated by detection ofneutrophil proteins such as elastase and calprotectin in
the gut lumen (Tibbie et al, 2000). Subsequently, B and T lymphocytes are activated
resulthrg in exacerbation ofthe acute inflammatory reaction. Proteins such as IgG
may then be detectable in the intesthral contents. Biochemical markers of the early
phase of the acute inflammatory response in IBD may provide a useful indication of
the need for clinical intervention before full relapse occurs.
Despite published work on WGLF, the technique is yet to be validated in
terms of analyte recovery. Some proteins e.g., albumin are particularly susceptible to
proteolysis. Further work has been necessary to evaluate differences in protein
recovery as a prelude to considering relative loss of each protein. This could then be
exploited in consideration ofthe source ofproteins detected in WGLF. The first aim
ofthis thesis was to evaluate the integrity ofproteins in WGLF and how this affected
their detection. Because of the use of IgG as a marker of inflammation, it was
decided to focus on immunoglobulins.
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Following validation of protein recovery in WGLF, other proteins which might
reflect intestinal inflammation could be investigated. Complement protein C3 might
be involved in exacerbation ofthe intestinal inflammatory reaction via IgG mediated
activation of the complement cascade. Alternatively, C3 might also be activated by
the alternative pathway via interaction with luminal bacteria. To investigate the role
of C3 in intestinal inflammation it was decided to establish a method for quantifying
C3 in WGLF.
The remainder of the thesis has focused on clinical studies to evaluate the
relationship between detection ofC3 in WGLF and intestinal inflammation. This
incorporates work to elucidate whether the C3 lost to the gut comes from serum or
might be produced in the intestinal mucosa. Finally, the potential for WGLF C3 to
predict relapse ofCrohn's disease has be studied. This work has focused on Crohn's
disease partly because of interesting preliminary findings with WGLF C3.
Furthermore, CD is a heterogeneous condition with increasing incidence which has
high morbidity amongst young people (Armitage et al, 1999). Management ofCD
has been more problematic than that ofUC, in which surgery is an effective method.
AIMS
1) To test whether proteins in WGLF are intact or not, using immunoglobulins as an
example. Chr omatography will be used to extract immunoglobulins from the protein
mixture before subjecting the immunoglobulins to SDS-PAGE electrophoresis to
assess their molecular size and the likely extent ofproteolysis. The relevence of these
results to the reliability of quantifying proteins in WGLF will be discussed.
2) To develop an ELISA for quantification of complement component C3 in WGLF.
3) To compare WGLF C3 in patients with and without intestinal inflammation to see
if this parameter is an indicator of the severity of inflammation.
4) To use albumin as a marker ofplasma leakage to identify whether C3 lost to the
gut is likely to come from plasma or might be synthesized by the intestinal wall.
5) To investigate the relationship between WGLF C3 and disease outcome in patients
with inactive Crohn's disease. A biochemical indicator of the likely course of disease
would be a useful tool to the gastro-intestinal physician.
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CHAPTER ONE
Review of the literature
1.1 Study of the intestinal immune system
The gastrointestinal immune system is physically inaccessible, creating
practical and ethical difficulties to its study in man. The intestinal wall is difficult to
access and material can be obtained only in requirement for histological investigation
of a clinical condition. For research puiposes, biological fluids would be easier to
obtain. Serum might be expected to contain some ofthe substances produced in the
gut wall. However, it may not be valid to extrapolate detection of a protein in serum
to immunological activity hi the gut wall: patients with ankylosing spondylitis or
Crohn's disease had raised serum IgA to the gut bacterium Klebsiella. However, only
the CD patients show raised specific IgA in WGLF. (O'Mahoney et al, 1992).
Immunological function ofthe intestinal mucosa should therefore be investigated
using material obtained from the gut.
1.2 Intestinal disorders where study of mucosal immunity may
be useful
1.2.1 Inflammatory bowel disease
Ulcerative colitis and Crohn's disease and are chronic, spontaneously
relapsing disorders ofthe intestine. Although the cause is unknown, they are
immunologically mediated and have genetic and environmental influences. Symptoms
for the two diseases are very varied and diagnosis is made on the basis ofhistological
examination of inflamed intestine. Differences in the type and site of inflammation in
the two diseases may indicate different causes. Many of the secondary processes
which exacerbate inflammation are common to both diseases. It would be of interest
to know which agents the intestinal immune response in IBD is directed against and
why there are abnormal reactions to this agent.
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Immunological mediators produced during active disease may provide clues to the
nature of the inflammatory pathways, so contributing to the development ofnew
treatments. Biological markers of intestinal inflammation may also provide a tool for
monitoring response to treatment or prediction of clinical outcome.
1.2.2 Coeliac disease
Coeliac disease is an intolerance ofthe intestinal immune system to dietary
gluten. Ingestion ofgluten causes a powerful immune response characterized by
increased numbers of intraepithelial lymphocyte, especially of those bearing yS
receptors (Arranz et al, 1994). In addition, there is also abnormal intestinal
production of IgA antibodies to gliadin, a digestion product of gluten. New evidence
suggests that these antibodies are produced as a by product of an antibody response
to an enzyme, tissue transglutaminase, which is hwolved in protein cross-linking
(Dieterich et al, 1997). Gliadin is a substrate for this enzyme and the gliadin-
transglutaminase complex may reveal novel epitopes against which an immune
response may be mounted (hi subjects having the necessary major liistocompatabihty
antigens/ T-cell receptor). Transglutaminase is involved hi tissue re-modeling and is
probably only released in response to tissue injury. Patients with untreated coeliac
disease show a flat intestinal mucosa (no villi) with crypt hyperplasia and rapid loss of
immature epithelial cells to the gut. On removal of gluten from the diet, a complete
recovery is seen. This may indicate that tissue transglutaminase is required hi the
healing process. The intestinal antibody response to gliadin or transglutaminase could
be monitored using WGL, providhig an hidicator of compliance to the gluten free
diet.
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1.3 Invasive methods of obtaining intestinal material
Material can be obtained from the human intestine by either invasive or non¬
invasive methods. Invasive methods often include those for clinical investigation of a
particular patient. It may be difficult to obtain suitable patient groups and controls.
Intestinal examination by endoscopy involves insertion of a flexible tube fitted with a
camera into the intestinal lumen. Forceps attached to the endoscopy tube allow the
taking of a mucosal biopsy. Intestinal secretions can be aspirated via a draining tube..
1.3.1 Intestinal biopsy
Intestinal biopsy specimens have been used in several ways to study gut
physiology. Once the tissue has been treated with preservatives and thin sections cut,
the fixed image of the mucosa can be viewed by microscopy. Cells of a particular
type are recognized either by then morphology or by staining of cell surface
components with specific antibodies.
Individual cell types can be isolated and grown in culture. This allows
hivestigation of cell specific changes e.g. in response to inflammatory mediators.
Some cell types e.g., epithelial cells are difficult to grow, possibly because they lack
interactions with other cell types that are essential for regulation of then growth.
Immortalized cell lines have been used as models of intestinal cell types. However,
cell lines tend to be at an earlier differentiation stage and do not behave like
differentiated intestinal cells. For example, the intestinal epithelium-like cell, Caco-2
produces EL-1 and IL-6 in culture but freshly isolated intestinal epithelial cells do not
(Daig et al, 2000). Organ culture may be more physiological but it may be impossible
to identify the functions of individual cell types..
Other problems with the study intestinal biopsy specimens include the
requirement to strictly control for the anatomical site so that site specific differences
in tissue physiology are not assumed to be disease specific. When looking at changes
hi disease, specimens from several sites along the intestine should be taken. This
would avoid bias due to a particular specimen showing few or extensive signs of
inflammation.
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Control material for these studies has been typically taken fr om the edge of tumour
resections. Despite a histologically normal appearance, this material may have had
biochemical abnormalities.
1.3.2 Intestinal secretions
Jejunal fluid can be collected into a draining tube at endoscopy. As jejunal
fluid tends to be rich in pancreatic proteases, the recovery of secreted proteins may
be low. Also, secretion is not over a fixed time period and this limits the conclusions
that can be drawn from it's analysis. Jejunal fluid is therefore of little use for
monitoring subtle changes in mucosal immune activity but may allow detection of
gross changes e.g. detection of antigliadin IgA in coeliac disease (Volta et al, 1988).
The intestinal wall can be 'washed' at endoscopy and these washings will
contain secreted proteins. This may flush out pre-foimed proteins and so not reflect
protein synthesis at that time. As only a small area of the intestinal mucosa is studied,
abnormalities elsewhere may be missed..
1.4 Non-invasive methods of obtaining intestinal material
1.4.1 Faeces
Faeces is simple to collect and contains proteins secreted from the whole gut.
However, measurement ofproteins from faeces has several drawbacks. In addition to
proteins secreted from the intestinal mucosa, faeces contains bacteria, digestive
enzymes, dead cells and food breakdown products. These have been shown to
interfere with quantification of faecal proteins by ELISA (Viscidi et al, 1984).
Protease enzymes either ofhost or gut bactexial origin are capable of
degrading proteins within faeces (Macfarlane et al, 1986). The extent ofprotein
degradation will depend on the propeities of the protein (Lebek and Cottier 1992),
the activity and type of eirzymes present and the time that the protein is in contact
with those enzymes.
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Diarrhoeal stools may take less time to pass through the colon than a solid stool and
so this material may have been subjected gut proteases for less time. Protein recovery
might therefore be greater from diarrheoal stools than from solid stools. It is difficult
to say that greater protein concentrations of diarrhoeal stools only reflect increased
secretion in that disease. We have demonstrated that specific IgA to food antigens
was detectable more frequently hi diarrhoeal stools than hi solid stools. This was not
seen in WGLF from the same patients. Immunological tests on faeces may therefore
be misleading (Ferguson et al, 1995a).
Protein recovery from faeces may depend on the chemical nature and
extraction efficiency of that protein e.g. IgA has been shown to be bound to bacterial
antigens and these may sediment upon centrifugation (Retz and Steele 1977). The
water content of the stool will influence the protein concentration and so must be
taken into account before comparisons can be made. As the production of faeces is
variable, the quantity produced per unit time needs to be known before protein
secretion can be compared (Meillet et al, 1987).
1.4.2 Gut Perfusion
A non absorbable fluid was used to wash the intestinal walls, collecting any
released proteins. These studies are usually performed in the fasting state to reduce
the degradation of collected proteins by digestive enzymes and contamination with
food or faeces. A perfusion is established when the rate of fluid influx into the
intestine balances the rate of fluid collection. Intestinal perfusion allows study of
protein secretion over a known time period.
Polyethylene glycol (PEG) in a balanced salt solution has been used for
intestinal perfusion. It is chemically inert, not absorbed by the gut and the salt content
prevents net water movement (Beck et al, 1985).
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PEG is a large water soluble molecule which mixes well in aqueous solutions. It can
be assayed chemically or labelled with radioactive markers. Complete recovery of
PEG has been demonstrated following transit through healthy or inflamed colon
(Soergel, 1968).
Although PEG is chemically inert, it does interact with proteins (Busby and
Ingham, 1980) and it can interfere with immunoassays, particularly by disrupting
antigen binding to plastic surfaces (Tobi et al, 1991)
1.4.2.1 Closed loop perfusion systems
These are a specialized means of collecting proteins secreted from a particular
gut segment. An inflatable balloon is used to isolate a segment of the intestine and a
system of tubes allows separate fluid infusion and collection (Knutson et al, 1989).
The placement of segmental perfusion apparatus is difficult and uncomfortable for the
patient.
An advantage ofperfusing an occluded gut segment is that secreted proteins
are uncontaminated by fluid from the upper bowel (which may include pancreatic
enzymes). This fluid is aspirated clear of the balloon and a dye can be used to show
that leakage into the perfused segment does not occur (Rambaud et al, 1981). It has
been suggested that this technique is not detrimental to mucosal integrity, e.g.,
stretching of the bowel by the balloon does not alter protein secretion compared to
that seen without a balloon in patients with pancreatic insufficiency (Rambaud et al,
1981). However, extended use of an occluding balloon may be detrimental to
mucosal integrity as 3/9 healthy volunteers showed increased secretion of
complement and albumin on the second day (Hoj et al, 1981).
Effective perfusion requires efficient mixing of the luminal contents. This
might not occur when the bowel is fully distended using rapid flow rates ofgreater
than 7 ml/inin (Wingate et al, 1974). In healthy volunteers, immunoglobulin secretion
was unaltered by changing the perfusion rate from 5 to 10 ml/min (Brown et al,
1988). Tire use of a completely closed loop improves the recovery of perfusate. A
lower perfusion rate can then be used and secreted proteins are diluted less (Knutson
et al, 1989).
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One drawback of segmental perfusion is that in study of a defined area, abnormalities
elsewhere in the intestine are not detected. Crohn's disease is characterised by
discontinuous inflammation along the length of the intestine. The site and volume of
bowel perfused must be taken into account before comparing protein secretion in
different patients (Soergel, 1971).
Perfusion of the intestine with PEG solution is artificial in terms of the antigen
load to the gut and greater protein secretion is seen using a nutrient perfusate
(Colombel et al, 1992). Drinking large volumes of solution might alter gut physiology
by activating intestinal hormone and neuronal systems (Shah et al, 1982). This might
stimulate protein secretion.
1.4.2.2 Whole gut lavage
At the Gastro-Intestinal Laboratory (Western General Hospital, Edinburgh),
whole bowel perfusion with polyethylene glycol solution 'klean-Prep'(Norgine,
Oxford, UK), has been used to investigate patients undergoing examination for
gastro-intestinal disease. Intestinal secretions can be obtained routinely from per-oral
polyethylene glycol based bowel cleansing (gut lavage) prior to colonoscopy or
barium enema (Gaspari et al, 1988). This technique ofbowel cleansing is well
tolerated by most patients (Ernstoff et al, 1983). Standardization of the intestinal
secretions requires the patient to drink at a standard, consistent rate until the rectal
effluent is clear of faecal matter.
Once the fluid passing per rectum was clear, the rate of drinking has been
shown to equal the rate of excretion i.e. a steady state perfusion system (Choudari et
al, 1993). It has been demonstrated that protein secretion into the gut during the
whole gut lavage procedure was at a steady state. Protein concentrations were
equivalent in five sequential liquid stools, collected after passing of the first clear
specimen (SallamJ. Ph.D. thesis, University of Edinburgh 1993).
The whole gut lavage fluid has been processed by filtration and addition of
protease inhibitors to prevent further proteolysis ofproteins (Brydon et al, 1993). It
has been shown that immunuglobulins in processed WGLF were stable for up to two
years when stored frozen at -70°C (Allien et al, 1995).
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Advantages ofWGLF
The main advantages of the WGL technique as opposed to other forms of
intestinal perfusion are that it is easy to perform and material from patients is readily
available. A technical advantage is that the whole bowel is perfused.
Disadvantages ofWGLF
1. The main disadvantage of studying proteins hi WGLF is that there is no way of
knowing which region of the intestine those proteins are secreted from, ft is
assumed that inflammatory mediators are secreted from regions of the intestine
where there is radiological and endoscopic evidence of inflammation.
2. Although the effect ofgut proteases is reduced because ofthe short transit time,
some proteolysis of secreted proteins is likely to occur. This might have a greater
impact on proteins secreted more proxirnally in the gut.
3. As high flow rates of 17 ml/min are required to establish a perfusion, the secreted
proteins are diluted, limiting their detection.
Disadvantages common to all sources of intestinal secretions
1. Analysis of a single spechnen may give limited information if there was
intermittent protein loss, for example, blood loss to the gut has been shown to be
intermittent (Bouma et al, 1996).
2. It is impossible to control for plasma, lymph or interstitial fluid contents leaking
into the gut. This limits the conclusions that may be drawn from detection of a
protein. The source ofproteins leaking into the gut has been studied using
radiolabeled proteins (Jamum and Jensen, 1975) or, by comparison with albumin,
a marker ofplasma leakage (Jonard et al, 1984).
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1.4.2.3 Results of studies using WGLF
Leakage of plasma proteins to the gut resulting from intestinal inflammation
In patients with active IBD, intestinal loss of albumin, alAT, and IgG has
been shown to correlate with the disease activity as assessed by clinical indices based
on both subjective and objective measures (Choudari et al, 1993). Measurement of
these proteins in WGLF therefore provides a simple way assessing whether disease is
active and can be used to monitor changes is disease activity. In some circumstances,
e.g., in patients with Crohn's disease where the CDAI is heavily weighted by
subjective factors, measuring WGLF IgG may provide a more accurate indicator of
mucosal inflammation (Acciuffi et al, 1996). The presence of these proteins hi WGLF
shows high but not absolute specificity for IBD as raised levels are seen in many
other conditions, including colorectal cancer (Brydon et al, 1993).
The mechanism of inflammation in IBD
Inflammatory cellular migration into the intestinal mucosa has been studied
using WGLF. Neutrophils have been counted by cytology (Handy et al, 1995) or
indirectly by measuring granulocyte elastase (Handy et al, 1996). Numbers of
neutrophils in WGLF were increased hi patients with active IBD, particularly colonic
disease. This supports a theory that neutrophil migration may be enhanced in
response to chemotactic factors from luminal bacteria, these being more numerous hi
the colon. Neutrophils are activated by chemotactic signals or by uptake of foreign
material. This results in release of cytotoxic granules containing powerful enzymes
and production of reactive oxygen metabolites. These anti-bacterial functions have
the potential to cause bystander damage to the intestinal mucosa.
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Changes to intestinal humoral immunity in inflammatory gut disorders
The intestinal immune system usually functions in a state termed oral
tolerance. This is actually a misnomer which represents a specialized response against
luminal contents in which mainly IgA is produced and secreted across the gut wall.
The significance of this is that some antigens are excluded from the intestinal mucosa
and this avoids inflammatory reactions by immune cells hi the intestine. Systemic
immune responses to immunological challenge elsewhere is down-regulated (oral
tolerance reviewed by Weiner, 1997).
Alterations in intestinal humoral immunity could include changes in the
specificity of IgA produced, or a switch to production of IgG. This immunoglobulin
is less well adapted to antigen exclusion and more likely to trigger an inflammatory
reaction. Immunological changes in the gut have been detected by quantifying
immunoglobulins in WGLF. Patients with either coeliac disease or IBD had WGLF
IgA specific for food proteins more frequently than did healthy controls. In addition,
these patients also had serum IgG specific for food antigen whuch may have indicated
greater permeability of the intestinal wall to luminal antigen (Ferguson et al, 1996).
In another study, WGLF IgA specific for the outer coat ofBacteroides was
quantified by ELISA. WGLF from patients with CD gave significantly greater OD
readings than those with other gastrointestinal disorders or healthy controls (Poxton
et al, 1995). However, as samples with high readings hi the plateau region of the
standard curve were not re-tested at greater dilution, some results may have been
underestimated. This may have contributed to the finding that IgA specific for
Bacteriodes did not correlate with total IgA. However, other studies of intestinal
humoral immunity also suggest poor correlation of specific and total IgA because the
specific IgA only contributes up to 5 % ofthe total.
Production of cytokines by the inflamed intestine
Children with cystic fibrosis had detectable WGLF levels of pro¬
inflammatory cytokines EL-1(3 and EL-8, measured using commercial ELISA kits.
Children who were taking high dose enzyme supplements had high levels ofWGLF
cytokines and so may have been at risk of intestinal inflammatory damage (Croft et
al, 1996).
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These cytokines have a short half life in serum and so are likely to have resulted from
immune activity within the mucosa. Quantification of cytokines in WGLF can provide
mechanistic information about the nature of intestinal inflammation.
Patients with active IBD also had raised WGLF IL-1 and EL-8.
Unexpectedly, patients with inactive CD also had slightly raised WGLF cytokines,
indicating that remission ofCD may be a state of low grade intestinal inflammation
(Amott et al, 1997). When patients with inactive CD were stratified into low and
high WGLF cytokine groups, more of the patients hi the high cytokine group were
shown to relapse during a one year follow-up period (Amott et al, 1998). This
finding might have implications for patient management.
Healing of inflamed intestine
The healing process in IBD may be studied by measuring extracellular matrix
components such as hyluronic acid or enzymes involved in tissue remodeling, e.g.
metalloproteinases. Healing of intestinal lessions may hi itself produce more problems
such as narrowing of the intestinal lumen by fibrotic strictures in CD. Fibrosis
involves the production of excess collagen during tissue remodelling. The possible
role ofhormones which control collagen synthesis e.g. insulin like growth factor
(IGF-1) and transforming growth factor beta (TGF-(3) have been investigated by
measuring these in WGLF. This demonstrated that IGF-1 was detectable most
frequently in WGLF from CD patients with fibrotic strictures (Ghosh et al, 1997).
Monitoring of patient response to therapy
Loss to the gut ofplasma proteins (as indirect markers of inflammation) or
cytokines (as markers of intestinal hnmune activation) may provide a means of
demonstrating improvement ofhitestinal inflammation in response to therapy.
Patients with active IBD show elevated WGLF albumin and IL-1Q. Following
treatment with elemental diet, these WGLF parameters returned to normal levels
(Ferguson et al, 1998). WGLF IgG has been used as a tool for stratifying patients in
clinical trials (Ferguson et al, 1998).
37
Use ofWGLF as a research tool by other workers
Other research groups have used the technique ofWGLF for obtaining
intestinal material. In Italy, IgGl and IL- i were quantified in WGLF from children to
assess intestinal inflammation (Troncone et al, 1997). A group in Holland has
detected eicosanoids in WGLF and related these to the severity ofmucosal
inflammation (Hommes et al, 1996). And in Japan mucin has been extracted from
WGLF and chemical differences in mucin from patients with IBD investigated (Saitoh
et al, 1996).
1.5 Problems of quantifying proteins in biological fluids
When using antisera to detect proteins, it is important to consider the
specificity of antisera used because biological fluids may contain a plethora of
potentially cross reactive epitopes. This problem is compounded in WGLF where the
action ofprotease enzymes could create new, potentially cross reactive epitopes.
PEG might also interfere in assays by promoting antibody-antigen associations
(Lachmann, 1991).
1.5.1 The effect of gut proteases on protein recovery
Secretory IgA in colostrum has been shown to be more resistant to digestion
by trypsin or duodenal fluid than are serum immunoglobulins (Brown et al, 1970).
After digestion of colostrum with duodenal fluid for 8 h at 37°C, 57 % of the original
a chain activity was detectable. Recovery of serum IgA and IgG was much lower.
Digest proteins were fractionated using gel filtration and the fr actions assayed by
radial immunodiffusion with anti heavy chain, hi the colostrum digest, 51 % ofthe
original a chain activity resided in the fraction corresponding to intact slgA with only
10 % being detected in low molecular weight fractions. It was therefore unlikely that
an assay for IgA based on binding of anti a chain antisera would overestimate IgA hi
the digest because of detection of small fragments with a chain determinants.
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In another study, human slgA was shown to be more resistant to digestion with
pancreatic elastase. The size of digest products was analysed by ultracentrifugal
analysis. IgG and monomelic IgA were digested to give Fab and Fc fragments
whereas secretory IgA was resistant to digestion (Tax and Komgold, 1971).
Nick Croft at the Gastro-Intestinal Laboratory has shown that 22% of IgA in
WGLF is recovered after incubating unprocessed WGLF at 37°C for 8 h. There was
little inter-patient variation in IgA recovery as quantified by ELISA for a chain (Ph.D
thesis, University ofEdinburgh 1996). Digestion of secretory IgA in WGLF is
therefore more rapid than was observed using purified pancreatic enzymes or
duodenal juice. The reason for this may be because in addition to pancreatic
proteases, WGLF may contain bacterial proteases from the colon. Hie catalytic rate
of these proteases does depend on the protein substrate (Macfarlane et al, 1986).
The extent ofprotein degradation in WGLF will depend on gut protease
activity and the time that proteins remain in contact with the proteases. This second
factor depends on the region of the intestine from which proteins are secreted and the
gut transit time. The gut transit time for whole gut lavage has been measured in a
preliminary study with six patients (Jamal Sallarn, Ph.D thesis, University of
Edinburgh, 1993). This was assessed by comparing the volume of'Klean-Prep' drunk
per unit time with the volume ofWGLF excreted. This gave a plot of two graphs
which were roughly parallel, demonstrating that a perfusion had been established.
The time lapse between the two lines equates to the gut transit time; this varied from
one hour for an ileostomy patient to three hours for a patient with constipation i.e.,
much shorter than for faeces. These studies are difficult for the patient as they must
continue drinking the Klean-Prep solution beyond the time required to produce a
clear specimen to enable calculation of fluid excretion per un it time. The estimation
of transit time might have been simplified by inclusion of a dye in the ingested
solution.
As the total transit time forWGLF is about 2 h, the time for proteins secreted
into the intestine to reach the rectum will be shorter than this. Proteolysis of secreted
proteins may be less than expected.
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The proteolytic activity ofWGLF can be estimated by dye release from Azocoll.
This reagent consists of collagen beads which are peptide linked to a red dye.
Proteases break the peptide link and release the dye, the quantity of colour ofwhich
is measured spectrophotometrically. Protease activity as measured by this method is
completely inhibited by the addition ofprotease inhibitors (Gaspari et al, 1988). The
effect ofWGLF proteases on recovery of a specific protein can be examined by
spiking unprocessed WGLF with a known quantity of that protein. At set timepoints,
aliquots of the WGLF are taken and protease inhibitors added. The relationship
between protein recovery and time in contact with WGLF proteases can then be
examined. It may be useful to look at protein recovery during gut transit by inclusion
of an internal protein standard such as ovalbumin in the ingested solution. The likely
extent ofprotein proteolysis during gut transit might be indirectly estimated by
WGLF protease activity.
1.5.2 Implications of gut protease action for quantification ofWGLF
proteins
Less than expected detection ofWGLF immunoglobulins may indicate
proteolysis. Flowever, it is not known whether detected immunoglobulin represents
intact molecules or fragments. Detection of fr agments might result in immunoglobulin
overestimatation. Despite the finding that immunoglobulin fragments were not
detected disproportionately using a radial immunodiffusion assay, this may not be
true for more sensitive ELISA methods. ELISA to detect antigen specific antibodies
may not detect immunoglobulin fragments as an intact antigen binding site must be
associated with heavy chain. Proteolysis might lead to underestimation of antigen
specific antibodies.
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1.5.3 Relationship between immunoglobulin structure and stability in
WGLF
IgA
Most intestinal IgA is produced as a dimer of two monomer IgA units linked
witli a short joining chain between then Fc regions. Immunoglobulin producing cells
in the intestinal lamina propria show upregulated expression ofjoining chain, which
increases the proportion of dimeric IgA produced. Joining chain has affinity for the
poly-immunoglobulin receptor located on the baso-lateral surface of intestinal
enterocytes. This directs transport of IgA produced in the lamina propria to the
intestinal epithelium. On binding to this receptor, dimer IgA is internalized within the
enterocyte and becomes associated with a glycoprotein portion of the receptor which
has been enzymatically cleaved (Brandtzaeg, 1978). This portion is termed the
secretory component and it wraps around the secreted dimer IgA. This makes the
immunoglobulin chains less accessible to intestinal proteases, improving the stability
of secretory IgA (Underdown and Dorrington 1974).
Different IgA subclasses show different resistance to proteolytic digestion,
e.g., IgAl is cleaved in the flexible hinge region by proteases from Haempliilus (Aid
and Reinholdt, 1991). Binding of Fab fragments can mask bacterial epitopes without
opsonization of the bacteria, potentially enabling them to avoid detection by the
immune system (Russell et al, 1989). IgA2 lacks this hinge region and so is more
resistant to proteolytic digestion. The proportion of cells producing IgA2 as opposed
to IgAl increases from the ileum to colon. This may be an adaptation to the increased
numbers ofbacterial in the colon.
Monomelic IgA is susceptible to proteolytic digestion as is not associated
with joining chain or secretory component and is predominantly IgAl. Most
monomelic IgA is from serum.
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IgM
Intestinal IgM is pentameric, associated with joining chain, and is non-
covalently associated with secretory component. In intestinal secretions, IgM and
secretory component readily dissociate (Hjelt et al, 1988) and this may make IgM
more susceptible to proteolytic digestion.
IgG
IgG is not associated with secretory component and would be expected to
show similar stability to IgM. There may be differences in the stability of the IgG
subclasses e.g. IgG3 has fifteen inter chain disulphide bonds which may prevent the
molecule from fragmenting even if cleavage at some points in the chains had
occurred.
The extent ofproteolysis of immunoglobulins in intestinal secretions may be
revealed by structural analysis, allowing the potential impact on methods for their
quantification to be assessed.
1.6 Methods for study of the structural nature of
immunoglobulins
Conventional methods for the purification of immunoglobulins, such as
affinity chromatography with anti immunoglobulin heavy chain ligands, may be ofuse
as a preliminary procedure but can not fractionate intact from fragmented molecules.
However, methods for separation ofproteins on the basis of size do not work with
solutions containing a high concentration ofPEG such as WGLF. This is because
interactions between PEG and protein result in the apparent molecular size being
much larger than expected (Skoog, 1980). This is probably because the hydroxyl
residues in PEG can form hydrogen bonds with peptide bonds or the amino acid side
chains. An extraction technique not based on molecular size is required.
A method has been described which preferentially binds intact
immunoglobulins of different classes (Hutchens and Porath, 1986). This method
employs a novel absorption ligand which comprises a thio-ether group showing
thiophilic affinity for immunoglobulins (called a T-Gel).
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The method has been optimized to show high specificity for immunoglobulins and
was subsequently been used to purify immunoglobulins from human colostrum
(Hutchens et al, 1989). In this study the eluted immunoglobulins were shown to be
intact by a combination ofgel filtration and SDS-PAGE. This approach has potential
for separating intact and fragmented immunoglobulins from WGLF.
To verify this finding with WGLF immunoglobulins, two different methods
were used. As fragmented immunoglobulins are not detected by ELISA for antigen
specific antibodies, intact immunoglobulins should give a higher ratio of specific to
total immunoglobulins. Comparing this ratio in T-Gel binding and non-binding
fractions should clarify whether WGLF immunoglobulins are intact or not. Secondly,
immunoglobulins can be separated using polyacrylamide gel electrophoresis (SDS-
PAGE). After transfer of the separated proteins to a blot, immunoglobulin heavy
chain could be detected by probing with anti heavy chain antisera. Fragmented
immunoglobulins might show detection ofheavy chain at several molecular weights.
1.6.1 SDS-PAGE
Theory
Proteins are electrically charged and so will be attracted to an opposite
electrical charge. If an electrical field is applied, proteins will migrate towards the
positively charged anode or negatively charged cathode, dependhig on its net charge.
This movement is called electrophoresis. The direction of this movement is dependent
on the chemical nature of the protein i.e. the amino acid side groups and also the pH
of the solution, which affects the charge on those side groups. The chemical nature of
different proteins allows a mixture ofproteins to be separated on the basis of their
charge.
A supporting medium is required within which proteins can migrate but do
not flow non-specifically. Gels with a lattice like structure containing pores work
best. Polyacrylamide is now the most commonly used medium because a gel of
predictable and uniform pore size can be produced by using a particular concentration
of acrylamide. Also, polymerized acrylarnide is relatively inert and does not bind to
proteins.
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The migration of large proteins is restricted by the pore size of the gel.
Electrophoretic migration of a protein therefore depends both on charge and size.
Separation ofproteins solely on the basis of their size requires treatment to make
differences in charge obsolete. Treatment with Sodium lauryl sulphate adds plenty of
negatively charged groups to any protein, swamping its natural charge. This
treatment also encourages protein unfolding because interactions between charged
amino acids on different parts ofthe protein are disrupted. Unfolded proteins have a
similar shape and so migration is dependent on then molecular weight.
Eelectrophoresis performed in a single gel can give poor resolution of dilute
protein solutions because some proteins are separated by the time that others enter
the gel. This problem has been resolved by employing a two part gel; the fir st or
stacking gel is large pore and encourages rapid migration. The second or resolving
gel is of a smaller pore size which retards the rapidly migrated proteins. Protein is
concentrated against this boundary between the gels, so creating an even starting
point. The use of two buffers, a lower pH for the stacking gel and a higher pH for the
resolving gel also encourages this, ensuring that there are sharp bands for resolved
proteins of a particular molecular weight (Laernmli, 1970)
1.6.1.1 Western blotting
The position of separated proteins in polyacrylamide gels can be
demonstrated using a chemical stain. Unfortunately, direct identification of separated
proteins is not possible as the pore size of the gel is too small to allow free diffusion
of the antibodies. Separated proteins must first be transferred to a medium which will
support antibody binding. This is done by 'blotting' the separated proteins onto a
membrane such as nitrocellulose which is 'sticky' for proteins. An electric field is
used to promote protein migration from the gel and onto the membrane, giving the
same pattern of separation as on the gel (Reviewed by Towbin and Staehelin, 1989).
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1.7 What is the source of proteins lost to the gut ?
Proteins in the gut lumen include those of the commensal gut bacteria and
those lost from the intestinal wall. Bacteria can interfere with detection ofhost
proteins e.g., immunoglobulins bhid to bacterial cell walls. In addition, bacteria
secrete proteases that may degrade secreted proteins.
Host proteins in the gut might include those fr om serum and those produced
within the intestinal mucosa. It is difficult to tell which source a secreted protein is
from but the following approaches have been used:
1. Intravenous injection of radiolabelled proteins with detection of the label in the
gut (faeces).
2. Use of a serum protein as a biochemical marker ofplasma leakage.
Both have their benefits and problems.
1.7.1 Radioactive markers
Radioactivity is a safety hazard, both to the patient and to the investigator. An
apparent advantage ofusing a radiolabelled marker is that it is stable and so is likely
to be detectable hi the gut even if the protein carrier is degraded. However, in a study
monitoring faecal excretion of intravascular injected radiolabelled albumin, relatively
lower excretion was noted hi patients with proximal as compared with distal Crohn's
disease. As excretion of radiolabelled IgG was similar in both cases, this indicated
that albumin which is excreted more proximally may be degraded to a greater degree
and that the radiolabelled peptides might be reabsorbed by the intestine (Jamum and
Jensen, 1975).
1.7.2 The use of albumin as a marker of plasma leakage
Albumin may be a more specific marker ofplasma leakage to the gut as
compared with other plasma proteins. It is not synthesized in the intestine, it has a
relatively long half life hi serum (Rothschild et al, 1973) and there is no specific
transport mechanism for movement of albumin from serum or extravascular spaces to
the gut.
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In healthy individuals only small quantities of albumin are lost to the gut. In
inflammation, there may be an increased exchange ofvascular and extravascular
albumin (Ballmer et al, 1994). Ifpermeability of the intestine i.e. of the basement
membrane and epithelial cell junctions is increased, then increased loss of albumin to
the gut is likely.
One pitfall ofusing albumin as a marker ofplasma leakage is that it is
susceptible to proteolytic digestion in the gut. Albumin lost from the ileum is likely to
be degraded to a greater degree than that from the colon. This is supported by the
finding that albumin in faeces was low in patients with active CD but high in patients
with active ulcerative colitis (UC) (Saitoh et al, 1995). Contrary to this, WGLF
albumin was high for both diseases (Choudari et al, 1993). This discrepancy could be
because the gut transit time for WGLF is much shorter than for faeces.
Other serum proteins have been used as markers of serum leakage e.g. faecal
clearance of alpha-1-antitrypsin (alAT) is increased in patients with IBD (Kapel and
Gobert, 1992). The volume ofplasma lost per day has been calculated from the
quantity of alAT lost per day/ serum alAT concentration (Saitoh et al, 1995).
alAT is highly resistant to proteolytic digestion and so might show more
reliable recovery in faeces or WGLF. a 1AT might therefore be a very useful marker
ofplasma leakage. However, there is evidence that cells resident in the intestinal
mucosa may produce alAT e.g. monocytes (Van Furth et al, 1983) or intestinal
epithelial cells (Molrnenti et al, 1993). This might be more so in response to
inflammatory stimuli. It may be useful to quantify production ofa 1AT in the
intestinal mucosa e.g., by using culture ofbiopsy material and assay of the culture
supernatant.
1.7.3 Relative coefficient of excretion for protein secretion to the gut
Protein secretion into the jejunum was studied using an occluding balloon
perfusion system in subjects without intestinal immune abnormalities (Jonard et al,
1984). As the perfused intestinal segment is occluded fr om contact with intestinal
proteases, secreted proteins were not digested.
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The following proteins; orosmucoid (a serum protein), albumin and immunoglobulins
plgA, mlgA, IgM and IgG were quantified both in the intestinal perfusate and in
serum. The perfusate protein concentration was compared to the serum concentration
and this ratio expressed relative to that observed for albumin (which is serum
derived).This gave the relative coefficient of excretion (RCE) i.e.
(concentration ofprotein in perfusate/ concentration in serum)/(ratio for albumin)
By definition, the RCE for albumin is 1.0 and so an RCE for the other proteins
greater than this indicated either a specific transport mechanism or synthesis of that
protein within the intestinal mucosa.
The use of albumin as a marker ofpassive plasma leakage was validated by
measuring the recovery of an intravenous injection of radiolabeled albumin in healthy
subjects. The specific activity (ratio of labeled to unlabelled) of albumin was similar in
perfusate and serum, indicating that all the albumin was from serum. In contrast, the
specific activity ofperfusate plgA was much lower than that in serum, indicating that
most of the secreted IgA was produced in the intestinal mucosa.
Using the RCE, polymeric IgA and IgM had RCE values greater than 1.0.
This reflects intestinal synthesis of these proteins and polyimrnunoglobulin receptor
mediated transport across the gut epithelium. Other proteins such as IgG and
orosmucoid had RCE values less than one, indicating that these were serum derived.
The RCE values for these proteins was inversely proportional to the molecular
weight ofthe protein, indicating that leakage of these proteins from serum was
restricted and dependent on their size.
1.7.3.1 Use of the RCE in inflammation
Non-specific movement ofproteins from blood vessels into tissues may be via
gaps between overlapping vascular endothelial cells. Normally these gaps are small
and restrict protein movement according to their size. However, in inflammation
these gaps are enlarged resulting in greater plasma leakage (McDonald et al, 1999).
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Ifprotein movement from the cir culation was not restricted by its size the quantity
leaking to the gut might be more dependent on the concentration gradient between
blood and the gut. This may need to be considered when comparing excretion of
proteins to the gut in patients with intestinal inflammation.
1.7.4 The source of IgG lost to the gut
IgG is the most abundant serum immunoglobulin class at 14 mg/ml. Although
very little IgG is found in the intestinal lumen ofhealthy subjects, patients with
intestinal inflammation show increased loss of IgG to the gut (Choudari et al, 1991) .
These patients also lose albumin to the gut indicating that at some of the IgG is likely
to come from plasma leakage. The relative coefficient of excretion of IgG compared
to albumin may give an indication to the extent that plasma leakage contributes to
WGLF IgG.
1.7.4.1 Evidence for local production of IgG in intestinal inflammation
The intestinal mucosa ofpatients with active IBD contains increased numbers
of IgG B-cells in the lamina propria (Baklien and Brandtzaeg, 1975) whereas in
inactive Crohn's disease the number of IgG B-cells is normal (Rosekrans et al, 1980).
These IgG B-cells have been shown to produce IgG in culture of intestinal biopsies
(Danis et al, 1984) or isolated lamina propria mononuclear cells (Wu et al, 1989),
(MacDermott et al, 1981) from patients with IBD. The increase in intestinal IgG
might therefore be due to both an increased number of IgG producing cells and
upregulation of IgG production by these cells. Intestinal IgG may play a role in
exacerbation of intestinal inflammation.
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1.7.4.2 Why are numbers of intestinal IgG B-cells increased in inflammation?
Differentiation of intestinal antibody producing cells under normal conditions
The pattern of cell adhesion molecules on circulating antibody producing cells
has been shown to be dependent on the site of immunization. Healthy individuals
were vaccinated with Salmonella Typhi and cell adhesion molecule expression on
circulating lymphocytes studied by flow cytometry. Oral immunization resulted in
nearly all the S.Typhi specific circulating antibody producing cells expressing a4(37
with 45% of cells being positive for L-selectin. Perental immunization resulted in only
60% of antigen specific antibody forming cells expressing a4(37 whereas 90%
expressed L-selectin (Kantele et al, 1997). This suggests that the site of antigen
engagement for naive lymphocytes determines their expression of cell adhesion
molecules.
Immunohistochemical analysis for cell adhesion molecule expression on
lymphocytes in the Peyer\s patches, the site of lymphocyte priming in the gut has
substantiated this. Naive T-cells in the high endothelial venules and naive B-cells in
the follicle mantle both had high expression of L-selectin but only low expression of
a4(17. Contrary to this, memory T and B-cells in the afferent lymphatic area
expressed more a4(37 but with less L-selectin. This indicates that L-selectin is
required for recruitment ofnaive cells into the Peyer's patches but upon lymphocyte
activation, different cell adhesion molecules are upregulated (Farstad et al 1997).
B-cell blasts or plasma cells in the lamina propria express a4)37, providing
evidence that B-cells primed in the intestinal lamina propria are able to enter the site
of antibody production in the intestine (Farstad et al, 1995). IgA producing cells are
predominant in the intestinal lamina propria. Priming ofnaive B-cells in the Peyer's
patches therefore directs antibody production towards IgA (rather than predominant
IgG seen with priming in the peripheral lymph nodes) and upregulates adhesion
molecules which appear to facilitate homing of these IgA producing cells back to the
intestine.
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L-selectin is expressed in high levels on naive lymphocytes and is involved in the
initial tethering of these cells to vascular endothelium. In peripheral lymph nodes this
involves association with carbohydrate residues on an addressin (adhesion molecule)
specific to peripheral lymph nodes. In the Peyer's patch a different addressin, mucosal
adhesion molecule-1 (MAdCAM-1), is expressed. This has similar carbohydrate
units, allowing association with L-selectin bearing lymphocytes. Finn attachment of
lymphocytes to the vascular endothelium of lymphoid organs appears to be similar for
naive or memory cells, involving association of lymphocyte function associated
antigen with the endothelial intercellular adhesion molecules (ICAM). However, in
addition to adhesion, the extavasation of lymphocytes from the blood involves a
selection process where lymphocytes may need to respond to chemical signals
produced by the endothelium. Activated or memory lymphocytes might more readily
respond to these signals.
The vascular endothelium of the intestinal lamina expresses a form of
MAdCAM-1 that lacks the additional sugar residues expressed on MAdCAM-1 hi
the Peyer's patches. Naive lymphocytes do not usually enter the lamina propria
whereas lymphocytes primed hi the Peyer's patches that express a4(37 do.
Lymphocytes activated at other sites do not usually show high expression of cc4(37
and so do not enter the lamina propria.
Changes to lymphocyte homing that might occur in intestinal inflammation
The lamina propria ofpatients with 1BD contains greatly increased numbers
of IgG B-cells. Tliere are two probable mechanisms for this, firstly, priming ofnaive
B-cells in the Peyer's patches may be altered so that the emerging B-cell blasts
express immunoglobulin y-chain instead ofa chain. This might involve an altered
cytokine environment in the Peyer's patches. As B-cell blasts produced in the Peyer's
patches are known to express a4(37, the finding that a reduced proportion of lamina
propria B-cells express this molecule does not fit with this hypothesis. (Yacyshyn et
al, 1994).
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The second hypothesis to explain increased IgG B-cells in the intestinal mucosa in
inflammatory states is that the requirement of B-cells to express a4(37 to enter the
lamina propria is abrogated. This might be due to increased expression of other
adhesion molecules such as ICAM-1 on the vascular endothelium (Bernstein et al,
1998) or expression of adhesion molecules that are normally specific for peripheral
lymph nodes.
Immunohistochernical staining shows that most of the IgG B-cells in inflamed
intestine are located deep in the mucosa, near to the blood vessels. This might
suggest that IgG producing cells have been recruited from the blood (Baklien and
Brandtzaeg, 1975). B-cells have which have been primed in peripheral lymph nodes
preferentially produce IgG on re-encounter with their cognate antigen.
1.7.4.3 Specificity of intestinal IgG in patients with IBD
The antigen specificity ofWGLF IgG might indicate whether the altered
mucosal immune response in EBD is directed against a particular agent. Serological
tests have demonstrated high frequencies ofperinuclear antineutrophil cytoplasmic
antibodies (pANCA) in UC. However, pANCA are found in patients with various
autoimmune diseases, indicating that they may be secondary products of a chronic
inflammatory response (Yang et al, 1993).
Many patients with Crohn's disease show raised serum IgG to bacterial
antigens including anaerobic coccoid rods or a 45/48 Kd antigen cross-reactive with
Mycobacterium (Oudkerk Pool et al, 1995). It is not known whether serum
antibodies to intestinal bacteria are produced in the systemic compartment or reflect
mucosal overproduction and leakage ofthese antibodies to the systemic
compartment. IgG has no specific mechanism to transport it to the gut lumen and so
ifvascular permeability was increased, it may enter the circulation.
Under normal circumstances, the intestinal immune system does not produce
IgG or cell mediated immune reactions to the commensal gut bacteria. However, any
switch in the type ofmucosal immune response might result in intestinal inflammation
(because ofpositive feedback reactions resulting from trying to clear a large antigen
load).
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Evidence for abrogation of tolerance to gut bacteria in inflammation comes from a
study looking at proliferation of isolated lamina propria mononuclear cells (LPMNC)
in response to isolates ofgut bacteria. Healthy individuals show no proliferation in
response to their own gut bacteria but there is proliferation in response to gut
bacteria from others. In contrast, LPMNC from patients with IBD proliferated in
response to their own gut bacteria (Duclirnann et al, 1995).
Evidence for an altered intestinal IgG immune response to commensal gut
bacteria in patients with IBD comes from a study showing that IgG in endoscopic
washings binds to commensal gut bacterial antigens isolated from faeces
(Macpherson et al, 1996). By comparing IgG excretion to that of albumin, IgG was
shown to be of intestinal origin. The specificity of IgG was examined by fust
separating the bacterial antigens by electrophoresis and then taking a western blot
from this and probing using the endoscopic washing antibodies. IgG from serum or
the intestine of control subjects was found to bind to both cytoplasmic and membrane
bacterial antigens. In contrast, intestinal IgG from IBD patients bound preferentially
to cytoplasmic bacterial antigens. This indicates that in the control group, IgG in the
intestinal secretions and in serum are from the same source, possibly indicating a
systemic immune response to bacteria that have crossed the intestinal mucosa. In IBD
there appears to be an altered intestinal IgG response to commensal gut bacteria.
The IgG subclasses produced in the intestine may provide clues to the nature
of the immune response. In normal subjects, a lower proportion of intestinal IgG cells
are IgGl (45%) compared to blood (70%). IgG2 is increased in the intestine and
especially so in patients with Crohn's disease (Riithlein, et al 1992). The proportion
of intestinal IgGl cells is increased in patients with ulcerative colitis (Iizuka, 1990).
IgG2 is produced predominantly in response to particulate or carbohydrate antigens
whereas IgGl is produced in response to soluble or protein antigens.
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1.7.4.4 Howmight IgG result in inflammatory damage to the intestine ?
Interaction with Fc receptors on immune cells
Fc receptors are cell surface receptors specific for the Fc portion of a
particular class of immunoglobhi. IgG Fc receptors are expressed constituatively oil
monocytes, macrophages, neutrophils, T cells and B cells. Type one receptors have
greatest affinity for IgGl, IgG3 and IgG4 and are found on mononuclear cells. Type
two receptors are of low affinity, bind IgGl and 2, and are expressed on monocytes,
neutrophils, eosinophils and B cells. Type 3 receptors are of intermediate affinity,
bind IgGl and IgG3 and are expressed on some monocytes and T cells or neutrophils
and eosinophils. Tissue macrophages express all three types.
These receptors facilitate uptake of antigen in IgG immune complexes. This
may induce phagocytic cells to release enzymes and oxygen radicals to destroy
ingested antigen, possibly causing bystander damage. Antigen taken up via Fc
receptors is efficiently presented to T-cells, augmenting the immune response (Van
de Winkel and Anderson, 1991).
Interaction of IgG with complement
IgG immune complexes (containing IgGl or IgG3) are efficient activators of
the classical complement cascade. Under normal circumstances, IgA is the
predominant immunoglobulin produced in the intestine. As IgA is not an efficient
activator of complement this may prevent unnecessary inflammatory reactions.
Activation of the complement cascade within the intestinal mucosa may result
in recruitment ofneutrophils (via generation of anaphylotoxins C3a and C5a) and
activation ofphagocytes via C3b receptors. These cells produce reactive oxygen
species and proteolytic enzymes in response to uptake of complement coated antigen.
These can cause bystander damage to the surrounding tissue. Damage to the
intestinal epithelium might allow increased amounts of antigen into the intestinal
mucosa and this is likely to result in immune activation of local T and B lymphocytes.
In individuals primed to a heightened immune reactivity, this could result in an
amplified inflammatory relapse.
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1.8 Complement in the gut
1.8.1 Overview of the complement system
Complement refers to a group ofnine serum proteins (C1-C9) wliicli can act as
either an innate (the alternative pathway) or adaptive (classical pathway) anti
microbial mechanism. The two pathways differ only in their dependence on the
requirement for antibody in the initial activation step. The stages which follow form
part of an amplification cascade in which proteins produced from one reaction act as
catalysts for the next. The final result is polymerization of complement proteins
within the target cell membrane, forming a pore which results in cell death by fluid
uptake (Reviewed by Kinoshita, 1991)
1.8.1.1 The classical pathway
The first stage of complement activation requires antibody to be bound in an
immune complex. Activation requires simultaneous binding of two globular heads of
Clq to heavy chain domains of antigen complexed IgG or IgM. This requires two
adjacent IgG or one molecule of IgM. Clq is then able to bind other components Clr
and Cls, creating a serine protease. This enzyme acts on C4 to release a small
peptide C4a and remain bound to the larger C4b fragment. C4b is a binding site for
C2, which on binding is cleaved by the CI protease to release C2b. C4bC2a is the
classical C3 convertase.
As IgM can bind two molecules ofC l q simultaneously, it would be expected
that IgM is a more efficient activator of complement than is IgG. However,
complement activation with IgM is less efficient than expected for two reasons:
Firstly, C4b can not bind to IgM and so must be deposited on an acceptor (usually
non host) membrane before further activation can occur. Tire IgM immune complex
associated CI must be close to the site of C4b deposition to increase the likelihood of
C2a binding to it.
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Secondly, antigen in soluble IgM immune complexes (antigen excess) is less efficient
at activating complement than are IgM immune complexes in antibody excess (Van
Der Zee et al, 1986). Antigen is usually in excess during the early stages of an
immune response.
The classical C5 convertase
C3 convertase (C4bC2a) cleaves C3 to C3a and C3b. C3b has an exposed
thio-ether bond which is veiy reactive and rapidly binds to proteins. C3b is deposited
on nearby non-host cell membranes or upon the C4bC2a complex to form the C5
convertase.
1.8.1.2 Activation of the complement cascade by the alternative pathway
C3 slowly hydrolyses in solution, producing an activated molecule C3i. This is
similar to C3b in that it binds to nearby cell membranes (particularly ofbacteria)
although stabilization of this requires binding of factor B. Bound factor B is cleaved
by a serum enzyme, factor D, to release a small peptide, Ba. Membrane bound C3iBb
is the alternative pathway C3 convertase which dissociates rapidly without binding of
factor P. C3 convertase cleaves C3 to produce C3b which either binds to the non-
host membrane (producing a focus for C3 convertase production) or another C3b to
form the alternative pathway C5 convertase (C3bBbC3b).
1.8.1.3 Formation of the membrane attack complex
This sequence is common to both pathways and uses membrane deposited
C3b as a focus for binding ofproteins which are inserted into the cell membrane,
resulting in cell lysis. This sequence is started by binding ofC5 to the C3b of
immobilized C5 convertase. Cleavage ofbound C5 releases C5a, allowing binding of
C6 to C5b and then C7 to C6. C7 has a hydrophobic tail which is inserted into the
cell membrane. C8 then binds to C7, also embedding into the cell membrane. C8
allows insertion and polymerization of C9 within the cell membrane, resulting in a
hole in the cell membrane with subsequent cell lysis.
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1.8.1.4 Other biological functions of complement
Fragments C3a and C5a are chemotactic for neutrophils and trigger de-
granulation ofbasophils and mast cells, with subsequent release ofvasodilator
substances which increase blood flow to the area. Several cells have receptors for
C3b such as complement receptor l on monocytes or CR3 which binds the
breakdown product of C3b, iC3b on monocytes and neutrophils. Uptake of antigen-
complement complexes results in cellular activation, releasing enzymes and oxygen
metabolites which help to destroy invading bacteria but can damage neighbouring
tissues (Dahlgren et al, 1984).
1.8.1.5 Regulation of the complement system
Activation of complement is supported by immune complexes or non-host cell
membranes. Activated complement components in the fluid phase are usually
degraded by inhibitors e.g. CI inhibitor. Host cell membranes do not support
complement activation because an inhibitor, factor H, is able to facilitate cleavage of
any bound C3b. On non host cells bound C3b binds factor B better than factor H.
Host cell membranes contain proteins which inhibit complement activation;
decay accelerating factor (DAF), complement receptor 1 (CR1) and membrane
cofactor protein (MCP). These inhibit the binding ofC2 to C4b, promote the
dissociation of C2a from C4b and promote the catabolism of C4b. DAF and CR1 also
accelerates dissociation of the C3bBb C3 convertase. Another membrane protein,
CD59, inhibits insertion and polymerization ofC9 in cell membranes which have
bound C5b-8 (Reviewed by Lachmami, 1991).
1.8.1.6 Evidence for complement activation in the inflamed intestine
Deposition of activated complement, (iC3b, the breakdown product ofC3b),
has been demonstrated by irnnumohistochemistry to occur along the intestinal
epithelial basement membrane ofbiopsy specimens from patients with UC.
Complement deposition was also shown in other types of colitis, indicating that this is
not specific for UC (Ueki et al, 1996). In Crohn's disease, deposition of C3b at the
luminal face of the surface epithelium was observed (Halstensen et al, 1992).
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Deposited C3b was not associated with IgG indicating that intestinal complement
activation was likely to be by the alternative pathway (Halstensen et al, 1992).
Complement activation was not evident in the intestinal mucosa ofhealthy subjects.
1.8.1.7 Biosynthesis of complement components
The liver is the major source of complement proteins with some produced
constituatively e.g. C7 whereas synthesis of others is upregulated during an acute
phase response e.g. C3 (Morgan and Gasque, 1997). Patients who received a bone
marrow transplant with a complement allele mismatch subsequently had a small
proportion of serum C3 which had the marrow allele. Following liver transplatation,
most of the recipients serum C3 bore the liver allele. This demonstrated that although
the liver is the major source ofC3, there is significant synthesis elsewhere (Naughton
et al, 1996).
Several human cell types have, hi culture, been shown to synthesize functional
complement components. Monocytes produce C2, factor B and factor D (Beatty et
al, 1981) and have been shown to synthesize C1-C5 hi serum free culture (Hetland et
al, 1999). Synthesis of C3 by alveolar macrophages was upregulated by endotoxin.
Synthesis ofC3 by intestinal macrophages might be expected to be upregulated in
response to high levels of endotoxin hi the intestinal lumen.
In the Caco-2 colonic epithelial cell line, production ofC3, C4 and
complement factor B was constitutive. Production ofC3 was specifically increased in
a dose dependent manner in response to by IL-1(3 or TNF-a (Andoh et al, 1993). As
these cytokines were produced in the inflamed intestine, they might have increased
epithelial complement synthesis. In the context of a local inflammatory reaction, the
relatively small amounts of complement produced by these cells may have been
significant. .
In vivo synthesis of complement has been demonstrated using a jejunal
perfusion system. C3, C4 and factor B were quantified in the jejunal perfusate by
ELISA. Patients with CD had greater complement secretion than healthy subjects,
irrespective of their disease activity (Ahrenstedt. et al, 1990).
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Comparison of complement excretion relative to albumin indicated that complement
lost to the gut was likely to result from mucosal biosynthesis.
The drawbacks with this study are that only non-involved regions of the
jejunum were studied. Complement secretion may have been greater in inflamed
tissue. Measurement of complement in WGLF, a whole gut perfusion, may have
given a more complete picture as well as allowing study of complement loss to the
gut in ulcerative colitis, a colonic disease.
1.8.2 Methods for measuring complement in intestinal secretions
1.8.2.1 Measurement of complement functional capacity
The functional capacity of complement to undergo the classical amplification
cascade is usually measured by the capacity to lyse antibody sensitized sheep red
blood cells (Clark et al, 1985). The capacity of either the entire lytic sequence or a
particular component can be measured, ifpurified components are supplied. These
assays were designed for use in plasma and may not be suitable for WGLF;
complement being dilute and possibly cleaved by gut proteases. Detection of
individual complement component activity without the need for the intact cascade
may have been useful; an ELISA format using immobilized IgG as a platform for
complement activation with subsequent detection of fixed complement components
has been described (Zwimer et al, 1989).
1.8.2.2 Immunological detection of complement components
C3 is the most abundant complement component in serum and is pivotal to
the activation ofboth the classical and alternative pathways. C3 was therefore the
most useful component to measure in a study of complement loss to the gut.
How to measure C3 was dependent on whether total C3 or the extent ofC3
conversion was required.
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Detection of C3 conversion products
The most suitable fragment to examine was C3dg, the breakdown product of
C3b. This was because antisera to C3b usually cross-react with C3. Problems with
polyclonal antisera for C3dg which cross reacted with C3 were circumnavigated by
electrophoretic separation ofthe complement fragments (Petersen et al, 1988). This
required rng/ml concentrations of complement and so would be unlikely to work with
WGLF. New assays for C3dg capture the molecule with monoclonal antibodies. This
ensured that cross-reaction with C3 did not occur. (Peakman et al, 1987).
The extent of complement activation has been assessed from the ratio of intact C3 to
C3d (Riordan et al, 1997). However, proteolysis of complement in WGLF may result
in loss of the epitope that is detected by monoclonal antibodies to C3d.
Assay of total C3
Polyclonal antibodies against C3 also recognized C3b and C3c activation
fragments (Porcel et al, 1993). These might therefore be useful for detecting different
forms of C3 that might be present hi WGLF. A capture ELISA with immobilized anti
C3c as used with cell culture supematants (Mitchell et al, 1996) and a competition
ELISA using polyclonal anti C3c has been used with intestinal perfusion fluid and
serum (Ahrenstedt et al, 1990).
The quantity of C3 detected is likely to represent a balance catabolism and
synthesis (Porcel et al, 1993). hi inflammation, synthesis ofC3 is increased
(Naughton et al, 1996) but complement activation and consumption may have been
increased. C3 in intestinal secretions may reflect leakage ofplasma proteins rather
than mucosal synthesis. It may be useful to quantify C3 in serum in addition to
WGLF to clarify whether C3 in the gut reflects plasma leakage or mucosal synthesis.
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SECTION 2 MATERIALS AND METHODS
CHAPTER TWO
Methods to study the structural integrity of
immunoglobulins in WGLF
2.1 Background
2.1.1 Investigating the structural integrity of immunoglobulins in WGLF
The validity of sandwich ELISA to quantifyWGLF immunoglobulins depends
on the assumption that WGLF immunoglobulins are intact. Antibodies to
immunoglobulin heavy chain might detect both fragmented and intact
immunoglobulins. Immunoglobulin fragments might show disproportionately greater
binding of anti heavy chain as epitopes which are sterically inaccessible on the intact
molecule may be revealed in the fragment. This could result hi overestimation of total
immunoglobulins, reducing the value of any conclusions. Conversely, ELISA to
measure antibodies are dependent on an intact antigen binding site being associated
with heavy chain. Fragmentation of these antibodies would result in loss of detection.
2.1.2 Previous work on WGLF immunoglobulin structure
Colleagues at the Gastrointestinal Laboratory, Edinburgh, have used SDS-
PAGE followed by Western blotting to investigate the structural nature of
immunoglobulins in WGLF. The finding that anti heavy chain staining of the western
blot did not localize to a discrete band may have indicated that the immunoglobulins
are fragmented. This result could have arisen because of cross-reactivity of the
antisera with the myriad ofproteins in WGLF. A preparative extraction stage prior to
electrophoresis was required.
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2.1.3 Methods for purifying immunoglobulins
Affinity chromatography using immobilized anti immunoglobulin heavy chain
antibodies has often been used to purify immunoglobulins of a particular class
(Mannik and Stage, 1971). Several methods are available for linking antibodies to
cellulose chromatography resins e.g. Sepharose. However, the cyanogen bromide
method (Axen et al, 1967) has been the most frequently used. Both intact and
fragmented immunoglobulins bound to anti heavy chahi. Affinity chromatography
was therefore not suitable for separating intact from fragmented immunoglobulins.
2.1.4 Thiophilic ligand chromatography: a method which binds only
intact immunoglobulins
A chromatography method which binds intact immunoglobulins of all classes,
releasing them under gentle conditions has been described: "thiophilic absorption
column chromatography"(Poratli et al, 1985). Sepharose 4B gel which has been cross
linked with divynyl sulphone and, blocked with 2-mercaptoethanol, possesses a thio-
ether ligand (the resin was called T-Gel). In the presence of ammonium sulphate,
immunoglobulins showed a high affinity binding to this ligand. Removal of the
ammonium sulphate resulted in desorption ofbound immunoglobulins from the
column.
The authors claim that the recovery of immunoglobulins from colostrum was
almost quantitative (Hutchens and Porath, 1986). It was demonstrated by size
exclusion chromatography and SDS-PAGE that only irrtact molecules were binding
(Hutchens et al, 1989). It may therefore be possible to separate intact fr om
fragmented immunoglobulins using this technique.
The reactive ligand was ofthe form R-S-CH2-CH2-SC>2-CH2-CH2-0-polynier
where R is a small aliphatic residue. The tlrioether sulphur and the sulphone groups
needed to be in close proximity to maximize the thiophilic absorption of
immunoglobulins. It has been suggested that an electron donar/acceptor mechanism
or proton transfer between surface-accessible aromatic amino acids and the sulphone-
thioether sulphur atoms in the T-Gel ligand might be responsible for the T-Gel
interaction (Hutchens and Porath, 1997).
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Immunoglobulin binding to the T-Gel was found to be enhanced by salts which are
known to cause re-organisation ofwater molecules e.g., K2SO4. The interaction was
shown not to be the same as hydrophobic chr omatography as a hydrophobic column
did not remove the same proteins as the T-Gel clolumn (Porath et al, 1985). It is
thought that the protein T-Gel ligand association is stabilized by the displacement of
protein bound water (Hutchens and Porath, 1997).
2.2 Work with T-Gel
2.2.1 Production of T-Gel
Sepharose 6B was 'suction-dried' using a sintered glass tunnel attached to a
vacuum pump. Dried Sepharose (100 g) was then suspended hi 100 ml of 0.5 M
sodium carbonate. To this, 5 ml of divynyl sulphone (Fluka) was added whilst stirring
the suspension (this must be done in a fumehood). The Sepharose was then
transferred to sealed universal tubes and mixed end over end, overnight at room
temperature. This conjugated the sulphone group to the sepharose.
Unbound reagent was washed free by pouring the slurry into a sintered glass
funnel and then flushing 2 litres of distilled water through it under vacuum. Divynyl
sulphone treated Sepharose (80 g) was resuspended in 80 ml of 0.1 M sodium
hydrogen carbonate pH 9. To this, 8 rnl of 2- mercaptoethanol was added with
mixing. The slurry was then mixed end over end in sealed universal tubes as before.
This added the thioether sulphur and hydrocarbon residues to the end of the sulphone
conjugated Sepharose.
Unreacted mercaptoethanol was washed free by pouring the slurry into a
sintered glass funnel and then flushing with two litres of distilled water passed under
vacuum. Prepared T-Gel was stored suction dried at 4°C in a sealed container
containing silica gel desiccant.
In the original work the density of ligand in the final gel was assayed by
analytic chemistry techniques (Hutchens et al, 1989). For this study the facility to do
this was unavailable. The effectiveness of T-Gel ligand formation has been
determined indirectly by assessment of immunoglobulin binding.
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2.2.2 Testing the binding capacity of T-Gel for WGLF immunoglobulins
2.2.2.1 Reagents for T-Gel chromatography
a) T-Gel equilibrating buffer (promotes immunoglobulin binding).
20 rnM HEPES buffer pEl 8 containing 10% w/v ammonium sulphate, 0.5 M NaCl
and 0.02% w/v sodium azide as a preservative.
b) T-Gel elution buffer (to release bound immunoglobulins).
Equilibrating buffer without the ammonium sulphate.
c) Ethylene glycol elute (facilitates complete elution)
50% ethylene glycol in 20 rnM HEPES pH 8
d) T-Gel which has been pre-washed with 100 x volume equilibrating buffer before
suction-drying.
All buffers were degassed in a side arm flask for 20 mins under vacuum (0.5
atmospheres).
2.2.2.2 Preparing WGLF for binding to T-Gel
WGLF (filtered and processed as described in the thesis appendix) was
prepared for T-Gel as follows: Ammonium sulphate was added to a final
concentration of 10% w/v, with sodium chloride added to a final concentration of
0.5 M. The pH was adjusted to 8.0 with 0.5 M NaOH.
2.2.2.3 Immunoglobulin binding to T-Gel
The binding capacity of the T-Gel for WGLF immunoglobulins was
determined by measuring how much bound when varying quantities were added to a
constant amount of T-Gel. Suction dried T-Gel (0.37 g) was dispensed into several
screw top glass tubes. To one tube each, 2, 4, 8 or 16 ml ofWGLF was added and
the contents mixed by rotation for 30 mins at room temperature. Unbound material
was separated from the gel by centrifugation at 1,850 x g for 10 mins, an aliquot of
each supernatant being taken for total immunoglobulin analysis by class specific
sandwich ELISA.
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2.2.2.4 Removing unbound protein
The T-Gel was washed twice (resuspending in 5 ml of equilibrating buffer and
then centrifugation at 1,800 x g for 10 rnins). Removal ofunbound protein was
complete when the OD 280 nm ofthe supernatant equaled that for fresh equilibrating
buffer.
2.2.2.5 Elution of bound protein
Bound protein was eluted by resuspending the gel in 5 ml of T-Gel eluting
buffer and mixing by gentle inversion for 20 mins. Eluted material was separated
from the gel by centrifugation at 1,800 x g for 10 mins. Supematants were assayed
for immunoglobulin. From the result of this experiment, the quantity ofWGLF
immunoglobulins to maximize T-Gel column binding was predicted.
2.2.3 Chromatography using T-Gel
2.2.3.1 Preparing a column
A Pharmacia 20 cm by 16 mm glass column was assembled as per
manufacturers instructions. A polyamide/polypropylene bed support was fitted at the
base and polyethylene tubing of one mm diameter attached to the column outlet. Air
bubbles were flushed free from the bed support with equilibrating buffer expelled
through a syringe. The outlet tube was then closed with a phi, retaining 2 ml ofbuffer
above the net ring before clamping the column vertically in a retort stand.
2.2.3.2 Packing the gel
22 g of suction dried T-Gel was resuspended in 30 ml of equilibrating buffer.
The slurry was poured in one motion along the edge of a glass rod and into the
column. This allowed the gel to settle evenly without introducing air. An inlet column
adapter type C 16 (Pharmacia) was assembled as per manufacturers instructions and
then inserted into the top of the column. Air was displaced fr om the inlet tubing by
pushing the adapter down into the buffer head above the gel. The adapter was then
sealed in position, closing the '0' ring by means of an adapter screw.
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The column inlet adapter was then connected using 1 mm polyethylene tubing to the
peristaltic pump ( Pharmacia PI, Sweden, with 2.1 nam diameter rubber pump
tubing). Pump inflow tubing was secured in a reservoir of equilibrating buffer and the
column outflow sealed with a pin to prevent the column from drying out.
To pack the gel, the column outflow was released and T-Gel equilibrating
buffer was pumped onto the top of the column at 130 rnl/h for 45 mins. Once the bed
height had dropped to a constant level, packing was completed. The column adapter
was repositioned on the gel surface to ensure even sample loading. The flow rate of
the pump was checked by measuring the volume ofbuffer passed through the column
(collected hi a measuring cylinder) during a set time period. Forward flow (from top
to bottom of the column) was used unless otherwise stated.
2.2.3.3 Samples for chromatography
WGLF was selected from patients with EBD as these usually had high
immunoglobulin content. WGLF from a different patient was used for each
experiment. For studying serum immunoglobulins, a pool of serum fr om several
patients was used. Serum was filtered through a 0.22 pi cellulose filter (Millipore)
before use in chromatography. All samples were treated as follows: Ammonium
sulphate was added to 10%, NaCl to 0.5 M and the pH adjusted to 8.0 with NaOH.
2.2.3.4 General conditions for chromatography
For preliminary experiments (1-3) chromatography was performed at room
temperature with the loading sample being kept on ice and collected fractions being
transferred to storage at 4°C. During these experiments the influence of the rate of
loading and the sample volume were assessed. Later a cold room at 4°C was used.
WGLF was stored at -70°C and thawed once prior to chromatography(unless stated).
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Ill the original T-Gel work, immunoglobulin binding was unaltered on changing the
temeperature from 4°C to 20°C (Hutchens and Porath, 1986). Immunoglobulin
binding at 4°C could be improved by reducing the flow rate. This was considered
before selecting optimal chromatography conditions.
2.2.3.5 Chromatography stages
Sample was loaded onto the top of the column, with the column outflow
released to allow the sample to progress though the gel. The progress ofWGLF
through the gel was followed by the presence of a yellow band (probably bilirubin).
This gave a sharp front at an even height around the column, indicating that the gel
had no 'channels' and so had been properly packed. The void volume of the gel was
the volume ofWGLF loaded when the yellow band became visible in the column
outflow.
After sample loading, loosely bound proteins were removed by flushing the
column with T-Gel equilibrating buffer. The protein content ofthe column washings
was monitored spectrophotometrically at 280 nm (the OD 280 nm is an indirect
measure ofprotein concentration as aromatic amino acids absorb light strongly at this
wavelength). Washing was stopped when the OD 280 nm of the column washings
equaled that for fresh equilibrating buffer
Strongly bound proteins were released by pumping T-Gel elution buffer
through the column. Fractions were collected into siliconised glass tubes, at fixed
time intervals, using a fraction collector (Gilson Microcoll, France). Fractions were
stored at 4°C. For some experiments, tightly bound immunoglobulins were released
by the addition of ethylene glycol to the eluting buffer, either as a single step or after
a preliminary elution with elution buffer alone. The profile ofprotein elution was
monitored by measuring the OD 280 nm or quantified using the Biorad dye binding
version of the Bradford assay (described in the thesis appendix).
Total immunoglobulin were assayed by ELISA as described hi the thesis
appendix. Individual fractions were first assayed at a single dilution. From these
results fractions with similar protein content were pooled and then assayed at
doubling dilutions for quantification.
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The quantity of immunoglobulin was calculated from concentration x the fraction
volume (this being estimated from the difference in weight between the fraction and
the empty fraction tube). Buffer density at 20°C was:
Equilibrating buffer 1.07 g/ml
Elution buffer 1.03 g/ml
Elution buffer including 50% ethylene glycol 1.08 g/ml
2.2.3.6 Re-cycling of T-Gel
After each experiment, 60 ml of 0.1 M NaOH was flushed through the
column at 48 rnl/h to disrupt the binding of any residual protein. T-Gel equilibrating
buffer (90 ml) was then pumped through the column at 48 rnl/h. After two
chromatography runs the gel was either resuspended and the column repacked or
unused T-Gel used.
2.3 SDS-Polyacylamide gel electrophoresis
SDS-PAGE has been extensively for resolving protein mixtures according to
molecular weight. This was used to analyse WGLF proteins fractionated by T-Gel
chromatography.
2.3.1 Equipment, reagents and gel formation: see appendix
2.3.2 Sample preparation
T-Gel fractions ofWGLF proteins from experiment 1 had high concentrations
of IgG, IgM and IgA and were selected for structural analysis. Pools of those
fr actions with highest immunoglobulin content were made for the loading, washing
and elution stages. Fractionated immunoglobulins (10 ml) were dialysed in a Spectra-
Por (Medicell International, UK ) 3,500 mw membrane sac, overnight at 4°C against
two changes of 0.125 M Tris-HCl pH 6.8 (100 ml). Immunoglobulins were then
concentrated overnight using osmotic pressure at 4°C (Millipore Urofil, USA). In this
system, sample is loaded into a chamber which is isolated from chamber from a
sponge by a 7 Kd mw cut off selectively permeable membrane.
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Water is absorbed into the sponge, concentrating the protein. Unfractionated WGLF
was concentrated five fold and fractionated immunoglobulins concentrated ten fold.
2.3.2.1 Reduction of disulphide bridges in the protein samples
Samples were mixed 1:2 with reducing gel bulfer (6% SDS, 6% 2-
mercaptoethanol, 40% sucrose and 0.02% bromophenol blue in 0.125 M Tris-HCl
pH 6.8), before boiling for four minutes.
2.3.3 Running the electrophoresis
Reduced samples (30 pi) or 5 pi ofmolecular weight protein standards
(Sigma) were separated by electrophoresis overnight at room temperature, with
constant current of 30 rnA supplied by poweipack (Sbandon, UK). Electrophoresis
was stopped when the bromophenol blue dye had migrated to within 1 cm of the base
of the gel.
2.3.3.1 Gel staining with Coomassie brilliant blue
The gel had been loaded with the same samples in more than one location.
One part of the resolving gel was taken for protein staining with Coomassie blue, as
described in the thesis appendix. The other half of the gel was used for western
blotting with subsequent antibody staining.
2.3.3.2 Observation of the staining pattern
For both the test samples and the molecular weight standards, the distance
moved by the protein band from the top of the resolving gel was compared to the
distance moved by the bromophenol blue dye fr ont. This ratio, the Rf, was plotted
against the logio of the molecular weight for the standards. From this plot, the
molecular weight of the sample protein bands was interpolated.
2.4 Western blotting
SDS-PAGE separated WGLF proteins were transferred to a nitrocellulose
membrane by western blotting. Commercial antisera against human immunoglobulins
were then used to identify these proteins.
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2.4.1 Equipment, reagents and assemby of blotting apparatus
see appendix
2.4.2 Testing the immunoglobulin detection system
The suitability of antibodies to detect immunoglobulins was first tested on
small pieces ofmembrane onto which immunoglobulins bad been absorbed.
Nitrocellulose (0.45 prn pore, Whatman, UK) was cut into 0.25 cm2 squares which
were placed in separate compartments of a tissue culture plate. Nitrocellulose was
activated by wetting with distilled water, excess fluid then bemg aspirated. Purified
human colostrum (1 pi) was appbed to the comers of the square each at 2.3 mg/rnl,
0.23 mg/ml and 0.023 mg/ml of IgA to test the detection antibody sensitivity.
Unoccupied protein binding sites on nitrocellulose were blocked by incubating with a
3% w/v solution of fat free milk in TBS-Tween for 30 mins, room temperature (with
gentle rocking).
2.4.2.1 Detection system for IgA
Two systems were tested
Direct system: Goat anti human alpha chain alkaline phosphatase conjugate (Sigma)
Two antibody system: Goat anti human alpha chain (KPL) then rabbit anti goat Fc
alkaline phosphatase conjugate.
Reagents
a) Tris buffered saline (TBS):
10 mM Tris and 140 mM NaCl adjusted to pH 7.4 with 1 M HC1.
b) TBS-Tween:
TBS containing 0.1% (v/v) Tween 20.
c) Blocking solution:
3% low fat milk (Asda) in TBS-Tween.
Prepare fresh on the day, dissolving milk by stirring in distilled water first.
d) Antiserum
e.g. Sigma goat anti human IgA (a chain specific) alkaline phosphatase conjugate.
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e) Substrate:
For alkaline phosphatase use Sigma Fast BC1P/NBT phosphatase substrate
one tablet in 10 ml distilled water is enough to stain a 12 x 5 cm piece of
nitrocellulose.
2.4.2.2 Detection systems for IgG and IgM
Using a dot blot system as described for IgA, SPS-01 containing IgG and
IgM was spotted onto nitrocellulose and detected using different antibody
concentrations or incubation times. Optimum conditions giving clear staining with
low background were selected for use with western blots.
For IgG, Sigma anti human y chain, alkaline phosphatase conjugate was used.
For IgM, Sigma anti human p chain, alkaline phosphatase conjugate was used.
2.4.3 Running the transfer
A maximum recommended initial current of 2.5 mA/cm2 (370 mA for a 15 cm
x 10 cm gel sandwich) was used. A transfer time of one hour rather than the
recommended thirty minutes was used because of the gel thickness (1.5 mm) and
high percentage acrylarnide (12.5% w/v).
2.4.3.1 Confirming that protein transfer had occurred
Following transfer, the nitrocellulose sheet was placed in a plastic box and
rinsed by submersion hi TBS-Tween for two minutes. After decanting the wash,
protein was visualized by addition ofPonceau S solution (Sigma, UK) diluted to 1/10
in distilled water (which gives a pink stain with protein). Background staining of the
nitrocellulose was reduced by washing the nitrocellulose in TBS-Tween.
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2.4.4 Probing of western blot with anti human a,y and p. chain antisera
The nitrocellulose blot was divided into three, marking the gel running
direction on each with a small cut at the base (anode) end. Each section was placed in
a plastic box and unoccupied protein binding sites on the nitrocellulose were blocked
by bathing nitrocellulose in a solution of 3 % w/v fat free milk in TBS-Tween for one
hour. Immunoglobulins were detected using a single antibody system with Sigma
alkaline phosphatase conjugated goat anti human immunoglobulin heavy chain diluted
hi TBS-Tween (15 ml). This was incubated for 1.5 hours at rt with rocking.
IgG use anti y chain at 1/1,500
IgA use anti a chain at 1/2,500
IgM use anti p. chain at 1/2,500
Detection of bound antibody
Unbound antibody was aspirated by pipette and the nitrocellulose washed
with four times two minute washes with TBS-Tween. Sigma "Fast" BCIP/NBT
substrate was prepared by dissolving one tablet in 10 ml of distilled water. Substrate
was then poured onto the nitrocellulose. Clear purple staining of discrete bands with
low background was obtained, at which point the reaction was stopped by washing
away surplus substrate with TBS Tween. The blot was dried on filter paper and
stored in a sealed polythene bag hi the dark.
The enzyme reaction involved cleavage of the phosphate group from 5-Bromo-4-
Chloro-3-Indolyl Phosphate to allow coupling to Nitro Blue Tetrazohum. This
produced a purple precipitate.
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CHAPTER THREE
Development of an assay to quantify complement C3
in WGLF
3.1 Introduction
WGLF IgG has been validated as a useful marker of disease activity in
patients with active IBD (Choudari et al, 1993). Increased IgG hi the intestine may in
itselfhave exacerbated mucosal inflammation. One possible mechanism is via
activation of the complement system (Lake et al, 1975). IgG in immune complexes is
an efficient activator of the classical complement pathway. Deposition of activated
complement may directly damage mucosa cells or, chemotactic metabolites C5a and
€3a recruit activated neutrophils to the region.
If complement is to play an important role in the exacerbation of intestinal
inflammation, the first phase of study into this should look to detect complement in
the gut. As C3 is the complement component at highest concentration in serum and is
one which is pivotal to amplification ofboth the classical and alternative pathways,
C3 would be a logical component to study in WGLF hi relation to intestinal
inflammation.
3.1.1 The possible state of C3 in intestinal secretions
C3 may be converted to fragments by the specific activation pathways which
may occur during transit across the gut wall or within the intestinal lumen. Non
specific proteases ofpancreatic or bacterial origin may also increase complement
conversion or further digest complement fragments. In active IBD, increased
numbers of granulocytes in the intestine might have release enzymes which
subsequently digest proteins, including complement (Johnson et al, 1976). Proteolysis
of complement might result in underestimation of its biological activity.
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Conversely, immunological detection of complement may give an overestimation due
to detection of fragments. Consideration must therefore be given to the choice of a
suitable method for quantifying C3 hi WGLF.
3.2 The possible methods of analysis for C3 in WGLF
3.2.1 C3 fixation
Assay of the full classical pathway by haemolysis of antibody sensitized sheep
red blood cells may not be useful for two reasons:
1) WGLF may contain intact C3, but without the other complement components
formation of the membrane attack complex will not occur.
2): Only one biological activity of complement is estimated i.e. that of full activation.
C3 conversion contributes much to the biological activity of complement through the
generation of the chemotactic fragment C3a which attracts neutrophils to the site of
inflammation (Dahlgren et al, 1984). C3b coated immune complexes facilitate the
uptake of antigens by phagocytes with possible presentation of this antigen to T and
B-cells .
A method to measure intact C3 by measuring its capability for conversion
might be useful. In one assay, complement activation was promoted on immobilised
IgG and bound C3 is subsequently detected immunologically (Zwimer et al, 1989).
Complement fixation was optimized by using heat aggregated IgG (Maillet et al,
1992). It was decided to try the method ofZwimer et al with the adaptation ofusing
aggregated IgG. A further adaptation was to include magnesium and cofactors in the
sample buffer. These were necessaiy for classical complement activation but may
have been bound to EDTA, a chelating agent used in WGLF processing.
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3.2.1.1 Assay to quantify unspent C3 in WGLF
Reagents (from Sigma unless stated)
Coating buffer: 0.05 M carbonate/bicarbonate pH 9.6
Aggregated human IgG: Purified IgG was diluted to 20 jig/ml in coating buffer.
This was heated in a waterbatk at 63°C for 30 rnins and then insoluble complexes
removed by centrifugation at 250 x g for 10 mins. The supernatant was taken for use
as the coating antigen.
Wash buffer: 0.05% Tween 20 in 0.9% saline
Blocking buffer: 1% BSA in wash buffer
Sample buffer: 0.15 M Tris pH 7.5 containing 1.2 mM CaCl2.2H20 and 0.6 mM
MgCl2.6H20.
Standard: Random plasma/EDTA was chosen as an arbitrary C3 standard.
Samples: Filtered and processed WGLF (as described in the appendix).
Anti C3: Goat IgG fraction, anti human C3.
Anti goat conjugate: Rabbit anti goat IgG, alkaline phosphatase conjugate.
Protocol (All volumes 100 pi unless stated)
See appendix section on equipment for ELISA
1. Dynatech Immulon 1 plates (USA) were coated with aggregated human IgG and
then incubated overnight at 4°C.
2. Unbound material was removed by three wash cycles with wash buffer.
3. Unreacted binding sites on the plate were blocked by filling the wells with block
solution and incubating for 1.5 h at 24°C
4. Standard was diluted to 1/100 in sample buffer before adding to the plate in
doubling dilutions.
5. WGLF was diluted to 1/5 in sample buffer before adding to the plate in doubling
dilutions.
6. After addition of standard and samples, the plate was incubated for 2 h at 37°C.
7. Unbound material was removed by three wash cycles with wash buffer.
8. Bound C3 was detected by addition of anti C3 diluted in wash buffer. The plate
was incubated for 2 h at 37°C.
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9. Unbound anti C3 was removed by three wash cycles with wash buffer.
10. Bound anti C3 was detected by addition of rabbit anti goat conjugate, diluted to
1/5,000 wash buffer. The plate was incubated for 2 h at 37°C.
11. Unbound rabbit anti goat was removed by three wash cycles with wash buffer.
12. Bound alkaline phosphatase conjugate was detected with the substrate p-
nitrophenyl phosphate (see thesis appendix), reading the OD at 405 nm.
13. A standard curve ofOD against dilution was drawn and the response curve for
WGLF compared against this.
Other minor modifications to the original method have been to make use of readily
available or more cost-effective materials. This has been validated by the successful
detection of fixed C3 from EDTA-plasma (see results).
3.2.1.2 The effect of protease inhibitors on complement fixation
The possibility of inhibition of complement fixation by protease inhibitors
used in the processing ofWGLF was investigated. In a series ofpreliminary studies,
plasma-EDTA was processed using various combinations of SBTI, PMSF and NBCS
as used for WGLF.
3.2.2 Detection of total C3
Total C3 could be quantified using a polyclonal antisera against C3c, which
recognizes C3, C3b and C3c. Potentially useful assays included the double antibody
sandwich or competition ELISA. An advantage of a competition ELISA was that
only one antibody binding site is necessary for detection of the antigen. This removed
the possibility that the capture antibody engaged all the possible epitopes required for
detection with the second antibody. A potential disadvantage of the competition
ELISA was that fragments ofC3 or C3c might have lead to overestimation ofC3.
A competition ELISA had been used to quantify C3c in intestinal secretions
(Ahrenstedt et al, 1990) but no validation data was included. It was therefore decided
to develop and validate a similar competition ELISA for WGLF C3c.
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3.2.2.1 Development of competition ELISA for C3
Immobilized purified C3 competes with sample C3 for binding ofpolyclonal
rabbit anti human C3c. Anti C3c which is bound to the plate is detected with goat
anti rabbit alkaline phosphatase conjugate.
3.2.2.2 Optimization of assay
a. Concentration of antibody conjugate required to measure anti C3c
Dynatech Immulon 2 plates were chosen for their high percentage binding of
protein antigens. These were coated with 100 pi/well of anti C3c at different dilutions
for each column: 1/500, 1/1,000, 1/2,000, 1/4,000, 1/7,000, 1/10,000, 1/15,000,
1/20,000, 1/30,000, 1/40,000 and 1/50,000 in carbonate/bicarbonate pH 9.6. Binding
was completed on incubation for 3 h at 37°C. After washing 3x in saline/Tween,
unreacted binding sites were blocked using 1% w/v BSA in saline/Tween for 1 h at
37°C.
Block solution was decanted and goat anti rabbit IgG alkaline phosphatase
conjugate added (100 pl/well) at different dilutions for each row: 1/250, 1/500,
1/1,000, 1/2,000, 1/3,000, 1/5,000, 1/7,500 and 1/10,000. The plate was then
incubated for 3 h at 24°C, washed, and the colour developed with p-nitrophenol
phosphate substrate. The OD 405 run was read when the maximum reading reached
1.000.
b. Concentration of C3 for coating plate
An Immulon 2 plate was coated with purified human C3 at concentrations
from 0.05 pg/rnl to 10 pg/ml. Bound C3 was detected with anti C3c at dilutions from
1/2,000 to 1/5,000 followed by anti rabbit conjugate at 1/500.
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c. Further adjustment of conjugate antibody concentration.
An Immulon 2 plate was coated with human C3 at 3 pg/ml and then blocked
as before. Anti C3c (100 pi) was added hi doubling dilutions from 1/1,000 to
columns across the plate. After incubation and washing, goat anti rabbit IgG, alkaline
phosphatase conjugate (100 pi) was added hi doubling dilutions from 1/1,000 down
the plate.
d. Concentration of anti C3c to compete with added C3
For a competition ELISA, it is important that the detection antibody (in this
case anti C3c) is not in excess. Using a constant amount of immobilized C3,
competing C3 was diluted with varying quantities of anti C3c. Competition curves
were then drawn and the anti C3c concentration that gave optimum sensitivity was
selected.
To a plate coated with C3 at 3 pg/ml, C3 (50 pi) was added at doubling
dilutions from 10 pg/ml. Competing C3 had been treated similarly to that coated on
the plate, i.e., it had been incubated overnight at 4°C. Anti C3c (50 pi) was added to
duplicate columns in doubling dilutions starting from 1/2,000. The plate was
incubated at 37°C for two hours to facilitate antibody binding. After washing free
unbound anti C3c, anti rabbit conjugate was added at 1/16,000 and the plate
incubated for two hours at 37°C. After washing unbound conjugate free, bound
antibody was detected with the p-nitrophenyl substrate reaction (thesis appendix).
e. The state of the competing antigen - influence of duration of thawing
In a parallel experiment, purified C3 that had been freshly thawed was used as
the competing antigen and compared with antigen thawed overnight.
3.2.2.3 Competition with WGLF C3 and recovery of purified C3 from WGLF
To a C3 coated plate, filtered and processed WGLF (50 pi) was added at a
dilution of 1/2 and then doubly diluted. In parallel, the same samples at 1/2 with the
inclusion ofpurified C3 (2.5 pg/ml) were added to the plate and doubly diluted.
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As a standard, purified C3 (50 pi) was added to the plate in doubling dilutions from
5 pg/rnl. Anti C3c was diluted to 1/32,000 in two stages; 5 pi + 1595 pi saline, mix
then take 100 pi and dilute to 10 ml with saline. Diluted anti C3c (50 pi) was added
to all wells except the blanks (a true 'blank' in the competition assay was when no
detection antibody binds to the immobilized antigen). As it is expensive to use an
infinitely high concentration of competing antigen, the cheaper alternative was to
omit detection antibody as the blank). After incubation, bound anti C3c was detected
with anti rabbit IgG at 1/16,000.
3.2.2.4 Influence of gut proteases on detection of C3 in WGLF
The protease activity ofunprocessed WGLF was measured using the Azocoll
dye release method (see appendix). C3 was assayed in the corresponding filtered
processed specimens. Ifproteolysis during gut transit influenced the detection of
WGLF C3, it would be expected to see a relationship between protease activity of
unprocessed WGLF and the quantity ofC3 detected.
3.2.2.5 Quantifying C3 in serum
Method as forWGLF except that serum was doubly diluted from 1/500
3.2.2.6 Assay performance
a) WGLF C3 limit of detection (sensitivity)
b) Quality control
An aliquot ofWGLF (stored at -20°C), was tested on each plate, using duplicate
doubling dilutions from 1/2 to 1/16.
1) Within batch variation (WGLF)
A single WGLF sample was diluted 1/2 in 12 separate tubes and these treated as
separate samples, being doubly diluted to 1/8 in a C3 competition ELISA plate, and
the coefficient ofvariation (CV) determined.
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2) Between batch variation (WGLF)
WGLF C3 QC material was measured in 26 separate analytical runs and the CV
determined.
3) Within batch variation (serum)
A single serum sample was diluted into 12 separate tubes at 1/500. These were tested
as single samples, diluting on the plate to 1/2,000.
4) Between batch variation (serum)
Thirteen serum samples were analysed for C3 on two separate occasions. The
samples were frozen and thawed for a second time as additional aliquots were
unavailable. The standard deviation for the duplicate results was obtained from:
SD = VSd2/n where d = difference between duplicate values and n = number of
pairs.
3.3 RESULTS
3.3.1 Modifications of fixation assay for WGLF
TABLE 3.1 Effect that addition ofWGLF processing reagents to plasma had on the
detection ofC3 fixation
Sample OD 405 nm for C3 fixation % inhibition
Plasma alone 0.959
Plasma + SBTI 1.061 0
Plasma + PMSF 0.463 52
Plasma + NBCS 0.033 97
Plasma + SBTI + PMSF 0.648 32
Plasma + SBTI + NBCS 0.067 93
Plasma + 1/100 PMSF 0.845 12
Plasma + 1/100 NBCS 0.819 15
Protease inhibitors soyabean trypsin inhibitor and phenyl methyl su phanyl fluoride or
newborn calf serum (a source of non human complement) were added separately and in
combination to plasma, using tire same quantities as for WGLF processing as described in the
thesis appendix. The possible interference on C3 fixation was then assessed by assay of C3
fixation in both processed and unprocessed plasma.
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These results show that reagents used for processing WGLF interfered with the
ability of the fixation assay to detect unspent C3 in serum and this may have also been
the case with WGLF. PMSF is a serine protease inhibitor which may have inhibited
the activity of activated Cls, a serine protease. This would have reduced the
conversion ofC4 and subsequent formation of the classical pathway C3 convertase.
Interestingly soyabean trypsin inhibitor, another serine protease inhibitor, had no
effect, indicating that conversion ofC3 in this assay is via a specific pathway and not
via the action of other proteases. Newborn calf serum (NBCS) gave almost complete
inhibition ofC3 fixation, possibly due to competition ofbovine C3 for binding sites
resulting from classical pathway activation on the immobilised IgG complexes. The
antisera detecting human C3 will not detect bound bovine C3. In addition, human
serum might have contained antibodies to bovine proteins (e.g. food antigens). These
might form immune complexes with subsequent fixation ofC3 that was not detected
in the assay.
3.3.1.1 Alteration to WGLF processing
To further test fixation of C3 fromWGLF, three WGLF samples were
processed without PMSF and NBCS. As an alternative protein substrate for residual
proteases, bovme serum albumin (BSA) was added to 2 mg/ml.
No C3 fixation was observed so it was assumed that C3 in WGLF was spent.
80







0.0-I t—'~T T T 1 1 1 1
012345678
Doubling dilution (starting at 1/25)
Fig 3.1: Classical pathway activity ofplasma, serum and WGLF
Samples were added to 2 pg of aggregated human IgG and incubated for 2 h at 37°C to allow
classical pathway activation to occur. Fixed C3 was detected using goat anti human C3
followed by alkaline phosphatase conjugated rabbit anti goat.
C3 fixation was seen with plasma but not with WGLF. As the extrinsic
inhibitors of complement fixation had been removed by alteration of the WGLF
processing regimen, it was likely that C3 fixation did not occur because complement
in WGLF was spent.
3.3.2 Optimization of the competition ELISA for C3
3.3.2.1 Conjugate antibody
When the OD values were plotted against coating antibody dilutions, different
response curves were seen with different amounts of conjugate antibody. At
conjugate dilutions greater than 1/500 the slope of this response curve was reduced,
indicating a loss of sensitivity. A conjugate strength of 1/500 seems optimal as high
background colour is apparent at greater concentration (Fig 3.2).
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Fig 3.2: Optimization of the quantity ofgoat anti rabbit alkaline phosphatase
conjugate required to detect rabbit anti human C3c absorbed onto plastic.
100 pi of varying concentrations of anti C3c were absorbed onto the wells of an Immulon 2
ELISA plate, unbound material being washed free. Absorbed anti C3c was detected using
100 pi of anti rabbit conjugate at different concentrations. A log plot of anti C3c
concentration simplifies plotting a wide concentration range by condensing the graph. A logio
dilution of 3.0 is intended to represent a dilution of 1/1,000. The conjugate strength giving a
wide range in signal with low background was chosen as optimal.
The plateau in the response curves occured with an anti C3c dilution of
1/2,000. This was thought to be a suitable concentration for detecthig purified C3 in
the competition assay.
3.3.2.2 Coating
A concentration of C3 ofbetween 2.5 and 5 pg/ml gave the maximum signal
(Fig 3.3), hi agreement with 3 pg/ml used by Ahrenstedt et al, 1990.
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Optimizing the coating concentration of C3
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Fig 3.3: Optimizing the C3 coating antigen concentration for the competition ELISA
to detect C3
100 pi of human C3 was absorbed onto the wells of an ELISA plate. Bound C3 was detected
with 100 pi of rabbit anti human C3c at four different concentrations. Bound antibodies were
then detected with alkaline phosphatase conjugated goat anti rabbit at 1/1,000.
The colour developed extremely quickly (1 min), compared to a required
optimum of ten to fifteen minutes for a peak OD of 1.00. Fast development could
lead to differences in the OD readings across the plate being due to the time taken to
add the substrate from one side to the other. When anti C3c was previously absorbed
directly onto plastic at 1/5,000 (fig 3.2), binding of alkaline phosphatase conjugated
rabbit anti goat was sub-optimal giving an OD reading 80 % of the maximal.
However, when anti C3c was used to detect immobilised antigen, there was no
evidence to suggest that a dilution of 1/5,000 is sub-optimal.
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This indicated that the primary antibody, anti C3c was more efficiently detected by
the anti goat conjugate when the primary antibody is bound to an immobilized
antigen i.e. as it was in the competitive ELISA. The optimal conjugate dilution
should therefore be assessed under those conditions.
3.3.2.3 Further optimization of the conjugate strength
Optimization of the dilution of goat anti rabbit
conjugate required to detect bound rabbit anti C3c
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Fig 3.4: Further optimization of the conjugate strength in the C3 competition ELISA
An Immulon 2 ELISA plate was coated with 100 pi/well human C3. This was detected with
100 pi of rabbit anti human C3c used at a wide range of dilutions from 1/1,000 to
1/1,024,000. Bound anti C3c was then detected with alkaline phosphate conjugated goat anti
rabbit.
The criteria selected for choosing the optimum conjugate antibody strength
are that the colour reaction occurs within a reasonable time (OD of 1.0 in 10-30
minutes), that the conjugate differentiates a wide concentration range ofbound
primary antibody and that the background colour is low.
Only a conjugate concentration of 1/16,000 fulfilled all three criteria. This
concentration makes the assay less sensitive to small changes in anti C3c binding but,
possibly more robust.
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3.3.2.4 Optimizing concentration of anti C3c for competition against added C3
a) effect of anti C3c concentration
Result
A competition type dose response curve was seen with anti C3c at 1/32,000
and to a lesser degree at 1/16,000. The former gave a maximum optical density of 1.0
in 19 rnins. Anti C3c at 1/32,000 was chosen as optimal to detect competition
between immobilised and competing C3. This fits in with the finding hi Fig 3.4 that
anti C3c at concentration greater than 1/10,000 gives a response in the plateau area
of the curve i.e., anti C3c is in excess. At this antibody concentration, addition of
competing C3 was unlikely to modulate binding ofanti C3c to immobilised antigen.
Optimization of anti C3c concentration









Log10 of competing C3 concentration
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Fig 3.5: Optimization of the quantity of anti C3c required to detect competition for
antibody between immobilised and free C3
An Immulon 2 ELISA plate was coated with 0.3 pg of purified C3. Between 0.25 pg and 3.9
ng of competing C3 was then added, together with anti C3c at dilutions between 1/2,000 and
1/128,000 (0.125 pg to 2 pg). Anti C3c bound to the immobilised C3 was then detected with
alkaline phosphatase conjugated goat anti rabbit at 1/16,000
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b) The state of the competing antigen - influence of duration of thawing
Purified C3 which had only just been thawed gave less binding of anti C3c
(i.e. less competition and a higher signal due to anti C3c binding to immobilized C3
011 the plate) than was the case with purified C3 kept overnight at 4°C after thawing
(data not shown). This may have been because slow conversion of the C3 occurs
both on the plate and in the C3 kept for use as the standard. With C3 in the form of
C3c on both the plate and in the competing antigen, anti C3c reacted optimally with
both.
However, if freshly thawed C3 was used as the competing antigen it may have
been that the C3 is intact and since this lacked C3c, epitopes and would not compete
for the anti C3c to the same degree.
3.3.2.5 Assay Performance:
WGLF C3 limit of detection (sensitivity)
C3(c) was detectable in WGLF and it's detection by anti C3c gave a parallel
dose response curve to that seen with the purified C3 standard (Fig 3.6). From a
response curve for the C3 standard, at concentrations lower than 0.16 pg/ml the
response curve was no longer linear. Beyond this, the sensitivity of the assay reduced
with increasing dilution. This therefore represented the lowest concentration which
could be accurately measured from this standard curve. With a minimum testing
dilution ofWGLF at 1/2, this gave a lower limit of detection (sensitivity) of 0.3
pg/ml.
The recovery ofpurified C3 added to WGLF was generally high (>80%)
except for one case where the WGLF concentration was very high in relation to the
spike added. This indicated that the ELISA was valid for quantifying C3 in WGLF
but that detection ofhigh concentrations might not have been quantitative.
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Fig 3.6: Parallelism between puiified C3 and WGLF C3 in competition ELISA
Purified C3 was detected similarly if assayed alone or together with WGLF C3, indicating
that the assay detected WGLF C3 in the same way as the C3 standard.
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TABLE 3.2 Recovery ofC3 added to WGLF (quantified by competition ELISA)
WGLF WGLF dilution spike pg/ml C3 pg/ml mean result recoverv %
1 2 N 3.2 3.4
1 4 N 3.6
1 8 N 3.7
1 16 N 3.1
1 4 1.25 3.5 167
1 8 0.625 1.6 152
1 16 0.3125 0.7 133
1 32 0.15625 0.3 114
2 4 N 11.7 11.8
2 8 N 11.9
2 16 N 9.9
2 8 0.625 2.7 129
2 16 0.3125 1.2 114
2 32 0.15625 0.5 95
3 2 N 3.9 3.9
3 4 N 4
3 8 N 3.3
3 16 N 3
3 4 1.25 3.2 144
3 8 0.625 1.5 135
3 16 0.3125 0.6 108
3 32 0.15625 0.3 108
4 2 N 5 5.7
4 4 N 5.8
4 8 N 6.7
4 16 N 5.5
4 4 1.25 3.8 142
4 8 0.625 1.9 142
4 16 0.3125 1 150
4 32 0.15625 0.4 120
For each WGLF (1-4) take the unspiked (N) result for the dilution of interest and divide by
the dilution factor. Then, select that dilution for the spiked WGLF. Add the concentration of
the spike to that observed for the unspiked WGLF. This gives the expected result. Recovery
% = actual/expected x 100. Read off the actual result for spiked WGLF from the appropriate
test dilution.
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The table shows that the recovery of spiked C3 in WGLF was approximately 100 % .
The reduced recovery at greater test dilution may reflect the limit of sensitivity for
the assay.
3.3.2.6 Influence of gut proteases on detection of C3 in WGLF
There is indirect evidence that detection of C3 in WGLF is less affected by
the action ofgut proteases than is albumin
TABLE 3.3 Comparison of detection of C3 with that of albumin
WGLF parameter CDi CDa UCi UCa
raised albumin with raised
C3
0/13 9/13 0/13 13/14
raised C3 with normal
albumin
4/13 4/13 2/13 0/14
raised albumin without
raised C3
0/13 0/13 0/13 1/14
Number of cases in which WGLF C3 > 1 pg/nrl and albumin >20 pg/ml (here I have
assumed that ifWGLF albumin is >20 pg/ml then albumin loss is raised)
If degradation ofproteins during gut transit had a significant effect on the
concentration of that protein hi WGLF, it might have be expected to see a
relationship between the protease activity of unprocessed WGLF and how much of
that protein was detected in the processed WGLF. The assay for protease activity is
discussed hi chapter 6.
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Relationship between detection of C3 in WGLF
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Fig 3.7: Relationship between recovery ofC3 in WGLF and WGLF protease activity
C3 was detected in fdtered processed WGLF as described in this chapter. Protease activity
was measured in unprocessed WGLF by dye release from Azocoll as described in thesis
appendix.
Relationship between detection of IgG in WGLF
and protease activity of unprocessed WGLF
Protease activity of unprocessed WGLF
(Arbitrary units)
Fig 3.8: Relationship between recovery of IgG in WGLF and WGLF protease
activity
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Relationship between detection of albumin in WGLF
and protease activity of unprocessed WGLF
Protease activity of unprocessed WGLF
(Arbitrary units)
Fig 3.9: Relationship between recovery of albumin in WGLF and WGLF protease
activity
WGLF from 8 patients with active IBD with raised WGLF C3 was tested for protease
activity (in the unprocessed sample) using dye release from Azocoll as described in the thesis
appendix. The linear regression line shows a strong negative association between C3 detected
and WGLF protease activity. One patient with a spurious result, protease 0771, C3 13 pg/rnl
has been removed as inclusion of this data abrogated the negative association seen between
WGLF C3 concentration and protease activity of unprocessed WGLF
All three proteins showed a strong negative association between the WGLF
concentration of that protein and protease activity of unprocessed WGLF. This
indicated that proteolysis duiing gut transit resulted in less of that protein being
detected. As the same patients have been used for each protein, the strength of this
association should give an indication as to the susceptibility of that protein to
proteolysis. The results would suggest that the order ofprotein susceptibility to
proteolysis is albumin > C3 » IgG. This has implications in chapter 6, where the
relative loss of each protein has been compared. Ideally, the effect ofWGLF
proteases on recovery of C3 should have been assessed directly, by measuring C3 in
WGLF that has been incubated at 37°C prior to processing.
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One reason why this was not done is that a competition assay has been used to
quantify C3. Generation of fragments might have therefore produce greater
competition for the anti C3c antibodies, overestimating C3 concentration.
3.3.2.7 Quantifying C3 in serum
Serum gave a dose response curve which was not as parallel to the standard
as that for WGLF and this deviation was increased at greater dilutions of serum. If
the OD readings for serum at a dilution of 1/500 were above that representing
maximum competition, the test result was taken as the mean ofvalues obtained at
1/500 and 1/1,000. If the OD at was lower than that representing maximum standard
competition, the test result was taken as the mean of the results at 1/1,000 and
1/2,000. The accuracy and precision ofC3 concentrations calculated for serum were
therefore likely to be lower than that for WGLF.












(from 5 pg/ml for C3 std, 1/500 for serum)
Fig 3.10: Parallelism between C3 in serum and purified C3 in competition ELISA
50 pi of serum at dilutions from at 1/500 to 1/64,000 or, purified C3 at 0.625 to 5 pg/ml
were added simultaneously with 50 pi of anti C3c at a dilution of 1/32,000 to 0.3 pg of
immobilised C3. Tire graph shows that competition for anti C3c is similar whether purified
C3 or serum is used.
C3 standard
Serum
I i i i i i i i
1 2 3 4 5 6 7 8
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3.3.2.8 Assay Performance of competition ELISA for C3
a) Within batch variation (WGLF)
This gave a mean value of 4 p.g/ml with a standard deviation of 0.24 giving a
within batch coefficient ofvariation of 6%.
b) Between batch variation (WGLF)
Over 26 runs, the mean WGLF QC C3 concentration was 0.84 pg/ml, with a
standard deviation of 0.14, giving a coefficient ofvariation of 16.7%.
Two WGLF samples (C3 21.2 and 4.2 pg/ml respectively) were analysed on three
different days.. These gave a between batch standard deviation of 0.57 pg/ml and a
CV of4.5%. Therefore the assay might have been more reproducible with higher
concentrations of WGLF C3.
c) Within batch variation (serum)
This gave a mean value of 1,207 pg/ml with a standard deviation of 96.3
pg/rnl, giving a within batch coefficient ofvariation of 8%.
d) Between batch variation (serum)
SD = VZd2/n where d = difference between duplicate values and n = number
ofpairs. This gave a standard deviation of 313 pg/rnl with a CV of 31%. This high
between batch variability of serum C3 probably reflected the greater non-parallelism
between serum C3 and the purified C3 standard and the difficulty in choosing the
most parallel dilutions.
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Final method for detection of C3 in WGLF by competition ELISA
Reagents
Coating buffer 0.05 M carbonate/bicarbonate buffer pH 9.6
Sample/blocking buffer 1% BSA in a solution of 0.05 % Tween 20 in 0.9 % saline.
C3 standard Sigrna purified C3 stored at -70°C then thawed at 4°C for 16 h before
use.
Anti C3c Rabbit anti human C3c (Sigma)
Anti rabbit IgG Goat anti rabbit IgG alkaline phosphatase conjugate (Sigma).
Samples WGLF filtered and processed (as described in thesis appendix)
Procedure
1. Immulon 2 plates were coated 100 pl/well with purified human C3 diluted to 3
pg/ml in coating buffer. The plate was incubated overnight at 4°C.
2. Unbound C3 was removed by washing the plate 3 x with saline/Tween.
3. Unreacted binding sites were blocked by filling the wells with sample buffer and
incubating the plate for 1 h at 37°C.
4. After decanting the blocking solution, 50 pl/well of fresh sample buffer was
added (100 pi to 'blank' wells).
5. C3 standard was diluted to 5 pg/ml in sample buffer and then 50 pl/well was
added to duplicate wells and a doubling dilution series produced on the plate.
6. Test samples were diluted 1:1 in sample buffer before adding 50 pi/we11 to
duplicate columns and four doubling dilutions prepared on the plate.
7. Rabbit anti human C3c was diluted to 1/32,000 in two stages (1/320 then 1/100)
in sample buffer and 50 pi added to all wells except the blank. The plate was then
incubated for 2 h at 37°C.
8. Unbound antibody was removed by washing the plate 3 x with saline/Tween.
9. Goat anti rabbit IgG alkaline phosphatase conjugate was diluted 1/16,000 in
sample buffer and 100 pi added to all wells. The plate was incubated for 2 h at
37°C.
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10. Unbound antibody was washed free as before.
11. The colour reaction with p-nitrophenol phosphate was earned out as described in
the thesis appendix. The OD at 405 nrn was read.
12. Data for the standards OD readings and logio ofC3 concentration was fitted to a
one site competition equation (Graphpad Prism), giving a non-linear regression
equation. Unknown test concentrations were then calculated from the OD results
obtained. The final result was given as the mean value of two or more pairs of
doubling dilution points which were parallel to the standard curve.
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3.4 Discussion
Intact C3 is present in plasma and can be fixed. C3 was detectable over a
range of concentrations, although, the 'hook" of the response curve at high
concentrations may indicate that assay conditions were sub-optimal. Serum gave
much lower detection of intact C3, probably reflecting gradual tick-over conversion
of C3 during storage at 4°C. In plasma this was inhibited by EDTA and storage at -
20°C. The finding that no fixation occured with WGLF might indicate that either
there was no C3 or that C3 was spent.
It was possible to develop a competition ELISA using anti C3c that was
sensitive enough to quantify C3 in WGLF. C3 in WGLF showed parallel dose
response curves to that for a purified human C3 standard. This was true when
purified C3 used for the standard was kept overnight at 4°C before use, as for C3
used as the coating antigen. This pre-incubation may have resulted in slow turnover
of C3 to C3c. C3 in WGLF was likely to be in the form ofC3c (or other activated C3
fragments). This might explain the parallelism observed under these conditions. The
similar recognition ofWGLF and purified C3 by anti C3c was confirmed by the high
recovery ofpurified C3 when added to WGLF.
Between batch variability for the assay was quite high but this was not likely
to result in many false positive results. The high dilution factor used for anti C3c may
have been responsible for this. C3 was also detectable in serum although at low
precision. The dose response curve for serum was not parallel to the standard,
possibly because serum contained some intact C3 (as shown in the fixation ELISA).
Anti C3c might have bound differently to intact C3 and C3c. Consequently, serum C3
results were not used for direct patient comparison.
It is likely that the quantity ofC3 detected was affected by proteolysis during
gut transit. The extent ofproteolysis during gut transit was dependent partly on the
protease activity within the intestinal contents. This was supported by the strong
negative association between the concentration ofC3 in WGLF and the protease
activity ofunprocessed WGLF.
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The finding that the strength of this association was in between that observed for
albumin and IgG indicated that lability ofC3 due to gut proteases was between that
of these two proteins. There was a worry that proteolysis of C3 produced fragments
which would actually increase the quantity of C3 detected using a competition assay.
This concern appeared to be unfounded and so detection ofC3 reflected how much
was secreted. WGLF is therefore a suitable medium in which to quantify C3 lost to
the gut. The competition ELISA for C3 would later be used to compare complement





The structural nature of immunoglobulins in WGLF
4.1 WGLF immunoglobulin binding to T-Gel
The quantity bound was calculated by subtraction of amount in the
supernatant (unbound) from that added. The quantity eluted is that released upon
adding elution buffer.











2 ml 16 5 11 68 14
4 ml 32 20 13 40 25
8 ml 65 42 22 35 27
16 ml 130 107 22 17 34
Different volumes of filtered processed WGLF were added to 0.35 g of T-Gel in a test tube.
After mixing to allow immunoglobulin binding to occur, unbound immunoglobulins were
collected in the supernatant following centrifugation. After washing, tire T-Gel was
equilibrated with eluting buffer and the released immunoglobulins collected. Immunoglobulin
content was assayed by sandwich ELISA. IgM bound = what is added - what remains in the
supernatant. The % bound = this quantity/ what is added x 100. Quantity added = WGLF
concentration (pg/ml) x volume (ml) added to T-Gel.
The results for IgM binding demonstrate two effects: Firstly, not even at the
lowest loading did all of the IgM binds. Furthermore, the % of IgM which bound
drops as the quantity of IgM added was increased. This indicated that binding sites
on the T-Gel resin are hmiting. However, the finding that more IgM binds the more is
added would suggest that there was competition for binding sites.
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One speculative explanation to as why not all the IgM bound equivalently to the T-
Gel equivalently could be if some WGLF IgM molecules were partially degraded by
gut proteases. The finding that more IgM was eluted than was calculated to have
bound to the T-Gel could be due to partial degradation of IgM during the experiment
with subsequent detection of immunoglobulin fragments.











2 ml 104 30 74 71 38
4 ml 208 95 113 54 67
8 ml 416 252 164. 39 102
16 ml 832 693 139 17 118











2 ml 25 9 16 65 6
4 ml 50 27 22 45 10
8 ml 99 74 26 26 14
15.5 ml 198 178 21 11 ND
Optimal immunoglobulin binding of between 60 and 70% was obtained with a
loading of 2 nil ofWGLF/ 0.37 g T-Gel. Given a total WGLF immunoglobulin
content of 75 pg/rnl this equated to a loading of405 pg immunoglobulin/g of T-Gel.
It was decided to use this loading ratio for chromatography on the premise that
binding might be expected to be more efficient in a column.
Elution ofbound immunoglobulins from T-Gel in a test tube was poor. This
might be expected to be improved in a column as eluted protein cannot then re-
encounter the T-Gel bgand. The result ofmore IgM recovered from T-Gel than was
loaded suggested IgM fragmentation.
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4.2 T-Gel chromatography
A 30 ml (22.2 g of dry T-Gel) was used.
4.2.1 Definitions of the various column fractions
Protein passing through the column during sample addition is LOADING fraction.
Protein released with equilibrating buffer is the WASH fraction.
Protein released with the eluting buffer is the ELUTE fraction.
4.2.1.1 T-Gel chromatography run 1 (WGLF)
100 ml ofWGLF (total immunoglobulin content of 90 pg/ml) was added to a
column of 22.2 g T-Gel. From the results of the test tube study, this was predicted to
be equivalent to 65 % of the maximum immunoglobulin binding capacity. A flow rate
of 30 ml/h rather than the original 48 ml/h was used for loading. This was to improve
the binding efficiency fr omWGLF which has a low immunoglobulin concentration
compared to media used for testing the T-Gel.
In this experiment WGLF corresponding to a total IgA, IgG and IgM of
9,180 pg was added to 22 g of T-Gel, i.e., 417 pg of immunoglobulin per gram ofT-
Gel. This is similar to when 2 ml ofWGLF, corresponding to a total of 145 pg of
IgA, IgG and IgM was added to 0.35 g ofT-Gel (414 pg/g) in the test tube study.
The % ofWGLF immunoglobulins binding to the T-Gel using a column was lower at
an average of49 % than the 68 % seen in the test tube study. Immunoglobulin
binding to T-Gel in a column was less than predicted and it may be necessary to
reduce column loading to give maximum binding. Maximization of immunoglobulin
binding was necessary to allow inference that non-binding immunoglobulins were not
be structurally intact.
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pg igA pg igG pg IgM
WGLF 100 4,030 4,180 970
Loading fraction 100 30 1,340 270 450
Wash 100 30 946 1,715 65
Elute (overnight) 96 6 2,608 1,910 364
50 % ethylene glycol 60 60 233 45 20





WGLF was added to a T-Gel column (22 g of T-Gel). Fractionated unbound material was
collected by washing the column. Bound material was eluted by changing the buffer.
Theoretically, the quantity of immunoglobulin bound = that added -(that in the loading
fraction + that in the wash fraction. Eluted immunoglobulin = that released with elute + that
released with ethylene glycol. Recovered immunoglobulin = sum of all column fractions. The
% bound = (bound/added) xlOO.
For IgA aud IgG, a similar fraction of the added immunoglobulin bind to the
T-Gel, supporting the finding seen with the test tube binding study. However, the
Immunoglobulin recovery ofgreater than 100% may indicate immunoglobulin
degradation during the experiment. This may have been because chromatography was
run overnight at room temperature. It may be beneficial to run the column at 4°C to
preserve immunoglobulin structure.
It appeared that immunoglobulin recovery was greater than 100 % for IgA.
This implied that IgA is less stable than IgG or IgM, in contrast to previous findings
(Brown et al, 1970). It may alternatively have been that fragments of IgM and IgG
were rapidly degraded and not detectable by ELISA.
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As WGLF used in this experiment was xich in IgA, IgG and IgM, it was decided to
investigate the structural nature of these immunoglobulins.
WGLF immunoglobulin from the loading, wash and elution stages were subjected to
SDS-PAGE (described in the methods section).
TABLE 4.5 Quantity ofWGLF immunoglobulins used for electrophoresis
Chromatography
stage
IgA pg/ml IgA pg IgG pg/ml IgG pg IgM pg/ml IgM pg
WGLF 40 2.0 42 2.1 10 0.5
throughput 30 3.0 10 1 12 1.2
wash 16 1.6 28 2.8 1 0.1
elute 27 2.7 39 3.9 9 0.9
ethylene glycol 17 1.7 3 0.3 1 0.1
The quantity of immunoglobulin used in tine electrophoresis was calculated from:
a) Concentration in fraction pool.
b) x concentration factor (5 for WGLF, 10 for column fraction).
c) x 2/3 (to account for dilution by reducing agent).
d) x 30/1,000 (the volume loaded on the gel).
Detection of specific antibodies in T-Gel fractions
The detection of specific antibodies of a particular class requires an intact
antigen binding site associated with part of the heavy chain. This can be used to
investigate whetherWGLF immunoglobulins binding to the T-Gel are more intact
than those that do not, i.e. are the binding immunoglobulins enriched for specific
antibody ?
ELISA for antibodies against a cocktail of LPS core antigen (EndoCAb) from
luminal bacteria; E.Coli, Klebsiella,(Barclay, G.R. and Scott, B.B. 1987) was
performed by Dr Samiul Hoque. The method is outlined in the thesis appendix.
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WGLF 0.191 4.6 2.51 0.08
Loading fraction 0.009 6.9 1.50 0.01
Wash 0.004 0.8 0.44 0.01
Elute 0.092 4.9 0.31 0.30
Ethylene glycol 0.027 27.5 0.06 0.45
WGLF and T-Gel fractions were assayed by ELISA for IgG antibodies to endotoxin core
antigen as described in the diesis appendix. The number of arbitrary units is low because a
serum reference standard has been used and the antigen is likely to be encountered via a
mucosal rather than systemic route.





IgA units /mg IgA IgA units /mg protein
WGLF 1.26 31.3 0.50
Loading fraction 0.357 26.6 0.24
Wash 0.251 31.4 0.50
Elute 0.638 24.7 2.13
Ethylene glycol 0.058 14.1 0.97
WGLF contained more IgA than IgG EndoCab units, reflecting a mucosal
IgA immune response. The finding that IgA endoCab units expressed per mg of IgA
did not show enrichment in the T-Gel binding fractions might reflect the possibihty
that IgA against this antigen forms only a small part of the total mucosal IgA
response. EndoCab specific IgA were just as likely to be intact or degraded as any
other IgA. However, when EndoCab IgA is compared to WGLF total protein, it is
clear that detection of specific IgA is enriched in the T-Gel binding fr actions. This
suggested that T-Gel binding immunoglobulins are more intact than non-binding
immunoglobulins. Later this finding was verified by SDS-PAGE.
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Chromatography profile for IgA
Chromatography gave a clean separation ofbinding and non-binding
immunoglobulins (Fig 4.1) Notice that elution ofbound protein began after 30 ml of
eluting buffer has been passed. This represented the void volume of the column.











0 50 100 150 200 250 300
J \ volume (ml) ^
WE EG
W = washing off unbound protein
E = eluting bound protein
EG = elution with ethylene glycol
Fig 4.1: Chromatography profile forWGLF IgA using T-Gel chromatography
Graph represents T-Gel experiment 4.1
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4.2.1.2 T-Gel chromatography run 2 (serum)
The quantity of immunoglobulins binding to the T-Gel using WGLF were
much lower than 65 mg/g of T-Gel observed in the original work.
To test whether this might be because of the dilute nature ofWGLF, it was decided
to run an experiment using serum. An even slower flow rate was used as it was felt
that the faster flow rate had been detrimental to binding ofWGLF immunoglobulins.







IgM pg igA pg
Serum added 4 12 8,000 6,800
Wash 110 18 460 380
Elute 80 90 3,050 1,860
50% Ethylene glycol 80 90 0 0
Unaccounted for 4,490 4,560
% Bound * 94 94
Serum was added to a column of 22 g fresh T-Gel. After extensive washing, bound
immunoglobulins were released using a two stage elution process. As the sample volume was
less than that of the column, the wash fraction comprises initially non-binding material in
addition to that released during washing. Unaccounted for immunoglobulin = added -(wash +
elute + ethylene glycol)
Much of the added immunoglobulins are unaccounted for after an extensive
elution regimen. It has been assumed that unrecovered immunoglobulin remains
bound to the T-Gel after elution. The other possibility that immunoglobulins could be
degraded during that experiment was unlikely because chromatography was
conducted in a cold room and more rapidly than in run 1. The % bound has been
calculated from: [(elute + unaccounted for)/added] x 100. Both the efficiency (%)
and quantity of immunoglobulins binding were much higher than observed with
WGLF.
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Possible reasons for this could have been because WGLF is very dilute. WGLF
contains polyethylene glycol (PEG) which may interefere with immunoglobulin
binding as ethylene glycol, a similar chemical, has been used to enhance elution of
bound immunoglobulins from T-Gel.
4.2.1.3 T-Gel chromatography run 3 (serum diluted in PEG)
An aliquot of the serum pool used for the previous experiment was diluted
100 fold in polyethylene glycol 3450 solution (final concentration 4.7 g/100 ml as for
WGLF). This would show whether the low binding ofWGLF immunoglobulins was
due to the PEG. T-Gel was recycled and the column repacked for this experiment.





Flow rate ml/h igA pg IgM pg igG pg
Serum added 100 6 1,700 2,000 14,500
Loading fraction 100 580 290 6,000
Wash 84 40 220 180 410
Elute 70 40 250 280 3,590
50 % Ethylene glycol) 70 40 130 410 1,110
unaccounted for 520 840 3,390
% bound * 53 77 56
Serum diluted in polyethy ene glycol was added to a column of 22 g T-Gel. After washing,
bound immunoglobulins were eluted using a two stage procedure. Unaccounted for
immunoglobulin has been assumed to remain bound to the T-Gel following elution.
Despite a reduced immunoglobulin loading, the % of added immunoglobulins
which bind to the T-Gel was reduced. It is likely that the addition ofPEG was
responsible. The low % ofbinding in WGLF might have been because PEG interferes
with the interaction between immunoglobulins and the T-Gel.
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To override this and allow maximal binding ofWGLF immunoglobulins it was
necessary to reduce column loading. Binding efficiency for serum immunoglobulins
diluted hi PEG was slightly better than that observed for WGLF, possibly as a result
of slower column loading.
4.2.1.4 T-Gel chromatography run 4 (WGLF, cold room)
The column was cleaned, fitted with a new bed support and packed with 17 g
fresh T-Gel at 4°C, giving a bed volume of 23 ml. Chromatography was performed in
a cold room to minimize possible degradation ofWGLF immunoglobulins (apparent
from the first experiment run at room temperature, 21°C).
Reduced immunoglobulin loading was coupled with slow loading rates to try to
maximize binding. Elution was performed using reversed flow to enhance elution
efficiency (advice from Pharmacia).










WGLF 13.5 10 1,598 118 5.5
Wash 58.8 10 131
Elute 58.8 10 853
Elute (peak fraction) 4.2 124 6.1
Ethylene glycol 25.2 10 0
Unaccounted for 614
% bound * 92 %
* Assuming unaccounted for IgA remains bound to the co umn following elution. Individual
fractions of eluted material were assayed for total and specific IgA. Data for IgG and IgM is
not included as concentrations of these were very low.
The percentage ofWGLF IgA binding to the T-Gel was much greater than in
run 1. It would appear that a reduction in immunoglobulin loading combined with
slow flow rate has improved the efficiency of immunoglobulin binding.
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The efficiency of elution [eluted -(added -wash)]/100 is 58 % with an IgA loading of
94 gig/g ofT-Gel. This is similar to the 51 % seen in the test tube binding study with
an IgA loading of 297 pg/g T-Gel. The inability to release all of the bound
immunoglobulin was therefore likely to reflect sub-optimal performance of the T-Gel.
IgA antibodies to ovalbumin were assayed by ELISA (method in thesis
appendix) to assess whether T-Gel binding IgA was enriched for specific antibodies
and hence more intact than non-binding IgA. There was approximately 10 % more
anti ovalbumin IgA in the T-gel binding IgA then in the WGLF IgA. This agreed with
approximately 90 % ofWGLF IgA binding to the T-Gel (assuming that binding was
optimal).
4.2.1.5 T-Gel chromatography run 5 (unfrozen WGLF, cold room)
T-gel was re-cycled and the column re-packed at 4°C. WGLF was loaded at a
similar loading to the previous experiment to test whether the high % binding
achieved was reproducible. The only difference was that the WGLF was used directly
after processing i.e. it had not been frozen and thawed.











WGLF 19 18 920 2.06 23.5
Wash 1 15 36 45 2.19 1.4
Wash 2 15 36 90 0.55 10.9
Elute 1 15 36 90 0.19 31.6
Elute 2 15 36 386 0.35 73.5
Ethylene glycol 20 36 308 0.24 64.1
% Bound 85 %
Data for IgG and IgM is not included as these were at very low concentration.
Specific binding ofWGLF IgA to the T-Gel is demonstrated by the
enrichment in IgA/mg ofprotein in the eluted fractions. As in the previous
experiment, a high % of added IgA bound to the T-Gel.
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As the IgA loading was reduced for this experiment, it may have been expected to
see a greater % of added IgA binding. The finding that this had not changed indicated
that binding ofWGLF IgA was now maximal and so IgA not binding to the T-Gel
may be unable to do so. Results for antigen specific antibodies in the previous
experiment may indicate that this IgA was fragmented.
Unfortunately, ovalbumin specific IgA were undetectable in WGLF used for
the current experiment. It is of interest to note that the elution efficiency was much
higher in this compared to any of the other experiments. As the only difference was
that the sample had not been frozen and thawed inference might be made that
freezing and thawing immunoglobulins alters their structural nature in a manner
which changes their interaction with the T-Gel ligand. It must be assumed that the
original T-Gel work was done using unfr ozen specimens.
4.3 Electrophoresis
Migration of the molecular weight markers was proportional to the logio of
their molecular weight (Fig 4.2), validating the estimation ofmolecular weight of
unknown proteins by comparison of their migration to that of the markers.
Electrophoretic mobility of molecular weight markers








Sigma wide range markers
4.0 4.5 5.0 5.5
Log10 molecular weight
6.0
Fig 4.2: Relationship between electrophoretic migration and protein molecular
weight using SDS-PAGE
A 12.5 % discontinuous gel was loaded with 5 pi of Sigma wide range molecular weight
markers and electrophoresis peifonned as descnbed in the thesis appendix.
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4.3.1 Gel staining of T-Gel fractionated WGLF proteins
Coomassie blue staining ofT-Gel separated proteins was faint and sharp,
indicating low protein concentration but good separation. It was not possible to
obtain a photographic reproduction because of the faint staining. Observation at the
time revealed the following pattern:
LOADING fraction:
major bands at 66 Kd (probably albumin)
faint bands at 55 Kd and 25 Kd (probably heavy and light immunoglobulin chains).
fuzzy staining at just less than 55 Kd (several proteins of similar mass).
Elute:
bright staining at 55 Kd and 25 Kd
very faint 40 Kd band
This suggests that immunoglobulin is the major protein binding to the T gel.
4.3.2 Detection system for WGLF IgA on Western blot






1/500 1 h 4x2 min TBS-
Tween
BCIP/NBT all spots bright, high
background
1/1,000 1 h " u
1/2,500 1 h u bright spots, low
background
1/500 2 h " bright spots, high
background
1/1,000 2 h u "
1/2,500 2 h it
One microlitre of colostrum IgA spottec onto nitrocellulose was detected using goat anti
human IgA alkaline phosphatase conjugate. All volumes 1 ml, with antibody dilutions in
TBS-Tween.
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1/500 1/1,000 NBT/BCIP bright spots, high background
1/1,000 " " bright spots, some background







1/1,000 u weak spot staining
One microlitre of colostrum IgA was detected with anti alpha chain antisera followed by anti
species alkaline phosphatase conjugate. All antibody incubation periods were one hour at
room temperature.
Non specific binding of the anti goat Fc to human IgA makes the two antibody
system unsuitable. The single antibody system gave clear staining with low
background when using anti a chain at 1/2,500 incubated for one hour.
4.3.3 Staining of Western blot
a) General protein staining
Ponceau S gave a clear pink stain for transferred proteins. No staining was
evident at the low molecular weight end of the blot.
b) Antibody staining of immunoglobulin heavy chain
IgG developed quickest, then IgM but, IgA hardly developed at all. Heavy
chain staining at a band at 55 Kd was more intense and compact with the T-Gel
binding fraction compared to the WGLF loading fraction. IgG staining gave three
bands at greater than heavy chain molecular weight and two bands with lower
molecular weight, in addition to the major band at 55 Kd. IgM only gave staining at
60 Kd.
Ill
L = Loading fraction (WGLF)
U = Unbound fraction
W = Released by washing
EL = Elute







Fig 4.3 : Western blot from T-Gel run 1, stained with anti y chain
Anti y chain staining of the 55 Kd heavy chain band was several fold more intense
with the T-Gel binding fraction than with unfractionated WGLF. This difference in
staining intensity was greater than might have been explained from the difference in
gel loading. Intact heavy chain might therefore be enriched in the T-Gel binding
fraction., demonstrating that the T-Gel did bind mainly intact immunoglobulins.
Unfractionated WGLF gave weaker heavy chain staining and this might have
reflected the presence of immunoglobulin fragments.
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4.4 Discussion
We have previously shown that the recovery of immunoglobulins from faeces
is very variable and dependent on the gut transit time (Ferguson et al, 1995). The
whole gut lavage procedure reduces and standardizes the transit time. One
advantage of this is that immunoglobulins was improved and less likely to show
variation between patients. Rapid processing ofWGLF with protease inhibitors
reduces further degradation of immunoglobulins.
The assumption that immunoglobulins in WGLF are intact needed to be tested
to validate the assays used to quantify them. Sandwich ELISA using anti heavy chain
antisera detected heavy chains ofboth fragmented and intact immunoglobulins. Using
size exclusion chromatography it was shown that a chain was detected in a wide
range ofmolecular weight fractions fromWGLF (L.McLintock, abstract: society for
mucosal immunology, San Diego 1995). Immunoglobulin fragments could have given
disproportionate binding of anti heavy chain as epitopes which are sterically
inaccessible on the intact molecule might be revealed in the fragment. If
immunoglobulins were extensively fragmented in WGLF, immunoglobulins might be
been overestimated using sandwich ELISA.
Thiophilic absorption chromatography, a technique with selectivity for intact
immunoglobulins was selected to assess whether WGLF immunoglobulins are intact
or not. When chromatography conditions were optimized this method bound nearly
all WGLF immunoglobulin. Electrophoresis was used to study the structural nature
of fractionated WGLF proteins. Western blots probed with anti immunoglobulin
heavy chain, demonstrated brighter staining of 55 kd IgG heavy chain in the T-Gel
binding fraction than with unfractionatedWGLF immunoglobulins. This confirms
previous findings that the thiophilic resin selectively binds intact immunoglobulins
(Hutchens et al, 1989). Non T-Gel binding immunoglobulins which were detectable
by ELISA were not detectable on western blot indicating that these proteins might
have been fragmented. Comparison of the relative quantity of immunoglobulin which
bound or did not bind to the T-Gel has provided a useful means of assessing to what
extent WGLF immunoglobulins were intact.
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Further evidence for the intact nature of T-Gel binding immunoglobulins came from
the finding that antigen specific antibodies were slightly enriched in this fraction when
compared to unfractionatedWGLF. Antigen specific antibodies were undetectable in
the non-binding fraction providing further evidence that these immunoglobulins were
fragmented.
It was found that under optimal conditions, 85 % ofWGLF immunoglobulins
bound to the T-Gel. This figure was supported by the degree of enrichment of
antigen specific antibodies detected in the T-Gel binding fraction. Processed WGLF
would appear to be a source ofmostly intact intestinal antibodies and might be a
useful medium for further studies of intestinal immunity.
It may have been useful to repeat the electrophoresis work because there was
evidence of immunoglobulin fragmentation during the course ofthe experiment,
probably because chromatography was run at room temperature. IgG staining of the
western blot for T-Gel binding WGLF immunoglobulins gave, in addition to the 55
kd heavy chain, a 40 kd band that might represent a Fab or Fc fragment. In
unfractionated (which had been assayed directly after thawing) this band was very
weak, indicating that fragmentation of T-Gel binding immunoglobulins may have
occurred. Further evidence to support this came from the finding that T-Gel binding
immunoglobulins were enriched for antigen specific antibodies when compared to
total protein but not when compared to total immunoglobulin. The immunoglobulin
fragments were detected by ELISA.
Stability work on WGLF immunoglobulins shows that detection by ELISA is
reduced with time in contact with gut proteases (chapter 6). This would suggest that
immunoglobulin fragments are either not detectable or, they are broken down rapidly
by proteases. Processed WGLF might have been fr agmented at a slower rate and
fragments remain detectable.
The western blot work gave poor binding of anti a chain. This was
unexpected as 4 pg of IgA had been loaded on the gel and direct staining of a dot
blot had shown 0.02 pg of IgA to be readily detectable). In a subsequent dot blot
test, good binding of anti a chain was seen to unreduced IgA but poor binding to
reduced IgA.
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This explains why IgA was undetectable on the western blot. Anti p. heavy chain
staining of T-Gel binding WGLF immunoglobulins gave a single major band at 60 Kd
(not shown). This fitted with IgM having an extra domain in the heavy chain.
T-Gel ligand bindsWGLF immunoglobulins of IgG, IgA and IgM classes. In
a binding study, the % ofWGLF immunoglobulin binding was greatest for IgA > IgG
> IgM. This difference in binding efficiency might have reflected differences in the
structural integrity of the th ree immunoglobulin classes. This would support studies
which have demonstrated intestinal IgA to be more resistant to proteolysis by
intestinal enzymes than is serum IgG e.g., (Brown et al, 1970).
The quantity ofWGLF immunoglobulins which bound to the T-Gel was much
lower than the quoted immunoglobulin binding capacity. There were several possible
reasons for this:
1) Processing ofWGLF includes addition ofbovine serum. This contains
immunoglobulins that may have competed for T-Gel binding sites but would not have
been detected by ELISA's for human immunoglobulins.
This accounts for a small part of the shortfall as calculated:
a) Processing added 0.6 ml ofbovine serum per 12.5 ml ofprocessed WGLF i.e.
0.048 ml/ml.
b) As adult bovine serum contains a total immunoglobulin content of 25 g/1, this
contributed 25 x 0.048 mg of immunoglobulin mg per ml ofWGLF i.e. 1.2 mg.
c) 0.37 g ofT-Gel should bind 24 mg of immunoglobulin (from the quoted capacity
of 65 mg of immunoglobulins/ g of T-Gel). In fact only 70 % binding of 0.15 mg of
human immunoglobulin was seen with a loading including 2.4 mg ofbovine
immunoglobulin.
115
2) In the original optimization experiments, y-globulins were used as the source of
immunoglobulins i.e. this was relatively pure compared with biological mixtures of
protein which might have shown immunoglobulin-protein interactions that inhibited
T-Gel-immunoglobulin interactions
3) Binding capacity was less with low concentrations of immunoglobulin (<2 mg/ml)
(Hutchens and Porath, 1986).
Binding efficiency ofWGLF immunoglobulins to T-Gel was inversely
proportional to the immunoglobulin loading, indicating a limited number of ligands.
This might imply that the T-Gel ligand was not synthesized correctly: elemental
analysis apparatus was unavailable and so it was not possible to test this. However,
T-Gel bound more immunoglobulins from serum, both in quantity and percentage of
that added. It may have been worthwhile to test the immunoglobulin binding capacity
using serum to see if this compared more closely with the quoted figures.
As the efficiency ofbinding appeared to be lower for WGLF
immunoglobulins, possible reasons for this were investigated. When serum was
diluted in PEG so as to resemble WGLF, the binding efficiency for serum
immunoglobulins was reduced to that seen with WGLF. It might be inferred that
PEG interferes with the interaction between immunoglobulins and the T-Gel ligand.
PEG is likely to form hydrogen bonds with protein molecules in the same way that
water molecules do. This increases the number of interactions that must be broken to
allow protein interaction with the T-Gel ligand. This may have reduced the effective
binding capacity of the T-Gel. There could be another factor reducing T-Gel binding
ofWGLF immunoglobulins as the quantity of PEG diluted serum immunoglobulins to
give the same binding efficienct as for WGLF was two fold that in the WGLF tested.
When a low quantity ofWGLF immunoglobulins was used, the binding
efficiency was not increased on halving the quantity of immunoglobulins loaded. This
would indicate that the quantityWGLF immunglobulins loaded was less than the
column capacity. Unbound irnunoglobulins may have been fragmented and unable to
bind to the T-Gel ligand.
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It was found that a large fraction of added WGLF or serum immunoglobulins were
not eluted effectively from the T-Gel. This did not agree with the 95 % recovery
quoted (Hutchens and Porath, 1986) and was surprising in that I had followed their
conditions. I have assumed that unrecovered immunoglobulin does remain strongly
bound to the T-Gel and calculations of immunoglobulin binding have taken this into
account. The finding that immunoglobulin elution from the T-gel was much improved
using unfrozen WGLF may indicate that freezing and thawing ofWGLF was
deleterious to immunglobulin structure.
These findings have demonstrated that most of the heavy chain detected hi
WGLF represented intact immunoglobulins and so gross overestimation of total
immunoglobulin by ELISA was unlikely. This also validates the use of capture
ELISA to quantify antigen specific antibodies in WGLF, opening the doors for
further study of intestinal immunity. Dr Samiul Hoque at the GI unit has shown that a
high proportion ofhealthy volunteers from Edinburgh have detectable intestinal
immune responses to foods. In contrast, subjects in Bangladesh had strong intestinal
immune responses to intestinal bacteria but few people had antibodies to foods. This
may have reflected that improved sanitation in the west resulted in a less active
intestinal immune response against bacteria, but immune responses might have




C3 loss to the gut in inflammatory bowel disease
5.1 Introduction
Complement is important for normal clearance of antigens and immune
complexes from tissues (Reviewed by Thornton et al, 1996). Activation of
complement involves an amplification cascade which enhances interaction of antigen
with the immune system. However, at sites where there is a large antigen load, i.e.
the intestine, this could result in inflammation with damage to surrounding tissues. As
C3 is pivotal to amplification of the complement cascade, it was decided to measure
C3 in the gut and relate this to the presence of intestinal inflammation.
5.2 Methods
5.2.1 Patients
From a review of the gastro-intestinal laboratory database, 93 cases who had
undergone whole gut lavage as bowel preparation for further investigation were
retrospectively selected. 53 of these cases were confirmed cases of IBD, 12 were
patients diagnosed with non IBD intestinal diseases with an inflammatory component
and a further 28 were patients diagnosed as having non-inflammatory intestinal
disorders or, with intestinal symptoms which were of a non inflammatory nature. This
latter population was considered as a non-inflammatory control group. A group of 8
healthy volunteer individuals with no abnormal intestinal symptoms underwent whole
gut lavage to provide a baseline control group.
5.2.1.1 Definition of active and inactive disease
In development of the gut lavage technique for biochemical assessment of
intestinal function, a retrospectively cohort of 63 individuals comprising healthy
volunteers and hospital patients under investigation ofnon-imrnunological intestinal
problems was selected.
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WGLF proteins were analysed as described in the thesis appendix and 'normal'
reference ranges were selected on the basis of excluding values above the 95th
percentile. These ranges were assigned as unlikely to represent intestinal
inflammation and were as follows: IgG 0-10 pg/ml, alAT (alpha-1-antitrypsin)
0-19 pg/ml, haemoglobin 1-5 pg/ml and albumin 0-26 pg/ml (O'Mahoney et al,
1991). In a later prospective study, IgG was quantified in WGLF from 53 well
characterized patients, 35 with CD and 18 with UC. For both groups ofpatients
chnical indices were assessed at the time of gut lavage. WGLF was then correlated
with either the CDAI or the Powell-Tuck index. It was found that patients with raised
indices generally had raised WGLF IgG and statistically significant correlation was
seen between clinical index value and WGLF IgG in those patients with a raised index
(Choudari et al, 1993). Raised WGLF IgG is therefore likely to reflect active
intestinal inflammation.
Most patients without immunological abnormality of the intestine had low
WGLF below 5 pg/ml. It may be that the restriction ofpatients used in the disease
control group was not tight enough and included some patients who lose plasma
proteins to the gut via mechanisms other than active inflammatory processes. For the
sake of this study, I have designated patients with IBD with WGLF IgG of 7 pg/ml
or greater as having active disease, using the proviso that there should be evidence of
plasma leakage to the gut (raised WGLF alAT or albumin).
Patients with Crohn's disease
Inactive = 13
4 females, mean age 48.5 yrs, SD 12.5
9 males mean age 46.3 yrs, SD 17.3
Active =13
8 females mean age 35.9 yrs, SD 12.2
5 males mean age 38.6 yrs, SD 12.3
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One male is included in both the active and inactive CD groups. He underwent whole
gut lavage on two separate occasions in between which his disease activity had
changed.
Patients with Ulcerative Colitis
Inactive = 13
6 females mean age 58.7 yrs, SD 11.3
7 males mean age 47.4 yrs, SD 14.1
Active = 14
5 females mean age 29.6 yrs, SD 20.2
9 males mean age 51 yrs, SD 10.7
Non inflammatory GI diseases
28 patients
19 females mean age 50.5 yrs, SD 13.5
9 males mean age 41.1 yrs, SD 13.9
see results table for diagnosis of these patients
Non-IBD intestinal diseases with inflammatory component
12 patients
6 females mean age 65.8 yrs, SD 19.9
6 males mean age 66.3 yrs, SD 12.7
Healthy volunteers
Control WGLF was collected as a baseline part of a vaccination study
7 males mean age 33.6 yrs, SD 7.4
1 female aged 30
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5.2.2 Samples for analysis
Filtered processed lavage (see thesis appendix) was stored at -70°C prior to




Complement C3 was assayed by competition ELISA as described in chapter
3. Serum and WGLF from the same patient were assayed in the same batch.
5.2.3.2 Other WGLF proteins
IgG, albumin, alpha- 1-antitrypsin (A1AT) and haemoglobin (Fib) were
assayed as part of a routine battery of tests done on WGLF. Methods are outlined in
the thesis appendix. Flaemoglobin gave an indication ofblood loss, alpha-1-
antitrypsin and albumin reflected plasma protein leakage and IgG indicated
gastrointestinal inflammation.
5.3 Results
5.3.1 WGLF protein concentrations



















1,950 0.4 2 9 0 3
1,950 0.3 1 8 0 1
1,500 0.3 1 0 4 2
1,750 0.3 1 1 3 2
1,100 0.3 1 2 3 3
NA 0.3 3 31 19 6
1,750 0.4 NA 17 6 NA
1,200 0.3 NA 11 5 NA
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4 1,400 0.3 1 4 1 2
1 1,450 2.4 2 10 6 9
1 1,600 0.3 1 1 1 3
1 NA 0.4 1 6 2 2
1 1,850 0.3 1 5 14 38
1 800 3.2 7 8 2 3
2 NA 0.3 4 5 8 3
2 1,100 0.4 1 5 4 2
3 1,450 1.1 1 7 5 6
3 900 0.3 2 7 2 1
3 1,100 0.3 2 6 5 5
3 1,050 0.8 3 5 5 5
3 1,100 1.1 7 15 0 1
Crohn's disease distribution




There does not appear to be any trend in WGLF C3 with extent of disease or, from
proximal to distal intestine.
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1 1,700 9.3 119 27 33 5
1 1,050 2.5 12 49 28 2
1 1,100 21.3 45 122 62 22
2 800 2.8 10 31 5 1
2 1,300 13.3 14 1 24 68
2 1,900 5.6 46 28 11 3
2 1,400 3.8 51 30 14 11
2 1,400 6.8 78 82 21 11
3 1,550 20 72 11 67 87
3 1,300 8.5 34 27 20 1
3 900 2.7 10 6 24 7
3 1,550 5.9 68 20 7 8
3 1,000 3 14 9 10 2
Again no trend in WGLF C3 was seen with the location ofCD from proximal to
distal. The highest WGLF C3 values occured when WGLF IgG is highest but, there
does not appear to be a perfect correlation between the two parameters.
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2 650 0.3 6 7 3 3
2 1,100 0.5 2 4 4 7
2 1,250 0.3 1 4 2 5
2 1,100 4.2 5 4 2 22
2 750 0.3 1 2 1 5
2 1,300 0.3 2 4 4 5
1 2,000 0.4 4 6 3 1
1 1,300 0.3 1 6 4 3
1 1,150 1 2 9 4 5
1 1,400 0.5 2 6 6 9
3 1,550 0.5 1 5 3 2
3 1,550 0.3 1 5 1 1
4 1,100 0.3 1 6 7 4
UC disease distribution
1 = left side

























2 1,200 5.0 24 22 3 2
2 NA 7.8 74 35 42 9
2 1,600 2.5 14 44 13 69
1 1,350 7.0 115 91 18 15
1 1,350 3.5 26 70 8 1
1 1,200 0.5 7 74 12 3
1 1,300 3.0 17 58 9 1
1 1,050 21.0 129 200 45 11
1 800 38.6 107 200 24 12
3 2,050 14.5 131 141 20 14
4 1,300 3.5 16 101 16 31
4 1,450 8.7 27 83 8 1
4 1,000 4.2 8 63 6 4
4 NA 2.9 10 55 5 5
Although the highest WGLF C3 values were seen in the left side UC group (the
group with the shortest section of affected colon), the results matched up to the
highest WGLF IgG values and so were probably a reflection of the severity of
inflammation hi a particular patient.
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TABLE 5.6 Loss of serum proteins to the gut in patients with non-inflammatory GI
diseases
Diagnosis Serum WGLF WGLF WGLF WGLF WGLF
C3 C3 igG Albumin A1AT Hb
pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml
1 1,100 0.5 2 4 3 2
1 1,350 1.1 1 4 6 10
1 1,350 0.3 1 1 5 1
1 1,200 0.3 1 2 4 2
1 1,650 0.4 1 1 3 3
1 1,700 0.9 3 6 13 4
1 1,150 0.3 2 2 1 1
1 1,450 0.4 2 2 2 5
1 1,150 0.5 1 5 2 3
1 1,350 0.3 1 5 6 2
2 500 0.3 4 1 1
2 NA 0.5 1 3 4 5
3 1,100 0.3 1 1 1 1
3 950 0.5 1 5 5 2
4 1,700 0.3 6 3 2
4 1,700 0.3 1 5 7 5
4 1,700 0.3 1 1 3 5
4 1,450 0.3 1 2 4 2
5 1,400 0.4 1 5 1 4
5 1,600 0.3 1 4 8 2
5 1,250 0.3 1 7 6 1
6 NA 0.9 23 5 32
6 1,600 0.5 1 5 5 3
6 1,650 0.4 1 5 4 2
6 1,350 1.6 13 6 16
7 1,400 0.3 5 3 1 ,
7 700 0.4 1 5 3 1 I
7 1,600 0.3 1 4 1 3
1 = Irritable bowel syndrome
2 = Ischaemic colitis
3 = Haemorrhoids
4 = Other (abnormal liver tests, haemosiderosis, pneumocystic cystoides, systemic lupus
erythramatosis)
5 = Constipation
6 = Gastrointestinal bleeding
7 = Functional bowel disorders
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Table 5.7 Loss of serum proteins to the gut in patients with non-IBD intestinal
disorders with an inflammatory component
Diagnosis Serum WGLF WGLF WGLF WGLF WGLF
C3 C3 IgG Albumin A1AT Hb
pg/ml gg/ml gg/ml pg/ml pg/ml pg/ml
1 1.050 18.1 2 52 48 9
1 2.000 0.3 1 1 3 2
1 700 0.3 1 1 1 1
1 1.050 2.6 7 28 6 16
1 1.700 0.3 2 8 4 2
1 1.700 0.4 3 13 1 2
1 1.300 0.3 1 3 1 2
1 NA 2.3 9 55 8 4
2 900 0.3 1 6 5 6
2 1.400 0.3 1 1 2 4
2 1.450 0.4 2 9 10 2
3 NA 7.5 23 71 21 2
1 = Cancer/ investigation of cancer
2 = Diverticular disease
3 = Coeliac disease
Three patients with colonic cancer and one with coeliac disease showed raised
WGLF C3. Loss ofC3 to the gut would therefore appear to reflect intestinal
inflammation but not specifically that of IBD.
5.3.2 Statistical analysis
WGLF and serum C3 concentrations were compared between the patient
groups. Data was negatively skewed (more cases show low than high values) and so
inter-group differences in median C3 values were compared using the non parametric
Mann-Whitney test.
5.3.3 'Normal range' for C3 in WGLF
For the purpose of this study, a reference range forWGLF C3 was assigned
on the basis ofvalues found in a non-inflammatory disease population as it was
hypothesized that individuals with intestinal inflammation would show raised loss of
C3 to the gut.
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This comprised 28 patients with non-inflammatory intestinal diseases and 8 healthy
volunteers. The upper 95th percentile ofvalues from this group gave 0.9 pg/ml as the
upper limit of 'normal'.
Frequency distribution for WGLF C3 in
non-inflammatory control population
0.30 0.50 0.70 0.90 1.10 1.30 1.50 1.70
WGLF C3 pg/ml
Fig 5.1: Frequency distribution ofWGLF C3 values in non-IBD hospital population
5.3.4 Comparison ofWGLF C3 in different patient groups
TABLE 5.8 WGLF C3 (median and range) in different patient groups







CDi n = 13 0.4 (0.3- 3.2) 4/13 0.22 v CDa 0.0001
CDa n = 13 5.9(2.5-21.3) 13/13 0.0001 v UCa 0.83
UCi n = 13 0.3 (0.3-4.2) 2/13 0.70 v UCa 0.0001
UCa n = 14 4.6 (0.5- 38.6) 13/14 0.0001
non-IBD
inflammatory
disease n = 12
0.4 (0.3-18.1) 4/12 0.42
non
inflammatory
Control n = 28
0.3 (0.3-1.6)
Most patients with active fBD have raised WGLF C3 whereas fewer patients with inactive
IBD or non-IBD intestinal inflammatory conditions do
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Compared to the control group ofnon inflammatory gastro-intestinal diseases and
healthy volunteers, patients with active inflammatory bowel disease showed
significantly raised loss of complement to the gut. Only one patient with 'active' IBD
(WGLF albumin of 74 pg/ml and IgG of 7 pg/ml had WGLF C3 within the reference
range. There was some overlap hi the inactive IBD groups, two patients with UC and
four with Crolm's disease showed raised levels ofWGLF complement. This reduced
the value of a raised WGLF C3 value to asses whether patients with IBD had active
disease.
Predictive values for raised WGLF C3 to predict active disease have not been
assigned as the number of cases with inactive disease has been under-represented,
increasing the frequency ofpositive results in the population studied. The presence of
raised WGLF C3 in patients with inactive disease could indicate one of three things:
1. C3 could have been an inflammatory parameter that was slow to return to normal
once intestinal inflammation has subsided. This is unlikely as raised C3 is likely to
exacerbate inflammation.
2. Ifplasma leakage was the source ofC3, cessation of inflammation would bring
about closing of the endothelial gaps, with leakage of the larger C3 molecule
stopping before that of the smaller albumin. Plasma leakage may not have been
the source ofWGLF C3 in patients with inactive disease.
3. Raised WGLF C3 in patients with inactive IBD might indicate a pre-clinical
change that occured prior to full scale inflammation. This could have potential in
predicting whether a patient is likely to have a clinical relapse.
2 and 3 are investigated in later chapters.
5.3.5 Serum C3
Serum C3 values were widely distributed within each patient group but
tended to show a rectangular distribution. Differences between the median values
were tested with the Mann-Whitney U test.
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TABLE 5.9 Serum C3 compared in different patient groups
Patient qroup C3 pg/ml P v control
CDi 0131 1.300 (800-1.8501 0.13
CDa 0131 1.100 (800-1.9001 0.25
UCi 0131 1,250 (650-2,000) 0.10







C3 median and range given. Groups compared by Mann-Whitney U test
Tliere was a wide range ofC3 values within each patient group, limiting the
value of comparing median values. This may have been because of the large intra-
assay variability in serum. It was probably due to this that these results do not agree
with the findings ofRoss et al, 1979 that serum C3 is higher in patients with CD.
5.3.6 Correlation between WGLF IgG and WGLF C3
IgG in WGLF has been shown to correlate well with indices of disease activity
in IBD, especially in patients with active disease. It was of interest to see whether
WGLF C3 mirrored this relationship. Spearman's rank coefficient was used because
WGLF C3 values show a negatively skewed distribution.
TABLE 5.10 Correlation between WGLF IgG and C3
Patient group WGLF IgG v C3 (r) P
CDi (13) 0.389 0.038
CDa (13) 0.590 0.275
UCi (13) 0.450 0.094
UCa (14) 0.854 0.005
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IgG and C3 are proteins of similar molecular mass (160 and 180 kd respectively).
Assuming that gaps between endothelial and epithelial cells were large enough to
allow movement of these proteins across the intestinal wall, the quantity of these
proteins lost to the gut would be largely dependent on the concentration gradient.
This would depend on the serum concentration and the degree ofmucosal synthesis.
Correlation between concentrations of these two proteins in WGLF would therefore
be dependent on the relative importance ofthese two sources for each proteins. Two
factors considered were the relative recovery of the two proteins: evidence from
chapter 3 indicates that recovery ofC3 may be less than that of IgG. Secondly, the
serum concentration of IgG is typically ten times that ofC3. There would need to be
substantial mucosal synthesis ofC3 for WGLF C3 not to mirror IgG.
In inactive IBD there was a weak positive correlation between IgG and C3 in
WGLF which just failed to reach significance. Insensitivity at the lower limit of
detection ofthe assays for IgG and C3 may have been a factor. In active ulcerative
colitis there is a very strong, highly significant relationship. UC is a disease ofthe
colon and this minimizes differences in recovery of different proteins because the
transit time is shorter compared to more proximal protein loss. It is therefore likely
that the two proteins were from the same source in patients with active UC. Patients
with active CD showed a moderately strong but not significant relationship between
WGLF IgG and C3. Two plausible explanations for this could be that this disease
shows heterogeneity in terms ofthe disease process and, also in terms ofthe site of
the disease.
Some patients with more proximal disease might have shown reduced recovery
ofC3 in WGLF. The positive relationship seen in active EBD has indicated that
WGLF C3 reflects disease activity (as measured byWGLF IgG) and so may be a
marker of the same inflammatory component.
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5.4 Discussion
C3 was detectable in WGLF from most subjects but at levels close to the
lower limit of detection in those without intestinal inflammation, as was found with
intestinal perfusates from the ileum or jejunum ofhealthy individuals (Hoj et al,
1981). Loss ofC3 to the gut was increased in patients with active Crohn's disease, in
agreement of findings with jejunal perfusates (Ahrenstedt et al, 1990). In inactive CD
I found WGLF C3 slightly above that ofpatients with non-inflammatory intestinal
conditions but significantly below those of active CD, contrasting with the finding of
Ahrenstedt et al that intestinal C3 was similar in both active and inactive CD.
One reason for this may be that their methodology involved perfusion of
histologically non-involved regions of the jejunum. It is possible that this avoids those
areas with greatest complement loss, whether that be via up-regulated mucosal
synthesis or increased vascular permeability with concomitant loss ofplasma proteins.
Consequently, C3 may have been underestimated in active CD. In contrast, whole gut
lavage involves perfusion of the whole gut and will collect complement from both
inflamed and non-inflamed regions. This appears to improve the sensitivity ofWGLF
C3 as a marker of intestinal inflammation.
Their study also demonstrated that C3 was not increased in jejunal perfusates
from four patients with ulcerative colitis. Tire disease activity of these patients was
not mentioned and it may have been that these patients had inactive disease.
One flaw in the use ofjejunal perfusion to study protein loss in ulcerative colitis is
that the disease is primarily a colonic one with little evidence for abnormalities in
other areas of the intestine. In my work using whole gut lavage, loss ofC3 to the gut
was increased in patients with active but not inactive ulcerative colitis.
WGLF C3 was only raised in patients with intestinal inflammation but without
being specific for IBD. This study could be improved with larger patient numbers
which would allow the impact of extent of disease on loss ofC3 to be assessed.
WGLF C3 mirrors the results for IgG and so is an objective, ifnot as specific, marker
of disease activity. A more interesting finding was that 4/13 patients with inactive CD
had raised WGLF C3 compared with only 2/13 for inactive UC. Tins may reflect low
grade mucosal inflammation during remission.
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It is possible that mucosal C3 could be involved in the switch to full grade mucosal
inflammation in relapse. The role of raisedWGLF C3 in CD as a risk factor for
subsequent relapse is assessed in a later chapter.
C3 was quantifiable in serum from all patients using competition ELISA.
Median serum C3 concentrations were similar to those observed using ELISA
(Ahrenstedt et al, 1990) or radial immunodiffusion (Ross et al, 1979). However, my
results give large overlaps between the groups, probably due to poor precision of the
competition ELISA in quantifying serum C3.
One reason for this could have been due to C3 in serum being present as intact C3 or
converted C3c. As anti C3c was used, this component would be detected to a greater
degree. The quantity ofC3c detected in serum might depend on conversion invivo or
during sample storage. This may explain the failure ofmy results to confirm previous
findings of raised serum C3 in CD.
Other studies of complement in the gut
Other studies of complement in the gut have looked at deposition of
complement in the intestinal mucosa. Sections of resected bowel were stained with
monoclonal antibodies against C3b or terminal complement complex (TCC). This
demonstrated mucous associated C3b and epithelial deposition of TCC in sections
from patients with Crolm's disease.
In ulcerative colitis colonic epithelium showed deposition of IgGl and C3b, possibly
indicating an autoimmune reaction with classical complement activation (Halstensen
et al, 1992). The intensity of staining for complement was graded subjectively and
this showed a weak positive correlation with the histological severity of
inflammation.
One problem with this kind of study was that the intestinal inflammation in
these patients was probably long-standing and chronic, increasing the likelihood of
pathological features representing exacerbated rather than primary insult. It is
therefore difficult to make conclusions about the role of complement in intestinal
inflammation. Another criticism is that several tissue sections from the same patient
were assessed with variation in the grade of inflammation depending on the site.
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If complement activation was a feature of inflammation in only some patients, this
might add greater weight to the correlation between severity of inflammation and
intestinal complement deposition than if only one section per patient was included.
One advantage ofWGLF was that endoscopy is performed on suspicion of
intestinal inflammation. WGLF complement might reflect early inflammatory changes
in relapse. It would be useful to discover whether complement loss to the gut occurs
before that of other proteins and to what extent it is produced in the intestinal
mucosa. Activation of that complement could reflect a switch between low grade,
non pathological inflammation seen in inactive IBD and pathological inflammation
with concomitant cellular infiltration and loss ofplasma proteins in active disease.




The source of immunoglobulins and complement in
the gut
6.1 Introduction
6.1.1 Source of proteins lost to the gut
Detection ofplasma proteins in the gut can indicate increased intestinal
permeability relating to local inflammation. However, there is evidence that some
proteins e.g. IgG and complement can also be synthesized by the gut mucosa. The
extent to which WGLF C3 and IgG are locally produced needs to be determined as
these proteins have the potential to participate in an inflammatory response.
6.1.2 Albumin as a marker of plasma protein loss to the gut
Albumin has been used as an indicator ofplasma leakage as it is not
synthesized in the intestine. Although there are other serum proteins which are more
stable than albumin e.g. a 1AT, there is evidence that this can be produced by
enterocytes, making it unreliable as a marker of serum protein loss (Molmenti et al,
1993). Monocytes can also produce alAT (Van Furth et al, 1983) and these cells are
recruited to the intestine in increased numbers in IBD (Burgio et al, 1995). However,
other studies show that detection ofa 1AT in faeces correlates well with excretion of
injected radiolabeled albumin (Bemier et al, 1978).
The metabolism of albumin is altered in active IBD with reduced biosynthesis
by the liver in chronic disease (Reviewed by Rothschild et al, 1973). With increased
loss of albumin to the gut due to changes in vascular and intestinal permeability,
serum albumin may be reduced. It was therefore necessary to compare the
concentration ofWGLF proteins to albumin as a ratio of the serum concentrations.
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6.1.3 Aim
It was proposed to compare WGLF concentrations of IgG and C3 to that of
albumin, i.e., WGLF IgG /WGLF albumin. Those patients with relatively greater
albumin loss probably lose most IgG and C3 from serum. Conversely, patients with
relatively greater IgG and C3 relative to albumin might lose a proportion ofthese
proteins from a non-serum source i.e., mucosal biosynthesis. To control for
differences in the concentration gradient it was necessary to divide the WGLF
concentration by the serum concentration. This gave the relative coefficient of
excretion (Jonard et al, 1984):
RCE = [(protein in gut (/(albumin in gut)] / [( protein in serum)/(albumin in serum)]
brackets denote the concentration ofprotein.
By definition the RCE for albumin is 1.0. An RCE greater than 1.0 for the protein of
interest indicated that this protein is lost to the gut to a greater degree than was
albumin. This may have meant that it was synthesized locally in the intestine or that
there is a specific transport mechanism resulting in faster protein loss than could be
accounted for by diffusion..
6.1.4 Potential pitfalls in looking at the relative excretion of albumin to
other proteins in the gut
A ratio ofparameters is subject to error from measurement of any of its
components. The use of the ratio value to make conclusions about the nature or
source of any ofthose parameters for a particular population needs to be treated with
caution. However, so long as the bias was similar in different patient groups, it may
be valid to compare the ratio observed in those groups e.g. to say that relative to
albumin, more ofprotein x was lost to the gut in group 1 compared to 2.
The accuracy of each parameter is dependent on:
1) The specificity of albumin as a marker ofplasma loss
2) Recovery and stability of the components
3) Accuracy and precision ofmeasurement of the components
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6.1.4.1 Specificity of albumin as a marker of plasma loss
Can albumin loss to the gut be attributed to bleeding ?
Albumin has been used as a marker ofplasma leakage, reflecting increased
mucosal permeability as a result of inflammation. Increased permeability could have
included both mucosal blood vessels and of the epithelial barrier. Intestinal
inflammation can also result in direct bleeding into the intestinal lumen via lessions
such as ulcers. Proteins lost by this process might not reflect disease activity. To
investigate the contribution ofbleeding to gastrointestinal plasma leakage a
theoretical exercise can show that WGLF albumin was in excess to that attributable
to bleeding (as assessed WGLF haemoglobin):
a) Using a WGLF albumin concentration of 30 pg/ml (which was just above the
normal reference limit) the extrapolated daily loss of albumin could be calculated: 30
tig/ml x 1000 ml Klean-Prep/h x 24 h = 720,000 pig.
b) From an average serum albumin concentration of 40,000 pg/ml, the quantity of
serum lost = 720,000 /40,000 = 18 ml.
c) Assuming an average haematocrit of45%, this volume of serum represents a blood
volume of 100/45 x 18 = 40 ml.
d) From an average blood haemoglobin of 135,000 pg/ml, this volume ofblood
represents a daily haemoglobin loss of40 x 135,000 pg/ml = 5,400,000 pg.
e) From the 24,000 ml ofKlean-Prep taken per day, this would equate to a WGLF
haemoglobin of: 5,400,000 /24,000 = 225 pg/ml.
The % contribution ofblood loss to WGLF albumin could be calculated from:
(WGLF Hb)/(WGLF albumin) /(225/30) x 100
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A plot of% contribution ofbleeding to WGLF albumin for cases with raised albumin
(>29 pg/ml) shows that in most cases, bleeding only contributes a small fraction.
















CD = Crohn's disease (n =13)
UC = ulcerative colits (n =12)
COE = Coeliac disease (n =2)
Fig 6.1: Contribution ofbleeding to intestinal loss of albumin in intestinal
inflammatory conditions
More albumin is lost to the intestine as a result of increased mucosal permeability
than is lost due to intestinal bleeding.
6.1.4.2 The stability of proteins in WGLF
As shown in chapter 4, IgG is relatively stable in WGLF. In chapter 5,
indirect evidence indicates that C3 is intact. However, Gordon Brydon at the GI unit
has shown that albumin is rapidly degraded in WGLF. (Ph.D thesis, University of
Edinburgh, 1996). Loss of albumin to the gut might therefore have been
underestimated byWGLF albumin.
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6.1.4.3 The assay performance of tests to quantify C3, IgG and albumin
a ) Measurement of albumin in WGLF
Albumin is quantified in WGLF using an 'in house' immunoturbidity method
(described in the thesis appendix). This gives a within batch variation of 8.5 % and
between batch variation of 7.4% at 45 pg/ml.
b) Quantification of albumin in serum
Albumin is measured in serum by colorimetric assay, measuring the shift of the
reflectance maxima in the dye bromocresol green. The colour complex formed was
measured by reflectance spectrophotometer (Vitros, Johnston and Johnston, UK).
The department of clinical chemistry at the Western General Hospital, Edinburgh
showed a within and between batch CV of 1.4 % for this method.
c) Quantification of C3 in WGLF
Competition ELISA for C3 in WGLF had a between batch CV of 16% and a within
batch variation of 6.4%. As this method detected intact as well as converted C3, it is
likely to detect all of the C3 present in gut lavage. Recovery experiments indicated
that 80% ofC3 wasdetected when purified C3 was added to WGLF.
d) Quantification of C3 in serum
C3 was quantified in serum by competition ELISA as described earlier. The between
batch variation of the assay is poor with a CV of 31% at 1,400 pg/ml.
This might have introduced errors into the C3 RCE ratio for individual patients. This
variability was due to the response curve for serum not being strictly parallel to the
C3 standard, giving higher results at greater dilutions. Results for serum C3 were
20% greater than published results (Ahrenstedt et al, 1990).
This was the case for all patient groups studied and so should not bias comparison of
the RCE values between the patient groups in this study. Conclusions about C3
secretion based upon the RCE would need to be treated with care because
overestimation of serum C3 reduces the apparent RCE, i.e. increasing the component
ofC3 loss attributable to serum loss.
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e) IgG in WGLF
Total IgG in WGLF was assayed by double antibody sandwich ELISA (see thesis
appendix) The between batch CV at 7 pg/ml was 8% and the within batch CV was
6%.
f) IgG in serum
IgG in serum was quantified by rate nephelometry using a polymer promoted immune
complex reaction. A Beckman Array analyzer was used at the department of clinical
biochemistry, Western General Hospital, Edinburgh. The within and between batch
CV were less than 4%.
From the performance characteristics of these assays, the RCE for C3 will be most
affected by assay variability.
6.1.5 Assumption about the site of protein loss to the gut
It has been assumed that in the IBD patients studied, protein loss to the gut
occured from the region of intestine which had been shown to be diseased by
radiological and endoscopic examination. Case reports were consulted after the date
of the gut lavage to determine changes in the extent of the disease i.e. from colonic to




6.2.1 Influence ofWGLF protease activity on albumin recovery
6.2.1.1 Measuring protease activity in WGLF
Azocoll, an insoluble ground collagen which is peptide conjugated to a bright-
red azodye has been used to measure protease activity (Chavira et al, 1984).
Breaking of the peptide bond by protease activity releases the dye into solution. The
colour intensity is measured spectrophotometrically and this is proportional to the
protease activity. This method has been used with WGLF to validate the effectiveness
of adding protease inhibitors (Gaspari et al, 1988) but it could be adapted to measure
the inherent protease activity in unprocessed WGLF. A version ofthis method is
described in the thesis appendix.
Protease activity in WGLF from different disease groups
Patients with IBD might have greater protease activity hi their gut lumen due
to increased numbers of activated granulocytes. This could influence the recovery of
proteins in WGLF from these patients. To assess whether protease activity ofWGLF
was disease dependent the Azocoll test was performed on unfiltered unprocessed
WGLF from the same 49 patients described in this chapter.
These included: 7 patients with inactive Crohn's disease, 6 patients with active
Crohn's disease, 7 patients with inactive ulcerative colitis, 6 patients with active
ulcerative colitis, 15 patients with non IBD GI disorders with no inflammatory
component and 8 patients with non IBD GI diseases with an inflammatory
component.
6.2.1.2 Recovery of albumin in WGLF
By quantifying albumin in unprocessed WGLF before and after incubation at
37°C the extent ofproteolysis that occured during gut transit can be estimated.
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WGLF was collected as samples became available and patient information was not
collected.
Procedure
50 ml from the first clear sample ofWGLF was collected and stored at 4°C
for up to thirty mins before further processing. It was then divided into four aliquots
of 10 ml into plastic universal containers. Protein reference standard SPS-01 (PRU,
Sheffield, UK) was used as a source of serum albumin (contains 40.3 g/1) for spiking
lavage. Aliquots were spiked nil, 6.5, 13 and 26j.il of SPS-01 respectively, giving a
spiking dose ofnil, 25, 50 and 100 pg/ml respectively. Each tube was vortex mixed
and the contents divided into 3 ml aliquots.
Instead ofusing filtration (during which lavage fluid is lost by absorption into
filter paper) solids were removed fromWGLF by centrifugation at l,800g for five
mins at 15°C. Gordon Brydon's work demonstrated that using centrifugation instead
of filtration for the first stage ofWGLF processing makes little difference to the
residual protease activity ofWGLF after processing (Ph.D, University ofEdinburgh
1996).
Aliquots from each spiked tube were spun and 2 ml of the supernatant
processed as described in the thesis appendix. Processed WGLF was stored at - 70°C
in small aliquots. The remaining aliquots ofunprocessed spiked lavage were
incubated in a waterbath at 37°C for between 30 and 200 minutes before removal and
processing. Albumin was assayed in a batch including all samples from a particular
recovery experiment, using the immunoturbidity method described in the thesis
appendix.
6.2.2 Stability of IgG in WGLF
In an experiment similar to that done with albumin, unprocessed WGLF was
incubated for various periods at 37°C before processing.
Either unspiked WGLF or WGLF spiked with IgG from serum (SPS-01 standard)
was used. IgG was then assayed and the recovery of IgG calculated relative to
WGLF processed at time zero.
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6.2.3 Comparison of C3 excretion relative to albumin
Transport ofproteins across inflamed endothelium is more dependent on the
concentration gradient than the proteins size, contrary to the situation normally
(Ballmer et al, 1994). As the serum concentration of albumin is much higher than that
ofC3, a faster rate of transport of albumin from the blood to the intestine would be
expected than for C3. This was tested by calculating the RCE for C3.
6.2.3.1 Patient groups for WGLF C3 analysis
Patients were enrolled retrospectively using a review of the GI database. All
WGLF specimens were less than two years old at the time of analysis and had been
stored undisturbed at -70°C. Patients with CD were restricted to those with only
colonic involvement (as assessed by clinical and radiological examination). This was
to try to control for differences in albumin recovery due to the length of intestine that
secreted proteins had to travel before collection. This would influence the extent of
proteolysis (particularly for albumin).
TABLE 6.1 Patients for study ofC3 RCE






1 M 28 none 30 mesalazine
2 M 45 none 30 codydramol,
colifoam
3 M 22 none no none
4 M 52 none 20 salazopyrin
5 F 30 none no none
6 F 28 none 30 Mesalazine, ferrous
sulphate, Azacol
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7 M 30 none 20 none
8 M 34 none no none
9 M 72 none 20 Asacol
10 M 51 none no none
11 F 61 right helicolectomy no Cholestyramine,
Azacol
12 F 28 none 9 Mesalazine
13 F 53 None no Azocol
patient 12 = patient 6. She was assessed as having active disease on co onoscopy following
the first gut lavage (20/05/97). WGLF IgG was 19 pg/ml. On the second colonoscopy
(05/06/98) disease was assessed as inactive. WGLF IgG was 1 pg/ml






14 M 63 none no ferrous sulphate,
Sulphasalazine
15 M 55 none no Azothioprine,
Mesalazine,
colifoam
16 M 50 none 30 Mesalazine
17 M 42 none 20 Mesalazine
18 F 40 none no Azothioprine,
Colifoam,
Salazopyrine
19 F 22 ileo-anal pouch no none
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20 M 77 none 5 Sulpasalazine,
Aspirin
21 M 43 none no Mesalazine
22 M 43 none no Salazopyine
23 M 32 none no Salazopyrine
24 F 75 none no Salazopyrine
25 F 71 none no Mesalazine, Losec,
Bendrofluazide
26 F 44 none no Salazopyrine
6.1e Non-IBD gastrointestinal diseases without inflammatory component
Age Sex Diagnosis
63 F HAEMORRHOIDS
62 F PHEUMOCYSTIC CYSTOIDES
55 F IBS
54 F IBS












6.1f Non-IBD gastrointestinal diseases with inflammatory component
Age sex Diagnosis
95 F FH BOWEL CANCER
75 F DIVERTICULAR DISEASE
52 F SLE NSAID INDUCED DIARRHOEA
39 F ISCHAEMIC COLITIS
37 F CANCER OF COLON
82 M REMOVAL OF TUBULAR ADENOMA
72 M COLONIC DIVERTICULAR DISEASE
61 M ILEOCAECAL CANCER
49 M DIVERTICULITIS
6.2.4 Comparison of IgG excretion relative to albumin
The high serum concentration of albumin coupled with its low molecular
weight would be expected to result in greater leakage from plasma to the gut than for
IgG. However, it is known that there is a large increase in IgG producing plasma cells
in the lamina propria ofpatients with IBD. These might be expected to increase
luminal IgG relative to albumin. The same patients as studied for C3 were used.
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6.3 Results
6.3.1 Stability of proteins in WGLF
6.3.1.1 WGLF protease activity as measure of albumin degradation
Assay performance
Duplicate tests within the same run gave a CV of4.6%. Replication of the
same sample in a different run gave a CV of 4.9% (Using SD of duplicates = (V Z
differences2 / 2 x number ofpairs). The within batch variation was reduced with more
replicates, giving a CV of 2.5%.
Protease activity in WGLF from different patient groups
Differences between patient groups were compared by Mann Whitney U test
TABLE 6.2 WGLF protease activity in different patient groups
Disease group Protease (OD 530 nm) compare P value
CDa (6) 0.48 (0.23- 0.69) v UCa 0.47
CDi (7) 0.54 (0.12-0.59) v CDa 0.83
UCa (6) 0.57 (0.29- 0.67)
UCi (8) 0.51 (0.23- 0.78) v UCa 0.65
non IBD G.I disease
without inflammatory
component (15)
0.56 (0.08- 0.73) v CDa 0.45
non IBD G.I disease with
inflammatory component
(8)
0.58 (0.06-0.64) v CDa 0.56
Protease activity (median and range)
There was no difference in WGLF protease activity between the patient groups.
Despite the numbers ofpatients being small, the distribution of results was similar in
each group. A high WGLF protease result for an individual patient might have
resulted in a low albumin because ofproteolysis. However, this was unlikely to affect
the albumin recovery for the group as a whole and also the relative protein excretion
ratio based on the WGLF albumin.
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6.3.1.2 Albumin degradation in WGLF
The recovery of albumin in WGLF was calculated in both spiked and
unspiked samples for several timepoints. Dilution ofWGLF due to processing was
taken into account. Graphs of% albumin recovery against incubation time are shown
for two WGLF samples. These show the two types of relationship seen, linear or
exponential decay type:





- WGLF +50 pg/ml
--•- WGLF +100 pg/ml
—WGLF +200 pg/ml
250
Incubation time at 37°C (mins)
Fig 6.2: Recovery of albumin in unprocessed WGLF incubated at 37°C (a)




—a— WGLF +25 mg/ml
-■»- WGLF +50 mg/ml
■-+- WGLF +100 mg/ml
Incubation time at 37°C (mins)
Fig 6.3: Recovery of albumin in unprocessed WGLF incubated at 37°C (b)
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In fig 6.2, time zero albumin recovery less than 100 % may indicate very high
protease active with proteolysis having occurred during WGLF processing. At longer
incubation times the rate of albumin digestion had slown down, possibly indicating
enzyme inhibition by digestion products or limited substrate (albumin). Albumin
recovery was consistent at different spiking doses but this was not the case with low
concentrations of endogenous albumin, possibly reflecting poor assay precision at
low concentrations. For each sample, the average % albumin recovery for all the
spiking levels was calculated. The rate of albumin digestion by gut proteases varies
between individuals.
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Incubation time at 37°C (mins)
Fig 6.4: Variability in recovery of albumin spiked in unprocessed WGLF and
incubated at 37°C. Albumin assayed following WGLF processing (a)
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Incubation time at 37°C (mins)
Fig 6.5: Variability in recovery of albumin spiked in unprocessed WGLF and
incubated at 37°C. Albumin assayed following WGLF processing (b)
Proteolysis is assumed by the reduction in detection of albumin.
6.3.1.3 Relationship between protease activity and albumin digestion
For comparison of albumin digestion between WGLF samples a reference
timepoint of 75 minutes was chosen as this is slightly longer than the time required
for colonic transit ofWGLF. Average recovery was calculated for each spike at all
timepoints and the % albumin recovery plotted against time. For each sample
recovery v time data was fitted to an equation using Graphpad Prism (either linear
regression or non-linear regression with exponential decay). The percentage albumin
recovery after 75 mins was then interpolated from this.
A graph ofprotease activity ofUFUPWGLF against albumin recovery at 75
mins gave a straight line relationship with more albumin being digested (lower
albumin recovery) in samples with higher protease activity.
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Association between albumin recovery and WGLF
protease activity
Protease activity of UFUP lavage
(O.D 530nm in Azocoll reaction)
Fig 6.6: Relationship between recovery of albumin in WGLF and WGLF protease
activity
Line fitting by linear regression revealed this association to be significant and
quite tight, with a coefficient of determination of -0.771. WGLF protease activity
therefore gave a good indication as to the likely digestion of albumin during gut
transit.
6.3.2 Stability of C3 in WGLF
The stability ofC3 inWGLF had not been studied in the same way as albumin
because complement fixation might have occured in addition to proteolysis. Also, as
a competition assay was used to quantify C3, it was likely that C3 fragments might
have given increased C3 recovery. In chapter 3 the plot ofC3 detected v protease
activity ofunfiltered unprocessed WGLF was similar to that for albumin (fig 6.6).
This indicated that the quantity ofC3 detected in processed WGLF did depend on the
protease activity in the gut during transit to a similar degree as did albumin. This
relationship was less strong with IgG, suggesting that IgG was more stable in the gut
than either albumin or C3.
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As very little complement was detected in WGLF from non-EBD patients it was likely
that the quantity of complement detected hi the gut represented a true finding rather
than an artifact due to complement fragmentation..
6.3.3 Stability of IgG in WGLF
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Fig 6.7: Recovery of IgG added to unprocessed WGLF after incubation at 37°C
In a recovery experiment with serum IgG added to unfiltered and unprocessed
lavage, 80% ofthe original IgG was still detected after two hrs incubation at 37°C
compared with only 50% for albumin. This confirms indirect evidence that IgG was
more stable than albumin.
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6.3.4 Influence of protein stability and assay performance on RCE
values
From the results of this chapter and that of chapter 3, recovery ofWGLF
proteins was likely to be greatest for IgG > C3 > albumin. AsWGLF albumin is a
critical reference point for the RCE calculation, underestimation of this was likely to
result in falsely raised RCE values. In calculation of the RCE for C3, this may have
been offset by overestimation ofC3 in serum (due to lack ofparallelism between
serum C3 and standard in the competition assay). Care is therefore required in
interpreting RCE results fromWGLF.
6.3.5 RCE Results
TABLE 6.3 WGLF protein concentrations (median and range)
Patient group Albumin
pg/ml
IgG pg/ml C3 pg/ml
CDa (6) 83 (6-150) 27.5(10-161) 12.5(2.7-30.3)
CDi (8) 7.5 (3-15) 2.5 (1-7) 1.3 (0.3-3.1)
UCa (6) 66.5 (22-200) 25 (8-131) 4.6 (2.5-21)
UCi (8) 5.5 (4-6) 1.5 (1-4) 0.4 (0.3-0.5)
non-IBD Gl diseases with no
inflammatory component
(15)
4 (1-13) 1 (1-2) 0.3 (0.3-1.6)
non-IBD Gl diseases with
inflammatory component (8)
6 (1-28) 2(1-7) 0.3 (0.3-2.6)
WGLF IgG was similar in both active CD and UC. It might be inferred that
the severity of inflammation was similar in the two groups. Differences in other
proteins might therefore have reflected differences in the mechanism of the two
disorders. Comparing WGLF C3 in active CD v active CD, no significant difference
hi WGLF C3 was found (P <0.23, Maim Whitney U test). Flowever when WGLF C3
was compared between inactive CD and inactive UC a significant difference was seen
in (P <0.0074). This might implicate complement in the early inflammatory reaction
in Crohn's disease but not in UC.
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IgG RCE C3 RCE
1 6,300 35,000 1,450 12 87 6.7 0.8 1.9
2 11,100 37,000 1,750 36 79 18.2 1.5 4.9
3 15,200 31,000 1,800 161 111 30.3 3 4.7
4 12,100 37,000 900 10 6 2.7 5 18.5
5 16,300 37,000 2,150 56 150 27.2 0.8 3.1
6 10,400 42,000 3,150 19 29 6.1 2.6 2.8



















IgG RCE C3 RCE
7 10,000 47,000 1,950 2 9 1.7 1 4.6
8 12,600 39,000 1,100 2 6 0.3 1 1.8
9 9,960 38,000 1,050 3 5 0.8 2.3 5.7
10 17,500 42,000 1,100 7 15 1.1 1.1 2.8
11 12,600 44,000 2,700 5 11 3.1 1.6 4.6
12 7,810 48,000 2,550 1 9 1.4 0.7 2.9
13 14,400 44,000 2,100 1 4 1.7 0.8 8.9



















IgG RCE C3 RCE
14 8,740 40,000 1,600 14 44 2.5 1.5 1.4
15 16,900 31,000 1,050 129 200 21.0 1.2 3.1
16 15,300 42,000 1,000 8 63 4.2 0.3 2.8
17 10,300 42,000 2,050 131 141 14.5 3.8 2.1
18 13,800 40,000 1,350 26 70 3.5 1.1 1.5
19 17,900 38,000 1,200 24 22 5.0 2.3 7.2
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IgG RCE C3 RCE
20 13,700 41,000 1,250 1 4 0.3 0.7 2.5
21 9,950 41,000 1,100 1 6 0.3 0.7 1.9
22 8,780 46,000 1,400 2 6 0.5 1.7 2.7
23 15,400 41,000 1,300 2 4 0.3 1.3 2.4
24 13,980 39,000 2,000 4 6 0.4 1.9 1.3
25 14,100 45,000 1,300 1 6 0.3 0.5 1.7
26 12,700 43,000 1,100 2 4 0.5 1.7 4.9
TABLE 6.8 Serum protein concentrations
Patient group Albumin mg/ml IgG mg/ml C3 mg/ml
CDa (6) 3.7 (3.1-4.2) 11.6 (6.3-16.3) 1.8 (0.9-3.1)
CDi (8) 4.3 (3.8-4.8) 12.6 (7.8-17.5) 1.9 (1.1-2.7)
UCa (6) 4.0 (3.1-4.2) 14.6(8.4-17.9) 1.3 (1.0-2.1)
UCi (8) 4.2 (3,9-4.6) 13.2 (8.0-15.4) 1.3 (1.1-2.0)
No significant difference was seen in serum C3 between patients with active
CD and those with active UC (P = 0.23), contrasting with the finding by others of
raised serum C3 in CD as a result of the acute phase response (Ross et al, 1979). The
discrepancy was probably due to the wide spread ofmy data and the poor precision
of the assay for C3 in serum. The finding of slightly reduced serum albumin in
patients with active CD as opposed to inactive CD (P = 0.01) could reflect reduced
liver synthesis combined with loss of albumin to the gut.
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6.3.5.1 Relative loss of C3 compared to albumin
TABLE 6.9 RCE for C3 relative to albumin
Patient groups RCE for C3 compare P value
CDi (8) 4.6 (1.8-9) CDi v CDa 0.81
CDa (6) 3.1 (1.9-4.9)* CDa v UCa 0.42
UCi(8) 2.4 (1.3-4.9) UCivCDi 0.06
UCa (6) 2.5 (1.4-7.2) UCa v UCi 0.72
All CD (14) 3.8 (1.8-8.9) All CD vAII UC 0.04
All UC (14) 2.4 (1.3-7.2)
* One outlier with RCE of 18.5 omitted
The RCE values were much higher than the 1.0 predicted to represent protein
loss as a result ofplasma leakage alone. It was likely that underestimation ofWGLF
albumin because ofproteolysis during gut transit was the major factor in this.
If 50% of albumin in the gut was degraded, the apparent RCE would be twice the
expected i.e. a ratio of two may point to serum being the major source of that
protein.
The RCE values obtained for C3 loss in patients with UC patients were just
above two, possibly indicating loss from serum. Patients with CD show a higher
excretion ratio which may indicate that some ofthe C3 lost to the gut was produced
in the intestinal mucosa. The RCE was greatest in inactive CD, prompting the
suggestion that mucosal synthesis ofC3 represents a fundamental metabolic change
in CD and not solely a feature of active inflammation.
In this group ofCD patients, serum C3 was raised and serum albumin depressed
when compared with UC. These would tend to lower the RCE value in CD, making it
unlikely that the finding of raised RCE for C3 in CD was an artifact. The finding that
the RCE was slightly reduced in active CD as compared with inactive might be
explained by increased plasma leakage in active CD. This data supports findings from
segmental perfusion studies ofmucosal complement production in Crohn's disease
(Ahrenstedt et al, 1990).
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Patients with inactive CD secrete pro-inflammatory cytokines to the gut, providing
evidence for a persistent low grade inflammatory process within the mucosa (Arnott
et al, 1997). It is possible that once a threshold level for production of inflammatory
mediators such as cytokines and complement is reached, full blown intestinal
inflammation ensues. In support ofthis hypothesis, those patients with inactive CD
who had greater quantities of cytokines such as IL-1 in theirWGLF had an increased
risk of chnical relapse (Arnott et al, 1998).
In a subsequent chapter, complement in WGLF as a potential predictor of
clinical relapse was considered. A possible mechanism of relapse based on
macrophage production of IL-1 with subsequent synthesis ofC3 is discussed.
Activation complement may produce chemotactic fragments such as C3a which
could attract neutrophils to the gut with inflammatory consequences.
6.3.5.2 Intestinal loss of IgG relative to albumin in patients with IBD
Results are given as median and range and differences between the groups tested by
the Mann Whitney U test.
TABLE 6.10 Comparison ofRCE for IgG in different patient groups
IgG RCE Compare P value
CDi (7) 1.1 (0.7-2.6) v CDa 0.52
CDa (6) 1.5(0.8-3)* v UCa 0.57
UCi (7) 1.2 (0.5-1.9) v CDi 0.79
UCa (6) 1.3 (0.3-3.8) v UCi 0.65
* One outlier with an RCE of 5 has been removed. This same patient had an RCE for C3 of
18.5
The RCE for IgG assessed using WGLF was comparable to the ratio of 1.17
obtained from colonic perfusion ofhealthy subjects (Prigent-Delecourt et al., 1995)
in whom most IgG in the gut would have been expected to be plasma derived
because of the relatively paucity of IgG B-cells.
Patients with IBD have increased IgG plasma cells in the intestinal lamina
propria (Rosekrans et al, 1980) which might contribute to IgG lost to the gut i.e. a
raised RCE. These B-cells produce increased amounts of IgG in active IBD.
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The finding that RCE for IgG was not increased in active disease was therefore
unexpected.
In a previous study using colonic washings a similar comparison between IgG
and albumin in the gut was made and it was concluded that leakage of serum
contributed a relatively low % of IgG found in the washings (Macpherson et al,
1996). This might be explained by their use of the equation:
{(albumin (washings) /(albumin (serum)}/[(IgG (washings)/(IgG (serum)]
If the fraction resulting from this was taken to be the fraction ofgut IgG derived
from serum this is incorrect as the lower term (IgG (washings)/(IgG (serum) actually
gave the proportion of IgG which is mucosally derived.
As it is undisputed that mucosal B-cells produce more IgG in active IBD, it is
difficult to explain these results. One explanation could be that the RCE is a relatively
insensitive indicator ofmucosal protein synthesis when the serum concentration of
that protein is relatively high. A change in the RCE for IgG from 1 to 2 would
require ten times the mucosal synthesis of IgG that would be required with C3 to
produce a similar shift in the RCE value. There may therefore be significant mucosal
synthesis of IgG in active IBD. It would be of interest to know whether production
of IgG is an early event in relapse with the possibility that mucosal IgG contributes to
this. IgG in the gut mucosa is also likely to exacerbate intestinal inflammation via
interaction with complement and Fc receptors of immune cells.
Another explanation for the failure to show a raised IgG RCE in active
disease could be a type 2 statistical error resulting from the number ofpatients
studied being too small.
6.3.5.3 The effect of steroids on the RCE value
Steroids down-regulate mucosal immune responses and this might have influenced
the apparent mucosal contribution to WGLF C3 and IgG, Patients with CD who
were on steroids were compared with those who were not.
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TABLE 6.11 Comparison ofRCE for C3 and IgG in CD patients on steroids v CD
patients not on steroids
Active:
Inactive
RCE C3 P value RCE IgG P value
CD steroids 4:3 4.6 (1.9-18.5) 0.73 1.5 (0.7-5) 0.78
CD non 2:4 3.9 (1.8-8.9) 1.1 (0.8-3)
These results show that the source of IgG or C3 lost to the gut in patients
with CD is unlikely to be affected by whether they were taking steroids
(prednisolone) or not.
6.3.5.4 Day to day variation in the pattern of protein secretion
WGLF protein measurements represent a single 'snapshot' of secretion in the
intestine. It is possible that day to day variation in protein loss to the gut might
account for small differences seen in the RCE between some disease groups. RCE
calculations for IgG based on WGLF results from more than one day were compared.
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TABLE 6.12 Inter-day variation in RCE values for IgG
Patient Day IgG RCE WGLF laG ua/ml
A 1 5.75 14
A 2 5.53 6
B 1 3.81 16
B 2 1.88 8
C 1 2.63 9
C 2 2.63 11
D 1 2.65 19
D 2 2.93 4
E 1 1.37 56
E 2 1.32 61
E 3 1.35 56
F 1 2.52 8
F 2 2.32 24
G 1 1.27 2
G 2 1.86 4
H 1 1.19 37
H 2 0.84 6
Comparing the RCE on day one and two gives:
Day 1 n =8 median RCE = 2.6
Day 2 n =8 median RCE = 2.1 P = 0.75 (Marrn-Whitney U test)
It is therefore unlikely that day to day variation in protein loss had a significant effect
on the RCE for a particular patient. From this, comparison between patient groups
for the RCE taken from a single WGLF appears to be valid.
6.4 Discussion
This study has shown that it is difficult but nevertheless possible to form
conclusions about the source ofproteins lost to the gut when using albumin as a
marker ofplasma leakage. Although the actual RCE values may be inaccurate
because of factors affecting recovery or quantification ofproteins, it may be valid to
compare values in different patient groups.
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Patients with active IBD appeared to lose more IgG to the gut through plasma
leakage than from mucosal synthesis of IgG. This was an unexpected finding since
there are a greatly increased number of IgG producing B-cells in the intestinal
mucosa ofpatients with active IBD. Without having a non biological marker (e.g.
radioisotope) for IgG from serum, it was difficult to identify IgG lost to the gut as
serum or mucosal derived.
The intestinal mucosa ofpatients with IBD contained increased numbers of
IgG B cells, as demonstrated by immunohistochemical study of the colon (Baklien
and Brandtzaeg, 1975). Immunohistochemical studies of the IgG subclasses in the
intestine ofpatients with inactive IBD demonstrated that IgGl B cells were increased
in proportion to their fraction in blood (Iizuka, 1990). These cells might have been
recruited to the intestine during inflammation. They could produce more IgG during
active disease in response to pro-inflammatory cytokines. IgG has the capacity to
exacerbate intestinal inflammation via interaction with Fc receptors and complement.
Loss of complement to the gut has shown a predictable finding of increased
loss in active IBD, reflecting increased loss ofplasma proteins. However, the finding
of raised WGLF C3 in patients with inactive CD but not UC presented an interesting
finding of a difference in the early inflammatory reaction of the two diseases.
Some of this C3 was likely to have been synthesized within the intestinal wall as the
RCE for C3 was raised in patients with inactive CD, supporting previous findings
(Ahrenstedt et al, 1990).
This might support an interesting hypothesis that remission in CD represents a
state of low grade inflammation and that relapse might represent breach of a
threshold level for intestinal production of complement and cytokines. A longitudinal
study ofWGLF C3 in individual patients might yield interesting results, especially if
an increase was seen prior to clinical relapse.
The role of C3 in intestinal inflammation is yet to be elucidated. However, the
finding of increased intestinal C3 without concomitant increased IgG might suggest
that if complement activation was important in relapse ofCD, it might not be
dependent on IgG i.e. the alternative pathway.
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Evidence for this came from the finding that deposition ofC3b on the intestinal
epithelium was not associated with IgG in Crohn's disease (Halstensen et al, 1992).
These results did not allow in depth speculation on the role of complement in
ulcerative colitis. However, as may be the case with CD, increased loss of
complement to the gut in active disease may perpetuate intestinal inflammation
through complement activation. Evidence for intestinal deposition of complement in
ulcerative colitis has shown that C3b was associated with IgG. This may indicate that
the classical pathway of complement activation is involved (Hakstensen et al, 1992).
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CHAPTER SEVEN
WGLF G3 as a predictor of relapse in Crohn's
disease
7.1 Introduction
Crohn's disease is characterized by periods of clinical remission, when
symptoms may be modest and intestinal inflammation resolves, interspersed with
clinical relapse with worsening symptoms and mucosal inflammation. Therapy in
Crohn's disease seeks to prolong the periods of remission and decrease the periods in
relapse. Where inflammation becomes very severe, surgical intervention may be
necessary. There are inherent risks associated with surgery e.g. infection. The risk of
future relapse is also increased following surgery. Earlier detection of relapse might
avert the need for surgery.
Clinical indices based on a physicians assessment ofthe patient e.g., the
Crohn's disease activity index (Best et al, 1976) are not sensitive enough to detect
early signs of relapse. Since this is a measure ofpatient well-being judged on
subjective factors and the number of stools per day it can give a high result even if
there is no evidence of intestinal inflammation, e.g., in patients with intestinal
obstruction or psychological problems. Objective markers of intestinal inflammation
e.g. WGLF IgG (Choudari et al, 1993) have been used to assess disease activity but,
by the time significant changes are seen, the patient may have already relapsed. A
more sensitive indicator is required.
Previous studies have examined serum proteins of the acute phase response in
Crohn's disease. There is a rapid change in the serum protein, C-reactive protein
(CRP) and this might be a useful indicator of relapse. One study has shown that
patients with inactive Crohn's disease who had not relapsed over a one year period
were more likely to relapse in the second year if their CRP remained high over that
time (Boirivant et al, 1988) .
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This study lacked sensitivity as one third ofpatients in remission and one third of
patients with active disease had elevated CRP. Raised CRP can also be increased
during microbial infections and is not specific for relapse ofCrohn's disease. It may
also be more relevant to look for a marker of relapse released from the intestine i.e. is
a direct indicator of intestinal inflammation.
The value of a biological marker in predicting clinical relapse reflects its early
release. In one study, intestinal tissue was taken from surgical resections and found to
contain high concentrations of IgG (Heimann, 1983) pinpointing high tissue IgG as a
predictor of relapse. However, an earlier index prior to requirement for surgery
would facilitate less radical therapy.
7.1.1 Whole gut lavage proteins
IgG
IgG in WGLF has been established as an objective measure of disease activity
by prospective comparison with the CDAI, showing good correlation with the CDAI
in active disease i.e. CDAI >150. The cut off"value for WGLF IgG of 10 pg/ml was
established from a cohort ofpatients with non-inflammatory bowel disorders.
Conveniently, this cutoffvalue corresponded to a CDAI of 150 (Choudari et al,
1993). Of 67 patients with CD(30 active), 8 hadWGLF IgG ofbetween 5 and 9
pg/ml and only one of these showing signs of active disease by a raisedWGLF
albumin. This indicated that WGLF IgG was relatively insensitive for detecting minor
inflammatory changes that may be a prelude to relapse.
7.1.2 Inflammatory cytokines
IL-ip and 11-8
The transient and local nature ofpro-inflammatory cytokines made them ideal
candidates to study as indicators of tissue inflammation. Measuring WGLF
concentrations might reveal early inflammatory events in the intestine.
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IL-1 (3 is produced by macrophages which have taken up foreign material. It is a
pivotal cytokine hi directing the immune response, promoting T-cell proliferation via
up-regulation of IL-2 receptors. It also up-regulates expression of adhesion
molecules such as ICAM-1 on vascular endothelium (Wyble et al, 1996) facilitating
recruitment of immune cells from the circulation to the site of inflammation.
IL-8 is produced by many cell types, including intestinal epithelial cells. It
recruits neutrophils to the site of inflammation as a first line back-up to clear foreign
material by phagocytosis.
Most patients with active CD had high concentrations of IL-ip and IL-8 in
then WGLF, reflecting active inflammation. Some patients with inactive CD also had
raised cytokine concentrations in WGLF, possibly indicating low-grade inflammation
or the onset of relapse. It was postulated that it was these patients who were at
greater risk of relapse.
To test this hypothesis, patients with clinically assessed inactive CD
underwent the gut lavage procedure. IgG, IL-1 (3 and IL-8 were assayed in the WGLF
by ELISA. Patients were then followed-up over a one year period and assessed as
possible relapse (change in symptoms requiring steroid therapy) or as in remission.
Patients were stratified according to the concentration ofWGLF proteins at initial
investigation and the number ofpatients relapsing compared in the high and low
WGLF protein groups.
Those patients with raised pro-inflammatory cytokines in WGLF were at a
significantly increased risk of relapse during the follow-up period (Arnott et al,
1998).
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7.1.3 Increased mucosal permeability and relapse in Crohn's disease
Dr Ian Arnott's work at the unit assessed intestinal permeability in patients
with inactive CD (CDAI <150) by urine excretion of oral administration of lactulose
and rhamnose. A significantly greater proportion ofpatients had raised intestinal
permeability compared with controls i.e. raised intestinal permeability was a feature
ofCrohn's disease (MD thesis, University ofManchester, 1998). The change in
sugar ratio was mainly because of increased permeability to the large lactulose probe,
reflecting increased access to the crypts. This is known to be the main route for
uptake ofmacromolecules.
Increased mucosal permeability might be a logical reason for relapse in CD
because of the increased access of luminal antigen to the mucosal immune system.
Foreign material is taken up by macrophages which are then activated to produce IL-
1(3 and possibly C3. Cytokines such as IL-1 (3 are known to increase vascular
permeability and might further increase intestinal permeability (Burke-Gaffiiey and
Keenan, 1993). Antigens are presented to T-cells, some ofwhich might be activated
to orchestrate an immune response. In the environment of the intestinal mucosa, this
is easily amplified with resultant inflammatory damage to the tissue.
7.1.4 C3 as a potential predictor of relapse in Crohn's disease
In a previous chapter it was shown that some patients with inactive CD
(assessed byWGLF IgG) had raised WGLF concentrations ofC3. In these patients,
WGLF albumin was generally low, possibly indicating that plasma leakage did not
account for all of the WGLF C3 seen.
It is known that cells within the intestinal mucosa can synthesize C3 e.g.,
macrophages (Hetland et al, 1999), (Beatty et al, 1981) or epithehal cells (Moon et
al, 1997), with this being augmented by pro-inflammatory cytokines such as IL-1 (3.
Consequently, it might be expected that WGLF C3 would mirror WGLF IL-1(3 in
predicting relapse ofCD. A mechanism of inflammation involving activation of
mucosal complement might have been a factor in relapse ofCD.
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7.1.5 Aims
The aim of this study was to determine whether WGLF C3 was useful in
identifying those patients with CD in remission who were at high risk of future
relapse; and also to confirm that raised WGLF EL-1 [3 predicted relapse.
The relationship between the role ofWGLF IL-1 (3 and C3 to clinical relapse ofCD
was examined. This has been used to show whether increased mucosal C3 is linked
to raised IL-ip, providing further information about the inflammatory process in CD.
7.2 Methods
7.2.1 Whole gut lavage
Whole gut lavage was performed as described in the thesis appendix, in most
cases as a bowel preparation prior to investigation by colonoscopy. In selecting the
number ofpatients to follow up, previous prospective studies ofCrohn's disease
were considered. Dr Ian Arnott had found that one third ofCrohn's disease patients
relapsed within one year ofgut lavage. We considered fifteen cases of relapse as
sufficient to perform chi square statistics on whether relapse was related to high or
lowWGLF C3. Forty five patients were therefore considered adequate for the study.
7.2.2 Patient follow-up
Patients were followed up until clinical relapse or up to one year post gut
lavage (Dr I Arnott, WGH, Edinburgh).
The patient status was designated as follows:
1) Remission. Not on steroids or immunosuppressives for at least 6 months prior to
assessment.
2) Resection. Major surgical intervention with bowel resection.
3) Immunosuppressives. Either continuation or requirement for azothioprine or
cyclosporin.
4) Relapsing. At least one clear relapse needing the introduction of oral steroid
therapy.
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IL-ip was assayed using a commercially available sandwich ELISA kit
(Cistron Biotechnology, New Jersey, USA). This was performed by Mrs
TLDrurnmond/ Dr I.Arnott as detailed in the chapter appendix.
I have investigated the relationship between WGLF IL-ip and relapse in my cohort
ofpatients to support previous work by Dr Ian Arnott using a separate cohort at an
earlier date (Arnott et al, 1998). This was to compare follow-up between two groups
ofpatients with CD and so validate my cohort for consideration ofmonitoring
disease outcome in relation to WGLF C3.
C3
C3 in WGLF was assayed using the competition ELISA described previously.
Blinding
A blinded protocol of sample identification using identifier numbers rather
than patient name was adopted to prevent bias and analysis performed after follow-up
to prevent clinical assessment bias through knowledge of laboratory parameters.
7.2.4 Patients
There were 42 patients with inactive CD (as assessed by CDAI or were not
appropriate, byWGLF IgG). There was a discrepency with the 43 patients quoted in
the study abstract (British Society ofGastroenterology, Birmingham, 2000). This was
an error and it should have been 42 patients with one patient having been studied on
two separate occaisions. This 33 year old man with ileocolonic disease required
immunosuppressents one year after follow up (WGL 2/8/96).
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However, if the follow-up period had been taken after a second WGL (2/11/96) he
had relapsed within the year. As the numbers for patients relapsing were small, I have
decided to include only the data from this second follow up-period.
A total of42 patients with inactive CD (assessed byWGLF IgG <10 pg/ml)
22 females, mean age 46.7, SD 14.1 yrs
20 males, mean age 52.3, SD 16.3 yrs
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TABLE 7.1 Patients with inactive Crohn's disease who were clinically followed-up










F 32 2 0 dependent 0 N N N
F 50 152 0 dependent 5 Y N N
F 63 316 2 dependent 2.5 Y N N
F 65 44 0 dependent 7.5 N Y N
M 60 31 0 dependent 5 N N N
M 63 366 1 dependent 10 Y N N
M 69 5 0 dependent 10 N N N
M 20 27 0 immunosup 0 Y N N
M 34 New 0 immunosup 0 Y N N
F 28 23 3 lost 0 N N N
F 52 New 2 lost 0 N N N
M 56 95 0 lost 0 N N N
M 80 New 0 lost 5 Y N N
F 20 3 0 relapse 0 N Y N
F 31 56 1 relapse 0 N N N
F 34 143 2 relapse 0 N Y N
F 57 321 3 relapse 10 N Y N
F 57 310 3 relapse 0 N N Y
M 33 32 0 relapse 30 Y Y N
M 34 72 1 relapse 0 N N N
M 36 4 0 relapse 0 N N N
M 37 1 0 relapse 40 N N Y
M 54 250 2 relapse 0 N Y N
F 33 103 0 remission 0 N Y N
F 43 180 0 remission 0 N Y N
F 54 234 0 remission 0 N Y N
F 54 359 2 remission 0 N Y N
F 54 62 1 remission 0 N N N
F 55 316 4 remission 0 N N N
F 59 298 2 remission 0 N N N
F 59 338 1 remission 0 N Y Y
M 53 185 3 remission 0 N Y N
M 58 New 0 remission 0 N Y N
M 62 374 3 remission 0 N N N
M 72 22 0 remission 0 N N N
M 76 14 0 remission 0 N Y N
F 29 58 2 resection 5 N Y N
F 33 118 2 resection 0 N N N
F 67 218 3 resection 5 N Y N
M 42 128 2 resection 15 N N Y
M 51 77 1 resection 0 N N N
M 57 74 3 resection 0 N N N
Pred = prednisolone, Azo = Azothioprine, Immunosup = immunosuppresent, Y = on drug,
N = not on drug
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This table shows that those patients requiring immunosuppressive therapy at the start
of the follow-up period were more likely to relapse. Some patients were new cases.
7.2.4.1 Clinical diagnosis of Crohn's disease
There are four features used to assign a diagnosis of CD:
1) A clinical history of abdominal pain, diarrhoea, nausea or loss ofbody weight
2) Mucosal abnormalities seen radiologically e.g. narrowing of gut lumen or
endoscopically e.g. apthous ulcers, cobblestone mucosa and strictures.
3) Occurrence of fistulae or abscesses.
4) Histological findings including transmural lymphocytic infiltration and the presence
of epithelial granulomas.
At least 2/4 features must be present for a diagnosis ofCrohn's disease to be made.
Several clinicians at the Western General Hospital have been responsible for making
the diagnosis for patients included in this study.
7.2.5 Data analysis
Patients were subdivided on the basis ofWGLF C3 or IL-1(3. Differences in
the frequency ofpatients who relapsed were examined by chi square test and by
Kaplan-Meier survival analysis (Graphpad Prism software) by log rank test.
Associations between WGLF parameters were assessed by correlation (Pearson).
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7.3 Results
TABLE 7.2 Patients who relapsed







20 F 0.6 7 UN 86
31 F 0.3 66 111 132
34 F 2.2 16 249 92
57 F 0.5 21 184
*
57 F 0.4 10 187
*
33 M 0.7 535 81 60
34 M 0.8 38 95 137
36 M 0.8 148 14 103
37 M 0.3 18 101 81
54 M 3.7 37 202 62
UN = patient relapsed but the date at which this occurred was not accurately noted. This
patient was therefore excluded from Kaplan-Meier survival curve analysis.
The CDAI was not assessed in two patients who had subtotal colectomy as bowel function
(number of loose stools) is not meaningful.
TABLE 7.3 Patients remaining in remission





33 F 1 6 86
43 F 1.5 10 85
54 F 2.1 4 75
54 F 0.9 16 124
54 F 1.4 49 136
55 F 0.4 19 NA
59 F 1.3 2 25
59 F 1.4 72 51
53 M 1.1 10 79
58 M 0.6 14 123
62 M 0.7 16 NA
72 M 0.8 18 40
76 M 0.3 9 91
In two cases (NA) the CDAI was not calculated. The first had an ileostomy and the second
had colectomy with major ileal resections.
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TABLE 7.4 Patients requiring surgery
Age Sex WGLF C3
pg/ml
WGLF IL-1 p pg/ml CDAI
29 F 2.1 32 NA
33 F 2.7 36 50
67 F 0.8 19 NA
42 M 0.5 6 65
51 M 1.1 31 NA
57 M 0.3 7 NA
NA = these patients either had coloctomy or ileostomy prior to the study. The CDAI is not an
accurate measure of disease activity in these patients
TABLE 7.5 Patients remaining steroid dependent
Age Sex WGLF C3 pg/ml WGLF IL-1 p pg/ml CDAI
32 F 1 13 133
50 F 1.1 26 149
63 F 1.1 12 134
65 F 1.8 13 102
60 M 0.3 7 81
63 M 0.4 12 41
69 M 3.2 10 102
TABLE 7.6 Patients requiring immunosuppressants
Age Sex WGLF C3 pg/ml WGLF IL-1 p pg/ml CDAI
20 M 1.4 104 79
34 M 0.3 12 44
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TABLE 7.7 Patients lost to follow-up
Age Sex WGLF C3 pg/ml WGLF IL-1 p pg/ml CDAI
28 F 2.7 144 145
52 F 0.5 NA ND
56 M 0.5 29 111
80* M 0.3 6 ND
* Patient died shortly after WGL. The other patients were lost to follow-up
ND data not available
7.3.2 Prediction of relapse in Crohn's disease
Analysis was only performed on those patients who relapsed or remained in
steroid free remission. This kept the data 'clean' since other outcomes may have
indicated that intestinal inflammation is prevented by steroid or immunosuppressive
therapy. Patients requiring surgery have also been excluded from the risk analysis on
the basis that surgery could be required for reasons other than intractable
inflammation e.g., stricturing.
7.3.2.1 WGLF C3 as a predictor of relapse
The median WGLF C3 value for all patients with inactive Crohn's disease
was 0.8 pg/ml (range 0.3-3.7 pg/ml). From this, a high C3 group was designated as
WGLF C3 of>0.8 pg/ml and a low C3 group with WGLF C3 <0.9 pg/ml. The upper
limit of the reference range forWGLF C3 has been set as 0.9 pg/ml. The frequency
of relapse in the two groups was tested by chi square test:
TABLE 7.8 WGLF C3 in patients with different Crohn's disease outcome




WGLF C3 <0.9 pg/ml 8 5 4.0, P = 0.047
WGLF C3 > 0.9 pg/ml 2 8
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There was a significant difference in the frequency ofpatients that relapsed in each
group (P<0.05). As a greater proportion of relapses occurred in the low WGLF C3
group, this indicated that relapse ofpatients with inactive CD was more likely when
the WGLF C3 was low. This appears directly opposite to the expected result,
especially in fight of the earlier finding where WGLF C3 was raised in patients with
active disease compared with inactive disease.
This finding has been supported by comparison of survival curves for time to
relapse in both high and lowWGLF C3 groups by Kaplan-Meier analysis. From the
graph (Fig 7.1) it was clear that those patients with inactive CD who had low WGLF
C3 relapsed more quickly. Comparing this difference by log rank test gave a small
significant difference between the survival curves with a 4.2% chance ofbeing
random. Although this was a relatively weak link, it would indicate that low WGLF
C3 was a predictor of relapse in patients with inactive Crohn's disease.
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Fig 7.1: Crohn's disease outcome in patients stratified according to WGLF C3
The final point on tire graph at time to relapse = 365 days represents patients who remained
in remission throughout the follow up period.




Relative risk = 4.4
—- WGLF C3 <0.9 pg/ml
(n =12)
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Ill the patients who relapsed, there was a significant, inverse correlation
(Pearson, r = 0.52 P <0.05) between WGLF C3 and time to relapse.
Sensitivity and specificity
The sensitivity ofWGLF to predict relapse = % of true positives
TP = true positive (number that relapse after lowWGLF C3)
FN = false negatives (relapse after raisedWGLF C3)
sensitivity = |TP/(TP+FN)} x 100
= (8/(8+2)} x 100 = 80%
specificity = % of true negatives
TN = remain in remission after raised WGLF C3
FP = remain hi remission after low WGLF C3
specificity = (TN/(TN+FP)} x 100
= (9/(9+4)} x 100 = 69%
Positive predictive value of low WGLF C3 to predict relapse = % ofpatients with
low C3 who do relapse
positive predictive value = (TP/(TP+FP)}
= (9/(9+2)} = 67%
To assess whether low C3 was a selective predictor of relapse in CD, a
relative operating characteristics curve was required. Patients were divided into those
who relapsed against those remaining in remission from all possible WGLF C3 cut¬
offvalues from the two data sets (0.3-3.7 pg/ml). Sensitivity was given by the
number ofpatients relapsing with C3 equal or below the cut-off divided by total
relapses. Specificity = patients remaining in remission with C3 above the cut-offvalue
divided by total in remission. The false positive rate = (1-specificity) and this was
plotted on the x axis v sensitivity on the y for all cut-offvalues selected. A diagonal
fine from zero sensitivity to 100 % specitivity and sensitivity gave the situation for a
test with random characteristics where it is equally likely to get a false as a true
positive result. Any test with a curve above that line had some ability to give true
positive results.
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At a C3 concentration of 0.9 fig/ml the line was at it greatest distance above the
random line, demonstrating that the WGLF C3 test is at it's most sensitive to predict
relapse at the cut-offvalue selected for Kaplan-Meier analysis.
Relative operating characteristic curve for WGLF C3
to predict relapse v remission in inactive Crohn's disease
1.0-




= true positive rate
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Fig 7.2: relative operating characteristic curve forWGLF C3 to predict relapse as
opposed to remission in patients with inactive Crohn's disease
The area under the curve was 0.66 (calculated using Graphpad Prism). This
means that 66 % of the time, WGLF C3 values below a cutoffvalue predicts relapse
as opposed to remission at one year follow-up ofpatients with inactive Crohn's
disease. This is a weak predictive parameter that is unlikely to be useful in the clinical
setting.
7.3.2.2 Relationship between IL-ip and relapse
The median WGLF IL-1p value for all patients with inactive CD was 16
pg/ml (range 2-535 pg/ml). Patients with a clinical outcome including relapse or
steroid free remission were assigned to a low WGLF IL- ip (up to 16 pg/ml) or a
high EL-ip group.
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From a population ofnon-inflammatory gastro-intestinal hospital patients and healthy
volunteers, the upper 95th percentile ofWGLF IL-1 (3 was 12 pg/ml. This is assigned
as the upper limit of 'normal' . In this group ofpatients with inctive CD, I have
selected a value of 17 pg/ml to give approximately equal numbers ofpatients in the
IL-1(3 high and low groups. Testing the frequency of relapse in the EL-ip high and
low groups gave
TABLE 7.9 WGLF IL-1P in patients with different Crohn's disease outcome




WGLF IL-ip < 17 pg/ml 2 8 4.7, P =0.030
WGLF IL-1p > 17 pg/ml 7 4
There was a significantly greater proportion ofpatients relapsing in the group
who had high IL- ip. Kaplan-Meier survival analysis shows that those patients with
high WGLF IL- ip relapsed more quickly. When the difference between the curves
was analyzed by log rank test, a significant difference in the relapse rate is seen with
only a low chance (1.8%) of this being random. Consequently, high WGLF IL-ip
does predict relapse in Crohn's disease, confirming previous results (Arnott et al,
1998). The relative risk was similar to that observed previously with a larger patient
group of 70 patients. .
178










Relative Risk = 5.4
o>
a
Q. WGLF IL-1 17 pg/ml or >
(n =11)
25
0 100 200 300 400
Days to relapse
Fig 7.3: Crohn's disease outcome in patients stratified according to WGLF IL-1
Sensitivity and specificity
A cut-offvalue of 16 pg/ml forWGLF IL-1 (3 was used to give equal numbers
in the EL-1(3 high and low groups. This prevents a possible bias caused by a chance
occurrence of a high proportion of a particular outcome in a small group for IL-1 (3.
Previously, a cut-off of 12 pg/ml (from the reference range) had been used. Using this
new cut-off, a sensitivity of 70% forWGLF IL-1 (3 to predict relapse as opposed to
remission was observed. The specificity for raised IL-1 (3 to predict relapse was 75%
and the positive predictive value was 64%. Compared to previous results the
sensitivity is lower but the specificity and positive predictive values are higher. There
was one patient with a borderline WGLF IL-1 (3 of 16 pg/ml who relapsed whereas
3/13 patients in remission had WGLF IL-1 (3 ofbetween 12 and 16 pg/ml.
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7.3.3 WGLF C3 in patients who remained in steroid dependent
remission
Patients requiring steroids thoughout the follow-up period to remain in
remission show similar concentrations ofWGLF C3 to those who remained in steroid
free remission.
TABLE 7.10 WGLF C3 in steroid dependent v hidependent remission ofCD
patient group WGLF C3 pg/ml, median
and (range)
P (Mann Whitney U test)
Steroid dependent 1.1 (0.3-3.2) 0.85
Steroid free remission 1.0 (0.3 -2.1)
Those patients with inactive CD who had raised WGLF C3 were more likely to
remain in remission. These patients had normal concentrations ofWGLF albumin,
and so plasma leakage was unlikely to be the source of this complement. This may
indicate local biosynthesis ofC3.
7.3.4 Correlation between WGLF C3 and IL-ip in follow-up patients with
inactive Crohn's disease
To investigate whether there was a link between WGLF C3 and IL-10, correlation
(Pearson) was used.
1) In patients who relapsed (n =10) r = -0.116
2) In patients who had remained in remission (n =13) r = 0.14
3) In all inactive Crohn's disease patients (n = 42) r = 0.023
There was no association between WGLF C3 and IL-1P in patients with inactive
Crohn's disease.
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7.3.5 Comparison of CDAI values
TABLE 7.11 Comparison ofCDAI values in CD patients prior to one year follow-
up. Patients assigned to groups of disease outcome
CDAI (median
and range)
P value (compare to remission)





Relapse (8) 89 (60-137) 0.41
No significant difference in initial CDAI value was seen in the different CD disease
outcome groups. Disease outcome was therefore unlikely to have been related to
their disease activity at the start.
7.3.6 Do the high relapse risk group show increased loss of plasma
proteins to the gut ?
Increased intestinal permeability is a risk factor for relapse in CD. In active
intestinal inflammation there was greater leakage ofplasma proteins to the gut,
reflecting increased intestinal permeability.
The association between raised WGLF IL-1(3 and loss ofplasma proteins (IgG and
albumin) was assessed in patients with inactive CD who either relapsed or remained
in steroid free remission.
TABLE 7.12 WGLF IgG in patients with different Crohn's disease outcome
Patient group WGLF IgG gg/ml (median and range) P (Mann-Whitney U)
Relapsed (n =10) 2 (1-8) 0.93
Remission (n =13) 3(1-8)
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TABLE 7.13 WGLF albumin in patients with different CD outcome
Patient group WGLF albumin pg/ml (median and range) P
Relapsed (n =10) 7 (2-21) 0.8
Remission (n =13) 8 (1-21)
This might indicate that a pre-clinical inflammatory state exists in the intestine
of some patients with inactive CD. This was characterized by increased production of
pro-inflammatory cytokines and increased epithelial permeability but not increased
vascular permeability as seen in active disease. Increased loss ofC3 to the gut
indicates that the epithelium must be permeable to large rnacromolecules (mw 180
Kd). If albumin (mw 69 Kd) was able to cross the vascular endothelium, then it was
likely that it could cross the intestinal epithelium. The finding ofvery lowWGLF
albumin suggests that the vascular endothelium was not permeable to
macromolecules.
7.4 Discussion
This study has shown that the risk of relapse in patients with inactive Crohn's
disease is linked to the concentration of inflammatory proteins in WGLF. My results
for WGLF IL-1 (3 confirm previous findings in this laboratory (Dr I.Arnott, MD,
1998). This demonstrated that the cohort ofCD patients studied did not behave in an
unexpected manner.
I have used a slightly higherWGLF EL-1 (3, cut-offvalue than did Dr Ian Arnott with
his cohort. This give a relative risk for the patients with raised EL-1(3 to relapse of 5.4
as compared with 5.8 from Dr Arnott's work. This finding supports the hypothesis
that remission in Crohn's disease is a condition of low grade inflammation and that
relapse occurs when mucosal concentrations of e.g. inflammatory cytokines reach a
threshold level.
This finding may be useful in the context of a clinical trial where it may be
important to have a group ofpatients 'at risk' of relapse in order that the efficacy of a
treatment to maintain remission can be tested.
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Because the patients studied were chosen on the basis ofhaving had a whole gut
lavage, it is likely that these patients had some symptoms to warrant endoscopic
investigation and so might have been at a greater risk of relapsing than the Crohn's
disease population as a whole.
It was expected that raised WGLF C3 would be a risk factor for relapse
because loss ofC3 from plasma would reflect intestinal inflammation as might
intestinal synthesis ofC3. The finding that lowWGLF C3 predicts poor outcome in
CD was paradoxical. As no correlation was seen between WGLF IL-1(3 and C3, the
role of C3 in relapse does not appear to be simple. Of ten patients with inactive CD
who relapsed during twelve month follow up, two who had raised WGLF C3 might
have been predicted to relapse on the basis of raised WGLF EL-1(3. Two patients with
normal WGLF IL-1(3 relapsed but had lowWGLF C3 that might have predicted this.
WGLF IL-1P and C3 therefore appear to work separately as risk factors for relapse
in Crohn's disease.
It is possible that failure to detect complement in WGLF does not mean that
complement is absent from the intestinal mucosa. It may be that complement is
activated and deposited on host intestinal cells in some patients. This would be more
likely to result in inflammatory damage to the intestine than complement which
simply oozed out of the mucosa. It is possible that complement plays a protective
role e.g., by clearing immune complexes and dying cells. In this scenario, detection of
complement in WGLF might indicate sufficient complement within the intestinal
mucosa to perform this role. Some patients with lowWGLF might have rapid
complement consumption in the intestine. In these patients low WGLF complement
might indicate intestinal inflammation and increased risk of relapse.
A local inflammatory reaction within the intestine might result in recruitment
of inflammatory cells such as neutrophils. When these cells have performed their
function of removing antigen, they die by apoptosis (programmed cell death). These
cells must be removed to prevent their deposition in the tissues, with potential release
ofpowerful enzymes and reactive oxygen species.
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Evidence for a role of complement in apoptotic cells comes from the finding that
expression of decay activating factor is reduced on apoptotic neutrophils in culture
(Jones and Morgan, 1995). It had been shown that apoptotic Jurkat cells (a T-cell
line) were able to bind C3b when incubated with serum (Matsui et al, 1994).
Deposition of iC3b upon apoptotic cells improved their uptake by macrophages
(Takizawa et al, 1996). Complement receptor 3 on macrophages has been shown to
be responsible for uptake of complement coated apototic cells by using the gene for
this receptor in cell transfection studies (Mevorach et al, 1998). A shortage of
complement (or an excess of apoptotic cells) may result in failure to remove
apoptotic cells from the intestine with release of cytotoxic agents and resultant tissue
damage.
The possibility that WGLF C3 was low in some patients because of
consumption associated with removal of apoptotic cells may be investigated by
counting apoptotic cells in biopsy specimens and staining of deposited C3 by
immunohistochemistry. In active IBD, leakage ofplasma C3 into the intestinal
mucosa might supply more than is required for opsonization of apoptotic cells. The
excess may be detected in WGLF.
Macrophages and intestinal epithelial cells have been shown to be capable of
producing C3. EL-1 appears to be a key cytokine involved in upregulating production
of complement by these cells (Moon et al, 1997), increasing both mRNA expression
and protein secretion. Later studies with transfected cells or inhibitors ofNF-KP have
shown that nuclear factor Kp is involved in the upregulation ofC3 synthesis by IL-1.
Macrophages produce EL-1 in response to phagocytosing foreign material. As EL-1
stimulates C3 synthesis, this might assist in removal of antigen. However, several
inflammatory cascades are linked to activation ofNF-Kp.
Intestinal production of IL-1 therefore has the potential to be inflammatory.
It would be of interest to look at macrophage expression ofNF-KP in intestinal
biopsy specimens from patients with IBD and also to detect rnRNA for C3 in these
spechnens. There may well be a correlation between WGLF IL-1 and C3 mRNA
expression.
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One explanation for lowWGLF C3 predicting relapse in CD could be that these
patients allready require immunosuppresents at the start ofthe follow-up period.
These agents might inhibit production of complement in the intestinal mucosa, giving
rise to a low WGLF C3. The requirement for immunosuppresents indicates that
abnormal inflammatory events are underway within the intestinal mucosa and that an
unknown event could trigger excerbation of this with subsequent relapse.
WGLF C3 is unlikely to be used as a tool for predicting relapse in CD
because low C3 is found hi most subjects without EBD. The study has ignored those
patients who had surgery during follow-up and yet this is a more important outcome
to predict than relapse. However, the findings have pointed to other mechanisms for
the inflammatory process in CD, with potential for further study.
These studies have demonstrated that complement is detectable in WGLF and
this may be a useful technique with which to study the immunological mechanisms of
intestinal disease. Whilst these findings may have some clinical relevance, this would
require a more rigorous clinical study. As a Ph.D student with a biochemistry




8.1 Detection of proteins in intestinal secretions
Whole gut lavage has been shown to contain proteins secreted from the
intestinal wall. The procedure is used routinely in preparation of intestinal
investigation of some patients and so lends itself to comparison ofprotein secretion in
different patient groups. With the WGL technique, protein secretion into the
intestinal lumen has been shown to be at a steady-state over a limited timespan. This
may allow comparison ofprotein secretion with that using other, more invasive
methods of intestinal perfusion. However, WGLF contains demonstrable protease
activity, which is very likely to influence protein recovery. Unfortunately, previous
studies ofWGLF proteins have not investigated protein recovery. To validate this
work and my own it has been necessary to investigate the structural integrity of
WGLF proteins and how this influences their quantification.
It was decided to investigate the structural integrity of immunoglobulins in
WGLF because they are present hi detectable quantities and are directly relevant to
the immune function ofthe intestine. Using a combination of column chromatography
and electrophoresis to separate intact from fragmented WGLF immunoglobulin, it has
been shown that IgG and IgA are mostly intact. Antigen specific antibodies are
therefore likely to be detected by capture ELISA and furthermore, total
immunoglobulins may be accurately quantified by sandwich ELISA using anti heavy
chain total immunoglobulins. Incubation ofunprocessed WGLF at 37°C results in
reduced immunoglobulin detection, my inference from which is that immunoglobulin
fragments are not detected by sandwich ELISA.
These results vahdate WGLF as a source of intact intestinal immunoglobulins,
supporting pubhshed results for detection of immunoglobulins in WGLF. However,
different proteins may show varying degrees of resistance to proteolysis.
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Immunoglobulins are relatively resistant because of their tight folded domain
structure which protects them from the active site ofproteolytic enzymes. Other
proteins such as albumin are more rapidly degraded in unprocessed WGLF. These
proteins may be underestimated in WGLF, reducing the value of quantitative results.
These findings have now lead to validation ofprotein recovery in WGLF before use
of that parameter in clinical studies e.g., with insulin-like growth factor-1, a cytokine
involved in intestinal fibrosis in CD (Ghosh et al, 1997).
8.1.1 More recent work with WGLF
More recent work at the GI lab has compared protein secretion in ileostomy
effluent (EE) to that inWGLF from the same patients. From the finding that daily
protein loss calculated fromWGLF was much greater than that calculated from EE it
was concluded that the high intraluminal flow during the WGL procedure stimulates
protein secretion (Croft and Ferguson, 2000). If this was true, it may invalidate all
results with WGLF. However, I believe there is flawed logic in that the output of
ileostomy fluid is not constant during the day and so calculation of daily protein
secretion from a single specimen is likely to be inaccurate. Secondly, the transit time
for the ileostomy effluent may be greater than during the gut lavage procedure.
Proteolysis during gut transit is therefore likely to be greater with IE. Protein
recovery in IE compared with WGLF was greatest for IgM, a protein which is less
resistant to proteolysis than other proteins. This suggests that protein recovery in IE
relative to WGLF was dependent on resistance of the protein to proteolysis.
Sami Hoque at the GI unit has used WGLF to demonstrate that intestinal
immunity in healthy volunteers from Dhaka, Bangladesh differed from that in subjects
from Edinburgh, UK. He showed that WGLF from the Dhaka individuals had higher
total IgA, IgA to lipopolysaccharide core antigens ofgram negative bacteria and
eotaxin, a chemoattractant of eosinophils. Conversely, WGLF from the Edinburgh
individuals contained higher levels of antibodies to food proteins.
The hypothesis from this is that where the intestinal immune system needs to
keep out high levels ofbacteria (from dirty drinking water), IgA antibodies to those
bacteria are produced by the intestine.
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However, because immune capacity in the intestine is stretched, antibodies to food
antigens are not produced to the same degree. One outcome of this is that the
strategy for mucosal vaccination e.g., against enteric infections such as rotavirus may
need to be adjusted for different regions of the world (Hoque et al, 2000).
Outside the GI lab, there are two quotations for measurement ofproteins in
WGLF from humans. In the first, radiolabeled chromium-EDTA was included hi the
ingested fluid as a marker of intestinal permeability. The percentage ofthe marker
appearing in urine was measured. This was correlated with the intestinal excretion of
calprotectin, a neutrophil marker which was quantified in WGLF by ELISA. Both
intestinal permeability and excretion of calprotectin were higher in patients with IBD,
levels were relative to the disease activity in CD. A strong correlation between the
two parameters was seen as evidence that increased intestinal permeability might be
caused by increased migration ofneutrophils (Berstad et al, 2000).
It might alternatively be the case that an increase in intestinal permeability
caused by something else results in increased migration of neutrophils to the gut in
response to chemotactic stimuli. Neutrophil migration to the gut is an early indication
of relapse in IBD. An advantage ofusing WGL in this type of study is that because of
the shortened transit time, the patient has reduced exposure to the radiolabeled
marker.
The second paper looked at detection of telomerase activity in patients with
colerectal carcinoma. Telomerase is an enzyme which replaces the protective cap at
the ends ofthe chromosomes. In most adult cells this enzyme is not expressed and
this cap is shortened at each round of cell division. This limits the number of times
that cells can divide. Cancer cells do express telomerase and this allows them to
divide repeatedly. Patients with colorectal cancer had detectable WGLF telomerase
whereas normal subjects did not. WGLF was used because it has been technically
difficult to detect telomerase activity in faeces (Ishibashi et al, 1999).
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WGL continues to be used in animal studies of intestinal immunity where problems of
patient number or heterogeneity are less troublesome e.g., in a study of J-chain
knockout mice, it was shown that protection against cholera toxin was abrogated
(Lycke et al, 1999). It may well have continued research/diagnostic use in humans
where the analyte of interest shows poor or variable recovery in faeces.
WGL as a method for obtaining intestinal contents for biochemical analysis is
inflexible in that it can only be performed 011 patients who require bowel cleansing
prior to further investigation. Despite drinking ofKlean-Prep being well tolerated in
most subjects, it does cause uncomfortable bloating and distension of the stomach.
From personal experience I would not like to undergo gut lavage again if it were just
for biochemical tests.
However, in those patients undergoing gut lavage for bowel cleansing, it is
relatively easy to collect specimens for analysis. As the material is liquid it is easier to
process and proteases inhibitors are added within fifteen minutes of sample
collection, reducing further proteolysis. Despite between patient variation in the
protease activity of intestinal contents, the similarity in transit time during the gut
lavage procedure may reduce biological variation in protein recovery due to
proteolysis. It is also possible to assess protein secretion over a short time-period by
collection of subsequent liquid stools. This may improve the sensitivity of comparing
intestinal protein loss between patients. This comes with the proviso that secretion of
proteins into the gut during high flow rate perfusion is unlikely to be the same as
under physiological conditions.
In contrast, collection of faeces is simple and non-invasive. However, before
it is suitable for biochemical analysis, proteins of interest must be extracted. This may
involve breaking the faeces up into a suspension with a buffer, followed by
clarification of the supernatant by centrifugation. Protein secretion can be assessed
using faeces but this requires collection of all faeces passed over the course of a day.
It is difficult to make sure that the patient retains all specimens and to process each
specimen as it is supplied. Faecal protein concentrations can be compared between
patients but the faecal water content needs to be estimated. The major drawback with
faeces is the wide variation in transit time and hence proteolysis during transit.
189
Despite this, some proteins such as the granulocyte marker calprotectin are resistant
to proteolysis. Faecal calprotectin was found to be a useful marker of intestinal
inflammation which was predictive of relapse in EBD (Tibbie et al, 2000). The
gastrointestinl laboratory in Edinburgh have since been using this test.
8.1.1.1 The source of proteins secreted into the gut
It is impossible to identify the secretion source of a particular protein in the
GI tract and this is one ofthe major drawbacks ofWGLF. However, since some
proteins such as IgG are secreted in increased amounts in patients with intestinal
inflammation (active IBD), it is reasonable to assume that those parts of the intestine
which are inflamed should be the sites where these proteins are secreted. The sites of
intestinal inflammation can be identified using endoscopic or radiological
procedures.
8.1.2 Do proteins lost to the gut in patients with intestinal inflammation
reflect alterations in mucosal biosynthesis or plasma leakage ?
The WGLF concentrations of IgG and C3 (which might be produced in the
intestinal wall) were compared to that of albumin (which is serum derived). To
control for the concentration gradient between serum and the intestinal lumen,
WGLF proteins were first compared relative to their serum concentrations before
comparing this ratio to that for albumin. Because of the relative instability of albumin
in the gut, it has been necessary to control for differences in albumin recovery in
several ways.
1. Only patients with intestinal inflammation restricted to the colon where examined,
thus minimizing the time of exposure of albumin to gut proteases.
2. The rate of intestinal perfusion (drinking polyethylene-glycol perfusate) was
strictly controlled to reduce variation in this.
3. Protease activity was measured in unprocessed WGLF. The use ofWGLF
albumin as a marker ofplasma leakage was restricted to those patients without
extremes ofWGLF protease activity.
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The relative coefficient of excretion ratio which compares the intestinal relative to
serum concentration for a protein as a ratio compared to the same comparison for
albumin, a marker of serum leakage, was developed for study of intestinal protein
secretion in healthy individuals (Jonard et al 1994). They used perfusion of an
isolated jejunal segment which is likely to reduce proteolysis of secreted proteins as
duodenal contents (containing digestive enzymes) were excluded from the perfused
segment. Consequently it is likely that their results show greater recovery of albumin
in the intestinal perfusate than is the case with WGLF. As the serum component is
underestimated in WGLF this bias tend to give RCE values greater than one i.e.
greater protein secretion into the gut than is attributable to leakage from serum alone.
In light of this, it was very surprising to find that my results for intestinal loss
of IgG in patients with active IBD did not provide evidence for greatly increased
mucosal synthesis. In active IBD, the number of IgG producing cells in the intestinal
mucosa are increased many fold and so it would be expected that the RCE for IgG
would be increased. Two explanations for this finding are 1) in the undamaged gut,
movement of serum proteins into the gut lumen is dependent on the size of the
protein because of the small size ofpores in the vascular endothelium ofmucosal
blood vessels. In contrast, inflammation in the intestine causes these pores to be
opened up and protein movement is then dependent on the concentration gradient
between the blood and the intestine. As this concentration gradient is high for IgG
(with a serum concentration of 15 g/1) it may be that the quantity of IgG which leaks
from serum is in excess of that which can be produced by the intestinal mucosa.
Consequently, despite massively increased mucosal synthesis of IgG, the RCE value
does not reflect this. 2) There was some difference in the IgG RCE between inactive
and active disease and the reason for this not reaching statistical significance may
have been a type 2 statistical error where there are not enough observations.
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In contrast, the RCE values observed with C3 were raised in patients with CD.
WGLF C3 was also raised in active ulcerative colitis but in this case it could not be
said that the RCE was definitely raised above that which indicates that intestinal C3 is
mostly serum derived. This may indicate greater mucosal synthesis ofC3 in CD
compared to UC.
As the serum concentration of C3 is much lower than that of IgG it is likely
that mucosal synthesis ofC3 needs to be raised to a lesser degree than does IgG
synthesis in order to register a raised RCE. This pinpoints a flaw in using the RCE
ratio to assess the source ofWGLF proteins in patients with intestinal inflammation
where the mechanism ofprotein loss to the gut is likely to be different to that in
individuals with an intact intestinal barrier.
The finding that some patients with inactive CD have raised WGLF C3
without raised WGLF albumin further supports the hypothesis that C3 is synthesized
in the intestinal mucosa. As the molecular weight for albumin is one third of that for
C3 this finding would indicate that was produced in the intestinal mucosa, the finding
that there is increased epithelial permeability without increased mucosal vascular
permeability. Increased permeability of the intestinal epithelium would increase the
interaction between the mucosal immune system and luminal antigen, potentially
resulting in an intestinal inflammatory response.
This may be an over-simplification because the intestinal mucosa is not a fluid
bag bordered by two permeable membranes (the vascular endothelium and the
intestinal epithelium). The lamina propria contains cells and extracellular matrix
which might restrict diffusion ofproteins to the intestinal epithelium. Interaction with
cells and the extracellular matrix by some proteins such as C3 and IgG may initiate
inflammatory reactions. During inflammation it is likely that macrophage
metalloproteinase activity results in a more fluid extracellular matrix.
8.1.3 WGLF C3 as a predictor of relapse in Crohn's disease
The finding that WGLF C3 was slightly raised in patients with inactive CD
supports the hypothesis that remission may be a subclinical state of intestinal
inflammation.
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AsWGLF C3 is further increased in active CD, it is possible that C3 contributes to
an inflammatory process involved in the switch between low-grade and pathological
inflammation. To test this hypothesis, patients with inactive CD were followed up for
a year after the whole gut lavage procedure. Disease outcome was compared in
patients stratified according to their WGLF C3. Paradoxically it appeared that those
patients with lowWGLF C3 were at greatest risk ofrelapse. From the literature, two
possible hypotheses could explain this finding.
1. Complement activation and deposition on intestinal tissues may consume C3,
reducing the quantity detected in WGLF. A falsely negative WGLF C3 result
would therefore be seen in those patients at greatest risk of an escalating
inflammation of the intestinal mucosa.
2. C3 may be consumed in a protective role in removal of apoptotic cells by
macrophages. Deposition of apoptotic cells in the tissues may release enzymes
and other potentially inflammatory agents, ft might be worth counting apoptotic
cells in mucosal biopsy specimens from patients with 1BD e.g, by using Hoescht
nuclear staining.
Immunological detection of complement fragments in WGLF gave an incomplete
picture as it was shown that WGLF C3 is incapable of fixation. It is not known
whether C3 activation has occurred within the intestinal mucosa or, in the gut lumen.
Macrophages have been indicated as a possible source of intestinal C3. More
recent work has used insitu hybridization to demonstrate the presence ofmRNA for
C3 in macrophages of the submucosa in patients with CD (Laufer et al, 2000). These
macrophages were CD68 positive which suggests that they are recruited from blood.
The crypt epithelium also contained C3 roRNA and this correlated with the presence
ofulceration and polymorphonuclear leukocytes in the intestinal lumen. This may
indicate that generation of chemotactic fragments of epithelial complement is
responsible for chemotaxis of reactive neutrophils.
From this, it is likely that any future study ofproteins in WGLF might be used
as a pilot study prior to using more sophisticated techniques.
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8.2 Animal models of IBD
Study of the immunological mechanisms involved in inflammatory bowel
disease by biochemical measurements from patients has two main problems: firstly
that it is difficult to know what stage of the inflammatory cascade the analysis is
detecting. Unless patients can be strictly monitored following their first episode it
may not be possible to pick up early events. In many cases, relapse/exacerbation of
the disease is detected. It is unlikely that patients having their first episode of IBD
can be efficiently recruited into studies because their diagnosis is not usually made
until much later.
Secondly, genetic and environmental differences between patients may influence the
severity/ nature of the inflammatory response, making it difficult to make conclusions
from detection ofparticular agents. One way around these problems is to use an
animal model of IBD.
IBD is a complex disorder with multiple manifestations. Not surprisingly no
single model encompasses all the features ofhuman IBD. The morphology of the
intestinal wall and it's immune cells is likely to differ between species. In addition, the
variable genetic background/ environment in the human population may contribute to
some of the features of IBD which only appear in some patients e.g., fistulae in CD.
A single strain of animal may not develop some ofthese features under any treatment
regimen. Nethertheless, the four different types of animal model have contributed to
our understanding of some of the pathophysiological features of IBD.
8.2.1 Spontaneous models
Cotton top tamarin
This is one of the best models of colitis as the disease spontaneously develops
in monkeys exposed to a normal gut flora. The disease follows a course of
relapse/remission which mimics human UC. (Madara et al, 1995)
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C3H-HeJBir mouse
This is an inbred strain which is prone to colits (Sundberg et al, 1994)
Inflammation is characterized by strong T-cell responses to common bacterial
antigens. The cytokine profile is high EFN-y and low IL-4 i.e. Thl. On transfer of
CD4+ T cells to immunodeficient mice, these develop colitis. Restricted V beta usage
suggests limited bacterial e.g, involved (Cong et al, 1996). Before transfer show no
signs of disease (regulatory cells present) CD45RB transfer- IL- 10/TGF-p
regulatory cells (Powrie et al, 1996)
8.2.2 Induced models
8.2.2.1 Models involving administration of exogenous agents
Enema
1) TNBS
TNBS (trinitrobenzene sulphonic acid) in combination with ethanol induces
cohtis characterized by a CD4+ T-cell infiltrate ofthe colonic mucosa. Pre-treatment
with antibodies to CD4 prevents development of the disease. TNBS is a contact
sensitizer which, if given orally without ethanol can induce oral tolerance. Use ofthe
TNBS/ethanol enema then gives reduced inflammation characterized by up-regulated
mucosal TGF-P and IL-10 and decreased EFN-y. TGF-P was shown to be responsible
for the protective effect by a worsening of disease following blocking antibodies.
Suppressor T-cells are believed to produce the anti-inflammatory cytokines EL-10 and
TGF-P but these cells may be less effective in inflammatory states were oral tolerance
may be abrogated (Neurath et al, 1996).
2) Acetic acid enema
In rats this results in acute inflammation of the colon with transient up-
regulation ofmacrophage cytokines e.g, TNF-a. Messenger RNA for these cytokines
returned to normal levels when the intestinal histology also reverted to normal. This
model is criticised because of its transient non-chronic nature and there is no evidence
for T-cell involvement as evidenced by levels of IL-2, DL-4 or IFN-y (reviewed by
Abreu-Martin and Targan, 1996)
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Oral administration
Dextran sodium sulphate (DSS)
When in introduced into the drinking water of rodents this causes an acute
colonic injury. On removal ofDSS colonic regeneration begins but a chronic colitis




This agent produces a granulomatous enterocolitis chacterized by T-cells.
Inflammation did not develop in athymic rats(Sartor et al, 1993). Inflammation could
be reduced by treatment with recombinant IL-10. This is also the case in CD.
8.2.2.2 Gene targeting: Knockout or transgenic
IL-2 -/- knockout mice
It is difficult to understand why lack ofEL-2 (required for T-cell proliferation)
should produce colitis. It is possible that other mechanisms are involved in regulating
T-cell responses in inflammation or that regulatory T-cells are down-regulated.
IL-10 -/- knockout mice
This is a model for CD as there is a dominant Thl type immune response in
this disorder. EL-10 usually counter-balances this. There is evidence that up-regulated
Tit 1 mediated immune responses in the gut might be directed against luminal bacteria
as there was no colitis under germ free conditions (Kuhn et al, 1993).
TCR a -/- knockout mice
These develop colitis dependent on whether a normal gut flora is present.
Inflammation is characterized by T-cells with a restricted clonality, possibly indicating
that immune responses are against a common bacterial antigen (Takhashi et al, 1999)
N-Cadherin dominant negative mice
This is a model to investigate the role of the intestinal barrier in IBD. N-
Cadherin is an integral part of tight junctions and this is dysfunctional in these mice.
The mice develop UC-like inflammation, possibly because of increased exposure of
immune cells in the intestinal wall to luminal contents. (Hermiston et al, 1995).
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8.2.2.3 Transfer of cells into immunodeficient animals
CD4+CD45RB1" T-cells into SCID or RAG knockout mice
Transfer ofnaive T-cells into immunocompromised mice results in
inflammation characterized by Thl T-cell responses with production ofTNF-a driven
by IL-12 or EFN-y (Fuss et al, 1998). Although memory T-cells also contained some
reactive T-cell clones, ifmemory cells were transferred with naive T-cells, no colitis
was seen (Claesson et al, 1999). This suggests that the memory subset contains
counter regulatory T-Cells which may produce IL-10 (Assesman et al, 1999) and
TGF-beta. In many spontaneous/induced models, hidden environmental or genetic
factors must be present for inflammation to occur. Some of gene targeted models
require particular bowel flora etc.
Effector mechanisms in models of mucosal inflammation
EL-12/IFN-gamma mediated pathways
Distinct histopathology of inflammation in the animal models is associated
with dominant Thl and Th2 cytokine profiles. With a Thl pattern transmural
inflammation featuring granulomas with few neutrophils is seen, resembling CD.
With a Th2 profile inflammation is more superficial featuring an acute inflammatory
cell exudate (neutrophils) with mucosal oedema. This resembles UC.
This dichotomy of cytokine profile between Thl CD and Th2 UC is supported by
TNBS induced colitis in Balb/c mice. These mice overproduce both EL-4 and IFN-
gamma but, with IL-4 predominant. The histopathology more closely resembles UC
(Dohi et al, 1999). IL-12 is the key cytokine in Till mediated injury. In the SCID
transfer and TNBS colitis (SJL/J strain) model, established colitis could be treated
with anti IL-12. In the TNBS model, anti EFN-gamma was not so effective This was
possibly because anti EL-12 results in fas-mediated apoptosis of activated Thl cells
whereas anti EFN-gamma does not (Fuss et al, 1999).
8.2.2.4 Similarities of disease in animal models v human IBD
From the 1997 review by Sartor, I have included some tables outlining the features of
animal models v IBD
197
TABLE 8.1 Clinical course ofmurine and rat inflammatory models vs IBD
Disease feature Induced Genetically
engineered
Human IBD
Diarrhoea DSS +, PG-SS -ve yes yes
Weight loss DSS+, PG-SS -ve yes CD +, UC -ve







Extra-intestinal PG-PS + B27 yes (20%)
Some animal models of IBD have clinical features ofhuman IBD. The major
difference is that phases of relapse and remission are not seen in the induced rodent
models. Another consideration may be the age of the animals and duration of disease.
TABLE 8.2 Histopathological features ofulcerative colitis vs genetically engineered
rodent models
Disease feature Models Human UC










Crypt abscesses occasional yes
Mucosal hyperplasia yes no
This shows that animal models of IBD can result in histopathological changes to the
colon which resemble those in human UC. Which features are seen depends on the
model of injury/ strain of rodent used.
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TABLE 8.3 Pathological features ofCrohn's disease and induced rat models
Disease feature PG-PS TNBS Human CD




Granulomas 80% rare 50%




Fistulae no no yes
TABLE 8.4 Cytokine profiles hi experimental colitis and IBD
Cytokine Experimental Colitis CD UC








Chemokines MIP2 increase IL-8 increased IL-8 increased
IFN-y increase increase not increase
IL-4 not increased not increased possibly
increased
IL-5 not increased not increased increased
IL-12 increased increased not increased
MIP2 = macrophage inhibitory peptide 2
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8.2.2.5 Potential of animal models to improve our understanding of
inflammatory mechanisms in IBD
As I have outlined, several animal models of intestinal inflammation do mimic
part ofthe disease spectrum seen in human IBD. The major advantage ofusing an
animal model is that the disease has a better characterized starting point than with
human IBD. This may allow detection of early changes with insight into what tips the
balance between self-regulated and self-perpetuating intestinal inflammatory events.
In human studies, it is the inflammatory sequalae rather than the initial event that is
detected. The animal models have demonstrated that many exogenous agents can be
involved hi producing similar types of inflammation. In human studies where a single
cytokine or complement component is detected, the usefulness of this information is
hkely to be limited. What may be a useful approach for the future is the use of
microarray technology to detect a battery of genes which might be up-regulated in
IBD. This may be useful for detecting overlap in susceptibility genes between rodent
strains and humans. However, I believe that data for gene expression may need to be
substantiated by detection ofthe protein, either in mucosal biopsy or in intestinal
secretions such as WGLF.
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Appendix: general G.I lab methods
9.1 Handling and storage of laboratory samples
All samples were given an adhesive label with an individual sample number.
This number, along with the patient details was stored on a database (Microsoft
Access).
9.1.1 Processing of samples
9.1.1.1 Blood
Blood tubes are centrifuged at 2,500 rpm for 10 mins (1,800 x g) and four x 1
ml aliquots of serum or plasma stored in screw capped tubes (Starstedt, FRG) at
-70°C
9.1.1.2 Whole gut lavage
The whole gut lavage procedure
Bowel cleansing preparation prior to endoscopic investigation ofbowel
dysfunction has been adapted so that the PEG-electrolyte fluid is taken at a rate
which maintains a gut perfusion. After overnight fasting to reduce gut solids, subjects
are encouraged by a nurse to drink 'Klean-Prep' (Norgine) at a rate of250 ml/15
min. Klean-Prep is made up with water as directed and is cooled to make it more
palatable. Usually the patient will defecate and after drinking approximately 4 1 of
Klean-Prep, large liquid stools are passed. The first of these which is free of solid




1. SBTI - Soya bean trypsin inhibitor (protease inhibitor)
0.1 g/100 ml PBS (BDH). Solid is stored desiccated at -20°C with solution being
stored at 4°C.
2. PBS - Phosphate buffered saline pH 7.2.
two tablets (Sigma) dissolved in 400 ml distilled water. The pH may need
adjusting to 7.2 by addition of solid potassium di-hydrogen phosphate or di-
potassium hydrogen phosphate. Solution is stored at 4°C.
3. EDTA - 0.3 M disodium ethylene diamine tetracetic acid (BDH) pH 8.0.
Dissolve (with warming) 11.0 g in 100 ml. Saturated solution is stored at room
temperature. EDTA is a chelating agent which binds calcium and magnesium
ions, reducing their action as co-factors for protease enzymes.
4. PMSF - 0.3 M Phenylmethylsulphonylfluoride (Sigma). 1.74 g/100 ml ethanol.
Store at room temperature. This is a protease inhibitor.
5. Sodium Azide. 2 g/100 ml distilled water. This inhibits bacterial growth.
6. NBCS - Newborn calf serum (Sigma heat-inactivated). This is stored in aliquots
at -20°C, with the current batch at 4°C for two months. NBCS is a protein
'decoy' to mop up residual protease activity.
Processing procedure
This is done within 20 min of the patient producing a clear specimen.
1. Two 25 ml universal containers of clear lavage fluid are collected. .
2. If the samples were not very clear, they are centrifuged at 1,800 x g for
five min.
3. 10 ml of lavage are filtered through Whatman GF/A 12.5 filter paper, collecting
filtrate in a universal tube.
4. Aliquots ofunfiltered unprocessed lavage are taken and 30 pi of sodium azide
added per 1.5 ml. Unfiltered unprocessed lavage is used for the estimation of
haemoglobin and for estimation ofprotease activity.
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5. Both filtered and unfiltered gut lavage fluid are taken for processing. 5 ml of
lavage is transferred to a new universal tube and treated as follows:
6.
Add 0.5 ml SBTI, mix (by vortex mixer).
Add 0.28 ml EDTA, mix.
Add 0.12 ml PMSF, mix.
Add 0.06 ml Na Azide, mix.
Leave for 2 min.
Add 0.3 ml NBCS, mix.
7 Processed gut lavage fluid is stored in 250 p.1 abquots. Filtered processed WGLF
is used for estimation of antibodies and other proteins. Unfiltered processed
WGLF is used for the estimation of IL-1, where filtration has been shown to
remove it.
8. All samples are stored at -70°C. Once an aliquot has been used for an assay it is
disposed of and not re-frozen. Repeated freezing and thawing ofWGLF is not
recommended and has been shown to be deleterious for the recovery of some
proteins.
All of the proteins measured in WGLF have been shown to be stable for at least one
year at -70°C.
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Human albumin reacts with it's specific antibody to quickly form precipitating
immune complexes in the presence ofpolyethylene glycol. If the antibody is present
in large excess, these precipitates produce turbidity which is related to the
concentration of albumin in the sample. Turbidity of immune complexes is
photometrically measured at 340 nm. Standards are used to generate a calibration




Turbidity is measured using a Pye Unicam PU8640 spectrophotometer, set up
as follows:
Set to ABS (absorbance) mode
Set wavelength to 340 nm
Set delay to 0.01 min. This time lapse between filling the sample cell and reading
reduces interference from sample frothing.
Set volume to 0.8 ml
Diluter
WGLF is diluted using the Gilson Dilugil V. This is set to take 0.05 ml of sample
with 0.95 ml of diluent
Test tubes
Assays are carried out in 2 ml polystyrene tubes (LIP Ltd) 64 x 11 mm
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Reagents
All reagents are analar grade and obtained from Merck (BDH) unless
otherwise stated. They are stored at 4°C unless otherwise stated.
PEG Reagent
40 g polyethylene glycol 6000 (biochemical grade), 6 g Tris, 2 g Tween 20 (Sigma),
and 1 g sodium azide dissolved in 800 ml distilled water, adjusted to pH 7.0 with
dilute hydrochloric acid and made up to 1 htre volume with distilled water.
Anti human albumin (sheep)
(SAPU - code S034-205). Store frozen in aliquots of 1.0 ml at -20 C.
Antibody Reagent
Dilute sheep anti human albumin serum 1 in 40 with the PEG reagent on the day of
assay.
Standard diluent
9 g sodium chloride, 60 g PEG 3350 and 1 g sodium azide in 1 htre solution distilled
water.
Standard serum SPS-01
(Protein Reference Unit, Sheffield). Keep at 4°C.
For each batch the accompanying sheet gives the albumin concentration. Standard is
diluted with diluent on the day of assay to give a calibration curve of: 0,10,20,50,100
and 200 pg/ml standards.
Quality control
This is WGLF from a healthy volunteer (blood donor) to which serum from the same
volunteer is added to simulate leakage as in inflammatory bowel disease.
Stored in aliquots of 0.5 ml at -70°C.
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Analytical procedure
1. Bring PEG and Diluent reagents to room temperature.
2. Blanks:
Dilute 50 pi diluent (Bl), standards (SB), and test samples (TB), with 0.95 ml PEG
reagent in 2 ml polystyrene tubes, in duplicate.
3. Tests:
Dilute 50 pi diluent (B2), standards (S), and test samples (T), with 0.95 ml Antibody
reagent in 2 ml polystyrene tubes, in dupbcate.
4. Read: Blanks and Tests after 15-20 minutes at 340 nm using the
spectrophotometer.
Zero reading with PEG reagent. This requires 3-4 aspirations before reading
stabilizes. Read corresponding blanks and tests for each sample followed by PEG
reagent; this will tend to minimize any errors caused by any baseline drift.
Calculations
1. Calculate B2 - B1 = OD value for 0 pg/ml albumin
S - SB = OD values for 10 - 200 pg/ml albumin, T - TB = OD values for test
samples.
2. Plot a graph ofOD 340 nm against standard concentration and read test sample
results from this; calculate and report mean values.
Assay performance
Repeat analysis within batch gives a coefficient ofvariation of 8.5% at a
value of40 pg/ml. The QC value should be within 17% (+/-) of expected value for
the run to be acceptable.
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Reference range
Reference range based on results from 62 individuals, seven ofwhom were
healthy volunteers and the remainder were patients with non-inflammatory
gastrointestinal conditions. Using the upper value encompassing 95 % of all results,
the normal range was designated from 0-26 ug/ml.
Clinical significance of results
In 102 patients with inflammatory bowel disease (71 Crohn's and 31
ulcerative colitis) with heterogeneous disease activity, 52% of cases show raised
WGLF albumin. IgG was raised in 64% ofthese patients. As it has been shown that
raised WGLF IgG >10 pg/ml correlates with a disease activity score of> 150, these
patients have active disease. Albumin is therefore less specific for active disease than
is IgG. The sensitivity of the assay is reduced because of the variable recovery of
albumin inWGLF due to action ofgut proteases.
9.2.2 Alpha-1-antitrypsin in Whole Gut Lavage Fluid
Principle of method
Human alpha-1-antitrypsin (A1AT) reacts with it's specific antibody, quickly
forming precipitating immune complexes hi the presence ofpolyethylene glycol. If the
antibody is in large excess, these precipitates produce a turbidity which is related to
the concentration of albumin in the sample. The turbidity is photometrically measured
at the wavelength of 340 nm. Absorbance readings obtained by assaying calibration
standards are used to generate a standard curve, from which the concentration of
A1AT in the sample is derived (Brydon et al, 1993).
Analytical procedure
This is similar to the method for albumin except that anti human A1AT (goat) is used
instead of anti albumin.
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Quality control
As for albumin assay. This gives a within batch variation of 10 % and between
batch variation of 12%.
9.2.3 Haemoglobin in WGLF
Principle of method
Haemoglobin is converted to fluorescing porphyrins by the removal of iron.
Total haemoglobin is determined by reaction with heated oxalic acid/FeS04 reagent
which converts haem to porphyrin without loss ofpre-formed porphyrins. A three
step purification procedure eliminates other interfering fluorescent materials which
may be present.
References: The haemoquant assay (Schwartz et al, 1983), was adapted for WGLF
(Brydon and Ferguson, 1992)
Sample storage and stability
UFUP WGLF stored at -70°C are analysed within 2 months.
Instrumentation
Fluorescence is measured using the LS-5B Luminescence Spectrometer. Set
the excitation wavelength to 402 nm and emission wavelength to 600 nm. Leave
instrument for 5 minutes to stabilize before using. The excitation slit width is set to
15 nm and the emission slit width to 5 nm
Reading
1. Place blank sample in cell carrier and press the autozero key. The digital display
reads zero.
2. Place standard sample in the cell carrier, set value e.g. 1,000 for 100.0 pg/ml and
press autoconcentration key. The digital display then reads 1000.
3. Repeat steps 1 and 2 to finalize calibration.
4. Test samples can now be read.
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Reagents
All reagents are analar grade and obtained from Merck (BDH) unless otherwise
stated. Solvents are stored in a metal cabinet and all reagents stored at room
temperature.
Oxalic acid reagent
4.0 g oxalic acid (analar) is made up to 10 ml with distilled water in a stoppered glass
tube. This is dissolved by heating in a water bath at 100°C. To this, 0.31 g FeS04 is
added with mixing before returning the tube to 100°C. Then, 0.10 g uric acid and
0.11 g mannitol are added with mixing and the final volume adjusted to 10 ml. The
reagent is left at 100°C for 15 minutes before use. The reagent is prepared fresh
before use and used as a suspension.
Ethyl acetate/acetic acid 10/1 v/v
Add 50 ml glacial acetic acid to 500 ml ethyl acetate and then mix.
Potassium acetate 3 M
29.4 g ofpotassium acetate (BDH) is dissolved in 100 ml distilled water.
Potassium acetate (3 M) in 1 M potassium hydroxide
Dissolve 147 g potassium acetate in about 300 ml distilled water. Add 28 g
potassium hydroxide, dissolve with stirring and make up to 500 ml with distilled
water.
n-Butanol
(Rathbuni Chemicals Ltd, Walkerburn).
orthophosphoric acid (2M) /glacial acetic acid 9/1 v/v
Dissolve 68 ml orthophosphoric acid in 300 ml distilled water. When cool, make up
to 500 ml with distilled water and add 58 ml glacial acetic acid.
PEG 4000 reagent
Dissolve 60 g PEG 3350, 9 g NaCl, and 0.2 g sodium azide in 1 litre of distilled
water. Use to make Drabkins reagent.
Drabkins Reagent: (Sigma cat, no, 525-2)
Each vial contains: 1 g sodium bicarbonate, 0.2 g potassium ferricyanide, and 0.05 g
sodium cyanide (NB poison).
Take 1 vial and reconstitute to 1 litre with PEG 4000 reagent.
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Cyanomethaemoglobin standard
Dissolve 10 mg haemoglobin (Sigma - H 7379) in about 50 ml Drabkins
reagent. Leave at room temperature for 15 minutes. Add 6 g of PEG 3350 and make
up to 100 ml with Drabkins reagent. To calculate actual haemoglobin concentration,
use a spectrophotometer to read the OD at 540 nm against Drabkins reagent (blank).
Molar extinction coefficient (540 nm) = 44.0. The haemoglobin concentration can
then be adjusted and sodium azide added to 0.02 % before ahquoting into 0.5 ml
Eppendorf tubes and storage at -70°C. This is stable for up to 6 months.
Quality control
Use UFUP WGLF where the patients serum has been tested for HTV and
Hepatitis status. Haemoglobin (Sigma - H7379) is added to give a haemoglobin value
of 10 pg/ml. Ahquots are stored at -70°C and the QC value should be determined
against an established control for several runs.
Analytical procedure
1. WGLF must be frozen at -70°C and then thawed to allow haemolysis of intact red
cells. After thawing cells are separated by centrifugation at 1,500 x g for ten mins and
the supernatant used for assay.
2. Add 0.4 ml of the oxalic acid reagent suspension to 0.1 ml ofWGLF supernatant,
quality control, haemoglobin standard, and blank (Klean-Prep) in 10 ml stoppered
quickfit tubes. Mix thoroughly and heat at 100°C for 30 minutes in a covered water
bath. After this time remove the tube stoppers and allow samples to cool for 2 mins.
3. Add 1 ml of the 3 M potassium acetate reagent, followed by 3 ml ethyl
acetate/acetic acid reagent. Vortex mix for 30 seconds. This extracts the porphyrin
analytes into the upper organic phase.
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4. Transfer 2 ml of the upper organic phase to a 30 ml stoppered quickfit tube and
add 0.8 ml butanol and 6 ml of 3 M potassium acetate in 1 M KOH. Mix the tubes
for 30 seconds. This removes coproporphyrin and other porphrins not derived from
haemoglobin haem (those containing more than 2 carboxyl groups are extracted into
the lower alkaline aqueous phase).
5. Transfer 1 ml of the upper organic phase to a 10 ml stoppered quickfit centrifuge
tube and add 4 ml phosphoric acid/acetic acid reagent. Mix for 30 s. Remove the top
layer which contains chlorophyll. Read the fluorescence ofthe lower acid extract.
6. See instrumentation section for reading the fluorescence. Tests readings /10 give
results in pg/ml.
Reproducibility of assay
The coefficient ofvariation (between batch reproducibility) of quality control
material currently gives a value of 8% at 14 pg/ml. The run is acceptable if the QC
value is within 2 SD ( 16%) ofmean value.The method is sensitive to 0.5 pg/ml.
Reference range
Reference values for lavage haemoglobin range from 0 -5 pg/ml (Brydon and
Ferguson 1992).
Clinical significance of results
The reference range forWGLF haemoglobin is 0-5 pg/ml which is equivalent
to daily blood loss of 1 ml. Values in excess of this indicate pathological GI blood
loss.
Interferences and limitations
Other haem containing proteins have the potential to interfere in this assay,
e.g. myoglobin in meat or peroxidases in vegetables, although neither of these should
cause significant interference in WGLF. WGLF which is contaminated with faecal
material should be avoided.
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9.2.4 ELISA assays
ELISA = Enzyme linked immunosorbant assay
General procedure
Non competitive ELISA assays are used to measure total or antigen specific
Immunoglobulins G, A or M in serum orWGLF. A double antibody sandwich
technique is used for quantifying total immunoglobulin, using a purified secondary
standard material. An indirect technique is used for estimation of antigen specific
immunoglobulins measured against a known high human sample.
Class specific antihuman immunoglobulin or pure antigen is bound in excess
to a solid phase and then washed. In these methods, a 96 well ELISA plate is the
solid phase, with different plate types have different binding characteristics. The
plates are incubated with a protein containing solution to "block" any non specific
binding sites. Samples are added to the plates in doubling dilutions covering a wide
range of concentrations whilst samples for antigen specific analysis are added at a
single predetermined dilution. Samples are incubated and then washed. The starting
dilution is predetermined by testing at what dilution the response is modulated by
further sample dilution.
Binding takes place between the antihuman globulin and the immunoglobulin
being quantified or between the specific antigen and corresponding antibody.
A class specific antihuman antibody conjugated with alkaline phosphatase is added to
the plate, incubated and then washed. This conjugated antibody binds to the complex
bound to the solid phase. On adding substrate, the amount ofproduct is proportional
to the amount of conjugate bound and hence the amount of antibody in the sample.
ELISA reagents
SPS-01
Standard serum for quantifying IgG and IgM. Dept.of Immunology, P O Box 894,
Sheffield S5 7YT. Once opened, this is stored for one month at 4°C
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Human IgA (colostrum)
Standard material for quantifying IgA in WGLF (Sigma, 1-2636). This is
reconstituted in distilled water to 210 (.ig/ml and stored in 110 pi aliquots at -20°C
Coating antibodies
Goat antihuman IgG. Fc specific
Affinity purified (Sigma I 2136)
Use at 1/5,000
Goat antihuman IgM. p. chain specific (Sigma I 2386)
Use at 1/5,000
Goat antihuman IgA. a chain specific (Dako)
Use at 1/600
Conjugated antibodies (alkaline phosphatase)
Goat antihuman IgG (Sigma A 95441
Use at 1/5,000 for estimation oftotal IgG
Goat antihuman IgM (Sigma A 3437)
Use at 1/10,000 for estimation of total IgM
Goat antihuman IgAISigma A3036)
Use at 1/10,000 for estimation of total IgA.
For detecting antigen specific antibodies, the conjugate antibody used must be




1 litre sterile water containers (Baxter , Australia) stored at 4°C.
Carbonate-bicarbonate coating buffer
0.05 M, pH 9.6 at 25°C. Dissolve the contents of 10 capsules (Sigma C 3041) in 1
litre sterile water. Mix to dissolve and store at 4°C.
sodium chloride
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0.9% sodium chloride in 1 litre sterile containers (Baxter Healthcare Code F7124) is
stored at 4°C.
Wash solution
0.9% saline + 0.05% Polyoxyethylene-Sorbitan Monolaurate (Tween 20, Sigma P
1379). Add 500 (j.1 Tween 20 to 1 litre of 0.9% saline. Mix and store at 4°C.
Adult bovine serum
Adult bovine serum (SAPU, S026-220, Law Hospital, Carluke, Lanarkshire, ML8
5ES). Store at -20°C. Before use this should be allowed to reach room temperature
before filtering through a 22 pm filter (Millipore).
ELISA diluent
0.9% saline + 0.05% Tween 20 + 1% adult bovine serum.
Add 500 pi Tween 20 and 10 ml filtered adult bovine serum to 1 litre of saline. Mix
and store at 4°C.
10% Diethanolamine (PEA) substrate buffer
For 2 litres, mix 200 ml diethanolamine (BDH)
0.20 g magnesium chloride (MgCl26H20) and
0.4 g sodium azide (NaN3) in 1.6 litres of sterile water. The pH is then adjusted to
9.8 with 6 M hydrochloric acid before making up to 2 litres with sterile water. This is
stored at 4°C and is stable for 4 months.
p-nitrophenylphosphate (substrate)
5 mg phosphatase substrate tablets, disodium p-nitrophenyl phosphate hexahydrate
(Sigma 104-105). Tablets are stored at -20°C.
Substrate mix for alkaline phosphatase
Diethanolamine buffer is allowed to reach room temperature. One substrate tablet is
dissolved per 5 ml buffer shortly before required.
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Oil adding substrate to alkaline phosphatase (immobilized on ELISA plate) the
following reaction takes place:
p-nitrophenyl phosphate (colourless) —> p nitrophenol (yellow)
The colour development takes place within an hour and the optical density at
is read on a dedicated ELISA reader (set at 405 nm with a reference filter at 630 nm).
A Dynatech system programmed with Revelation software is used. The absorbance
for all wells is read when that for the top standard has reached a previously
determined value. An OD of one has been used as the spectrophotometer is at
maximum sensitivity whilst the reading is high enough to give good separation of
positive and negative results.
Instrumentation
Dynatech Multi-Reagent Washer
This is a programmable ELISA plate washer fitted with a 16 way dispense
head. This allows simultaneous aspiration from two columns of a 96 well plate, which
can be immediately followed by filling of those wells with e.g. wash solution. The
wash head then moves to the next two columns until the final column where it moves
back to the start. Three wash cycles are usually used.
Waste from the ELISA plates is collected in a trap bottle and this can be
decontaminated with e.g. Presept, before disposal via the drains.
Dynatech Microplate Reader
The Dynatech MR5000 microplate reader is linked to a Gateway 2000
computer fitted with Revelation software. This allows either instant absorbance
reading or reading at a pre determined optical density reading (e.g. for the top
standard). A print out of the optical density readings can be obtained or alternatively
the program can be used to fit a curve to the standard points and calculate the test
unknown concentrations.
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9.2.4.1 Estimation of total IgG in WGLF
Test indication
The concentration oftotal IgG (and also albumin and a 1-antitrypsin) in
WGL fluid are raised in patients with active gut inflammation. Total IgG is therefore
measured inWGL to assist in the diagnosis of inflammatory bowel disease and in
patients with confirmed disease as an alternative/additional measure ofthe degree of
inflammation.
Principle of assay
Total IgG in WGLF is quantified against the protein reference standard
(SPS-01) using a double antibody sandwich ELISA technique (Gaspari et al, 1988).
This has been validated as a marker of disease activity in IBD (CFMahoney et al,
1991)
Sample requirement and stability
IgG in untreated lavage material is stable for 2 hours at 37°C. IgG should
therefore be intact in WGLF following gut transit. Filtered processed WGLF should
be used and IgG has been shown to be stable at -70°C for 3 months.
Standard
SPS-01 is diluted in ELISA diluent to give a concentration of 250 ng/ml.
Quality control
WGLF is taken from a patient suspected ofhaving raised inflammatory
parameters and a large volume is stored at -70°C. After the patient gives consent, an
aliquot ofWGLF is tested for Hepatitis B and HTV infection. If these tests are
negative and the WGLF contains suitable antibody levels, the WGLF pool is thawed
and processed with protease inhibitors. The sample may be diluted with Klean-Prep
to give an IgG concentration at the upper limit of the reference range. Aliquots of
this are stored at -70°C.
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Analytical procedure
Volumes are 100 pi unless stated
Coat ELISA plate
Dilute IgG coating antisera 1/5,000 in carbonate/bicarbonate coating buffer pH 9.6.
Add 100 pi/well to an Immulon 1 flat bottomed plate and incubate the plate
overnight at 4°C in a moist box.
Wash plate
ELISA wash with three aspirate/dispense cycles using automatic plate washer. Tap
plate dry on paper towel.
Block Plate
Add 250 pi ofELISA diluent/well and leave for a minimum of 1 hour at room
temperature..
Iffepare samples
AllowWGLF and QC to reach room temperature. Dilute the samples and QC
material 1/25 in ELISA diluent (40 pi plus 960 pi ELISA diluent).
Add samples to the plate
Dispel the blocking solution from the plate and blot dry on absorbent paper. Using an
8 channel multipipette, add 100 pi ofELISA diluent to all wells except for B1,B2 and
A3-A12. To wells B1,B2 and C1,C2 add 100 pi of the appropriately diluted
standard. Mix the standard solution and the diluent in C1,C2 by drawing up and
down the pipette tip 3 times. Then, transfer 100 pi from C1,C2 to D1,D2 and so on
to produce a series of doubling dilutions. Similarly, after vortex mixing diluted
WGLF samples, add 100 pi to duplicate columns (e.g., A3,A4 and B3,B4). Then by
mixing the sample and diluent in B3, B4, produce doubling dilutions. Cover plates
with a plastic lid and incubate overnight at 4 °C in a moist box.
Conjugate
Dilute the conjugated antisera to 1/5,000 in ELISA diluent. Wash the plates
before adding 100 pi of conjugate to each well. Cover the plate with a plastic lid and
incubate at 24°C for 3 hours.
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Colour development
Prepare alkaline phosphatase substrate (15 ml per plate) 30 mins before
required. After washing the plate, add 100 pi of substrate solution to each weft. The
plate can then be placed in the ELISA reader and the OD monitored. My program
read the absorbance at 405 nm against a reference of 630 nm when the OD for the
first standard reached 1.0 (after subtracting blank readings).
A standard curve ofOD against logio of concentration gives a sigmoid curve with a
linear central portion. A straight line equation can be fitted to this region using linear
regression. From this equation, test concentrations are extrapolated. Mean values
from the doubling dilution points most parallel to the standard are taken before
multiplying by the sample dilution factor.
Assay requirements
The correlation coefficient for the standard curve must be greater than 0.985
with QC values within 2 SD of the expected value. Samples must have 2 or more
points parallel to the standard curve. Samples with OD readings greater than that for
the top standard are tested again but at a greater dilution of 1/250.
Clinical significance of results
The reference range for WGLF IgG is 0-10 pg/ml. Total IgG is the most
sensitive parameter for inflammation in the gut with raised values indicating gut
inflammation.
Assay performance
Between batch CV =12.3% at 19.8 pg/ml
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9.2.4.2 ELISA for total IgA and IgM
are similar with the following changes:
Total IgA
Coating
Coat Dynatech Immulon 1 plates 100 pi/well with rabbit anti human IgA diluted to
1/600 in carbonate-bicarbonate buffer pH 9.6
Sample preparation
Filtered processed WGLF is diluted 1/100 in ELISA diluent before adding 100
pFwell to the plate. Doubling dilutions are produced as before.
Standard
Sigma human colostrum IgA (I 0633) is diluted in ELISA diluent to 1 pg/ml. This is
diluted hi doubling dilutions on the plate.
Conjugate antibody
Sigma goat anti human IgA (a chain specific) alkaline phosphatase conjugate is
diluted to 1/10,000 in ELISA diluent. 100 pi is added to all wells.
Total IgM
Coating
100 pi/well of anti human IgM (p chain) at 1/10,000
Samples
WGLF is diluted from 1/25
Standard
SPS-01 is diluted to give 1 pg/ml IgM, with doubling dilutions on the plate.
Conjugate antibody
Use anti IgM alkaline phosphatase conjugate at 1/10,000.
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9.2.5 ELISA for measuring antibodies to specific antigens
General assay differences
ELISA plate
Binding of a purified antigen requires a 'stickier' ELISA plate such as the gamma
irradiated Dynatech Immulon 2.
Coating
Test the optimum coating concentration of antigen but expect this to fall between 1
and 10 |ig/ml
Sample dilution
WGLF diluted from 1:1
Conjugate antibody
There will be fewer antibodies capable ofbinding to the immobilized antigen than
when detecting antibodies of all specificity (total antibodies). The conjugate antibody
should be used at a greater concentration e.g. 1/1,000
9.2.5.1 ELISA for detecting antibodies to ovalbumin
All volumes 100 p.1 unless stated
Coating
Coat Immulon 2 plates at 5 pg/ml with ovalbumin from chicken egg (Sigma)
dissolved in coating buffer. Incubate the plate in a moist box for 5 h at 24°C. Wash
3x with ELISA wash (0.05 % Tween in saline) and blot plate on paper tissue..
Blocking
Fill wells with ELISA diluent and leave for 2 h at 24°C
Samples
Dilute serum 1/100 for IgA and IgM, 1/200 for IgG. Lavage should be tested at 1:1.
Standard
A serum sample 96/1548 from a patient with untreated coeliac disease is used. This
has been designated as containing 528 arbitrary IgA anti ovalbumin units (by
reference to an original standard material). Storage of aliquots of standard material is
at -70°C. This is diluted from 1/264 on the plate.
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For IgG a starting dilution of 1/675 = 0.4 IgG units
For IgM 1/390 = 1 IgM unit
After adding samples and standards, the plate is incubated overnight at 4°C
Conjugate
Sigma anti human IgA, G or M are used at 1/500. Add 100 pl/well and incubate the
plate for 5 h at 24°C.
Colour reaction
After washing the plate, the colour reaction with p-nitrophenyl phosphate is carried
out as before. The OD at 405 nm is read when that for the top standard reaches 1.0
Reference range
By drawing a frequency curve ofvalues obtained from 120 hospital patients




IgM no clear cut-off.
Clinical significance
Many people have some serum antibodies to ovalbumin but patients
with coeliac disease more frequently have raised antibodies. However, the presence
of anti ovalbumin antibodies is not specifically indicative of coeliac disease. No
reference ranges have been assigned forWGLF and the chnical significance of these
antibodies has not been investigated in detail.
Quality control
Serum from a coeliac patient is used.
Assay performance
This shows a within batch CV of< 10% and a between batch CV of< 15%.
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9.2.5.2 ELISA for antibodies to LPS core antigen (EndoCAb)
This is a semi quantitative ELISA to detect antibody to endotoxin developed
by Dr Robin Barclay at the blood transfusion service, Edinburgh. From the original
method to measure specific IgG in serum (Barclay and Scott, 1987), Samiul Hoque
and myselfhave adapted and optimized the ELISA to measure antibodies in WGLF.
Principle of method
ELISA plates are coated with endotoxin core antigen cocktail (smooth an
rough mutant LPS from Eschericia Coli, Klebsiella pneumoniae, Pseudomanas
aeruginosa and Salmonella minnesota complexed with polymyxin B. Plates kindly
supplied by Dr Robin Barclay, blood transfusion service, Edinburgh.
Reagents (from Sigma unless stated)
Sample buffer (for plate washing and sample dilution)
1 tablet PBS buffer / 200 ml
1 ml Polyoxyethylene Sorbiton Monolaurate (Tween 20)
5 ml 10 % sodium azide
40 g Polyethylene Glycol
10 g endotoxin free bovine serum albumin
To one Htre with distilled water
Standard
Human serum with high titre, supplied by Dr Barclay. This has been designated a
number of arbitrary units for IgA, IgM and IgG against the median response from a
Scottish healthy volunteer population. This is diluted 1/250 for IgG, 1/50 for IgM
and 1/25 for IgA.
Samples
Filtered processed WGLF is diluted from 1:1
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Assay procedure
(all volumes 100 (ill)
Sample addition
The standard and WGLF samples are added to the plate and doubly diluted in
duplicate columns. After adding samples and standards, the plate is incubated for 90
mins at 37°C.
Conjugate antibody
The plate is washed 3x with ELISA wash solution to remove unbound material.
Conjugate antibody against the appropriate antibody class is then added at a dilution
of 1/1,000. The plate is then incubated for three hours at 24°C.
Colour development
Unbound conjugate is washed free and substrate (p-nitophenol phosphate 1 mg/ml in
10% Diethanolamine buffer pH 9.8) added. The optical density at 405 run is read
when that for the top standard reaches one.
Calculations
A plot ofunits on the x axis against OD on the y gives a sigmoidal curve with a linear
region usually over a range of four doubling dilution points. A linear regression
equation is fitted to those points and the test concentrations calculated from this
(Graphpad Prism).
Precision
The coefficient ofvariation within run was < 4% and between run < 12%.
9.2.6 Other non-ELISA methods
9.2.6.1 Total protein assay
Biorad total protein estimation
This method is a commercial adaptation of the Bradford dye binding
procedure. A colour change which can be detected spectrophotometrically results
from proteins binding Coomassie blue dye in acidic solution.
The dye binds to aromatic and basic amino acids, especially arginine. The method is
useful for quantifying the concentration ofproteins with MW greater than 5,000.
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A standard for the assay needs to be carefully chosen to reflect the nature of the
protein, as dye binding may vary for different proteins. ForWGLF, the commercial
serum standard, SPS-01 was chosen as this is likely to contain some proteins found in
WGLF.
Procedure
Essentially as per Biorad instructions. The optical density of the protein/dye
mix was read at 595 nm after 30 mins reaction.
The quantity of reagents used were scaled down for economy, 20 pi of sample + 1 ml
of dye instead of 100 pi of sample + 5 ml of dye.
I have found that saturation of dye binding usually occurred with protein
concentrations greater than 1 mg/ml. This gave a standard curve which was linear at
low protein concentrations but, which flattened off at high concentrations. Some
samples were diluted prior to testing so that the response was within the linear range
obtained for the standards.
9.2.6.2 Protease activity in WGLF
Gaspari et al (1988) have quantified the activity ofprotease enzymes in gut
lavage fluid, qualifying the requirement for the addition ofprotease inhibitors prior to
storage. They used Azocoll which is an insoluble, ground collagen which is
conjugated by a peptide type link to a bright-red azodye. Protease enzymes release
the dye into solution, the absorbance ofwhich can then be quantified
spectrophotometrically. Under optimal conditions the quantity of dye released is
proportional to the protease activity. A method adapted from Gaspari has previously
been set up in this laboratory.
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Method (Gordon Brydon Ph.D. University ofEdinburgh, 1996)
• Make a suspension ofAzocoll (Sigma) 10 mg/ml in PBS 0.01 M pH 7.2
• To 2 ml polypropylene test tubes add:
50 pi ofunfiltered unprocessedWGLF or 50 pi ofPBS as a blank
• Add 50pl ofAzocoll suspension and vortex mix.
• Incubate tubes for 15 min in a waterbath at 37°C
• Plunge the tubes into ice cold water and add 1.5 ml of cold PBS per tube to stop
the enzyme reaction.
• Centrifuge the tubes at 1,800 x g for 5 mins to separate any dye which has been
released into the supernatant
• Transfer the supernatant using a Pasteur pipette to fresh test tubes
• Read the optical density at 530 nm against the blank test ofPBS.
I found that this assay showed poor sensitivity, possibly due to differences in batches
ofAzocoll.
Optimizing the Azocoll reaction
a) Finding the optimum ratio of Azocoll to WGLF
UFUP WGLF (50 pi) was dispensed into several test tubes and to these,
between 50 and 400 pi ofAzocoll suspension (10 mg/ml in PBS) was added. The
enzyme reaction was carried out for 15 min at 37°C before stopping the reaction.
After separating the supernatant, the OD 530 nm was read against a blank reaction
tube ofPBS + Azocoll.
b) Testing the linearity of the enzyme reaction
To allow comparison of enzyme activity in different samples, it is necessary to
compare how much product has been formed within a defined time period. Choosing
that time period is a balance between the needs for assay sensitivity and the possibility
that at longer times, substrate may be limiting and so the amount ofproduct formed
might not truly reflect the enzyme activity. One way of doing this is to look at the
linearity of the amount ofproduct formed with time.
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If at a point when sensitivity is acceptable, the amount ofproduct continues to
increase in a linear manner with time then it is likely that even if testing a sample with
greater enzyme activity, it is unlikely that at that timepoint that the amount of
substrate would be limiting.
UFUPWGLF (50 pi) was dispensed into several test tubes and to these, 450 pi of
Azocoll suspension added. The reaction was proceeded at 37°C with duplicate tubes
being removed at two minute intervals. The reaction was stopped in these tubes
which were then stored at 4°C until all tubes had been stopped. All tubes were then
centrifuged and the OD of the supernatants read. The optimum conditions were then
used for all subsequent studies.
Within batch variability of assay
WGLF (UFUP) was assayed twenty times in the same run to test the within
batch variability. Between batch variation was tested with ten samples that had been
included in more than one run.
Protease activity in filtered unprocessed (FUP)WGLF
Filtered unprocessed WGLF was more frequently available than unfiltered
unprocessed WGLF freezer archives. Ifprotease activity could be reliably assayed in
FUPWGLF, this would allow a comprehensive retrospective study of albumin
recovery in relation to WGLF protease activity. Protease activity was assayed in both
UFUP and FUP WGLF.
a) Optimizing the concentration of Azocoll for estimating protease activity
The amount of dye released (OD) increases with increasing amount of
substrate added. The plateau in this curve indicates that maximum dye release can be
obtained by adding 450 pi ofAzocoll to 50 pi ofUFUPWGLF.
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optimizing the quantity of Azocoll required
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pi of Azocoll suspension (10mg/ml) added
to 50 pi of UFUP lavage
Fig 9.1: Optimizing the quantity ofAzocoll required to detect WGLF protease
activity
Linearity of the release of azodye from Azocoll
















Time (mins) of reaction of 50pl of UFUP WGLF
with 450gl of Azocoll at 37°C
Fig 9.2: Optimizing the Azocoll reaction time in protease assay
As the reaction gives a linear response beyond 10 mins, ten minutes was chosen as
the assay reaction time.
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9.3 T-Gel appendices
9.3.1 SDS-Polyacrylamide gel electrophoresis; equipment:
a) Vertical slab electrophoresis tank (Batheseda Research Laboratories, USA)
b) Glass electrophoresis plates
c) Plastic spacers (1.5 mm thick) and gel comb
d) Bulldog clips
e) Buchner flask with side arm
f) Vacuum pump
g) Gel loading pipette tips
h) Powerpack capable of delivering constant current (Shandon, UK)
Reagents:
From Sigma unless stated
a) Stock 50% acrylamide:
1.25% N,N -methylene bisacrylamide and 48.75% acrylamide (filtered through
Whatman no 1 paper and stored at 4°C in a brown bottle.
NB This is a neurotoxin and so gloves are worn.
b) 10% Sodium lauryl sulphate (SDS) in distilled water
store at rt. and warm to dissolve before use.
c) Stacking gel buffer, 1 M Tris HC1 pH 6.8
121.14 g Tris (Tris (hydroxymethyl) methylamine, BDH, UK)
d) Resolving gel buffer, 1 M Tris HC1 pH 8.8
e) Stock 10 fold electrophoresis buffer 1.92 M glycine , 0.25 M Tris pH 8.3 (BDH).
Before use this is diluted ten fold with distilled water and SDS included to a final
concentration of 0.1%
f) TEMED (fresh)
g) Reducing sample buffer:
6% SDS, 6% (v/v) 2-mercaptoethanol, 40% (w/v) sucrose and 0.02%
bromophenol blue in0.125MTris HC1 pH 6.8.
h) Sigma wide range MW markers (range ofMW from 6,500 to 205,000)
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i) Ammonium persulphate 1.5% in distilled water (made fresh)
Protein staining reagents
a) Coomassie brilliant blue stain (BDH, UK)
0.2% w/v solution in 1:1:0.2 mixture ofmethanol: d.H20 : glacial acetic acid.
Filter through Whatman n°l paper before use.
b) Destaining solution
0.5:8.5:1 mixture ofmethanol: d.H20 : glacial acetic acid
Assembling the gel mould
Glass electrophoresis plates for a 18 x 13 cm cast were cleaned with distilled
water followed by 70% ethanol. To the front and rear surfaces ofthe gel spacers,
silicone grease was smeared. Of the two glass plates, the front plate has a rectangular
cut out at the top, to allow access to the cast gel. The rear plate was lain flat and the
greased spacers placed in position on top of it, forming a continuous barrier along the
base and side edges. The front plate was then placed on top and the unit sealed with
bulldog clips.
Gel formation
A resolving gel of 12.5% w/v acrylamide was chosen because ofthe small
pore size which enables separation of low molecular weight proteins and also because
it's rigidity makes it easier to handle. For this size ofgel, 40 ml of resolving gel mix is
required.
Resolving gel
1. 50% stock acrylamide (10 ml)
2. 1M Tris-HCl pH 8.8 (15 ml)
3. d.H20. (13.7 ml)
mix in a Buchner flask and then degas by vacuum for twenty minutes. The following
were then added:
4. 10% SDS (0.4 ml)
5. ammonium persulphate (0.9 ml).
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The contents were mixed gently and polymerization started by addition of:
6. TEMED (30 pi)
Gel solution was drawn up in a syringe and slowly dispensed into the gel
mould along the edge of a side spacer, introducing as little air as possible. Air bubbles
were displaced by tapping the outside of the glass with a spatula. The gel surface was
overlain with 200 pi of 0.01% SDS (to stop air from getting in as this inhibits
polymerization). With the mould positioned vertically, the gel was allowed to set for
one hour at rt. Before adding the stacking gel, the surface of the resolving gel was
washed with three washes of SDS (2 ml), removing this by capillary action with a
filter paper.
Stacking gel
For the usual stacking gel protocol, 5% of acrylamide is used. Elowever,
7.5% acrylamide was used because this sets more readily and forms neater sample
wells.
1. 50% stock acrylamide (1.5 ml)
2. 1M Tris-HClpH 6.8 (1.25 ml)
3. d.EEO. (6.65 ml)
were mixed in a Buchner flask before degassing. The following were then added:
4. 10% SDS (0.1 ml)
5 ammonium persulphate (0.5 ml)
This was mixed by gentle swirling and polymerization initiated by addition of:
6. TEMED (20 pi)
The liquid gel was decanted onto the surface ofthe resolving gel and the gel
comb inserted into the top of the gel, without introducing air bubbles. The top ofthe
gel was overlain with 0.01% SDS and the gel allowed to set for one hour at rt.
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9.3.1.1 Preparing the electrophoresis assembly
When the stacking gel had set, the well comb was removed and
unpolymerized acrylamide rinsed from the wells with three washes of electrode buffer
(5 ml) The wells were left full of electrode buffer. The cast gel was fitted into a
vertical electrophoresis tank (Batheseda Research Laboratories, USA) with the
exposed side of the stacking gel against the upper buffer reservoir (cathode).
Adhesive rubber strips smeared with silicon grease help to give a water tight seal
between the glass plates and the upper reservoir, preventing buffer from that
reservoir leaking to the lower (anode) reservoir and so breaking the electrical circuit.
Bulldog clips were used to hold the electrophoresis plates firmly in position.
Upper and lower reservoirs of the electrophoresis tank were filled with
electrode buffer (0.192 M glycine, 0.025 M Tris pH 8.3 containing 0.1% SDS,
ensuring that the wire electrodes and the gel sample wells were covered.
Air bubbles sitting between the base of the resolving gel and the anode buffer were
displaced by means of electrode buffer squirted through a Pasteur pipette. This allows
an even electric field across the base of the gel.
9.3.2 Western Blotting
Equipment
a) Milliblot SDE transfer system
b) Consort E741 Power Supply
c) Whatman 3MM chromatography paper (UK)
d) Millipore 0.45 pm Nitrocellulose NCHAHY grade (UK)
e) Plastic incubation boxes with lids
Reagents
a) Methanol (Analar, BDH, UK)
b) Anode buffer 1:
0.3 M Tris, 10% Methanol pH 10.4 (adjusted with 1 M HC1)
c) Anode buffer 2:
0.025 M Tris, 10% Methanol pH 10.4
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d) Cathode buffer:
0.025 M Tris, 0.04 M glycine, 20% Methanol pH 9.4
e) Ponceau S stain
diluted 1/10 in d.H20
Assembling the blotting apparatus
Millipore semidry transfer apparatus was assembled as per manufacturers
instructions, in brief: The Mylar insulating matrix ensures that current can only flow
through the gel sandwich. This was placed over the edges of the lower (anode)
electrode.
Six pieces of3MM filter paper and a piece ofnitrocellulose were cut to the
size of the gel. The gel was first pre-soaked in anode buffer two to prevent it from
swelling during the transfer. One piece of chromatography paper was soaked in
anode buffer 1 and then drained to remove the excess. A spot of this buffer was place
in the centre ofthe carbon anode and the chromatography paper placed on top ofthe
this. Air bubbles under the sheet were removed by smoothing the surface with a glass
rod. Two pieces of chromatography paper were soaked in anode buffer 2, before
placing these on top of the first sheet as before.
Nitrocellulose was first activated by soaking in water before soaking in anode
buffer two. A corner was cut off the nitrocellulose to match with the electrophoresis
direction marker on the gel. This was then placed on top ofthe chromatography
paper stack. The gel was then placed in position on top of the nitrocellulose and air
bubbles between the gel and the membrane removed by smoothing the gel surface
with a gloved finger wetted with anode buffer 2.
Three pieces of3MM paper were soaked in cathode buffer before placing on top of
the gel. All handling was done wearing clean gloves to prevent proteins from skin
from contaminating the nitrocellulose. The cathode was then placed on top of the gel
sandwich and the retaining nuts tightened by hand.
232
Gel staining with Coomassie brilliant blue
Resolving gel was placed plastic box and flooded with Coommassie blue
reagent. The gel was incubated overnight (with rocking) at room temperature. To
remove the background staining, the stain was decanted, and destain solution added.
The gel was incubated for 2 h before decanting destain and adding fresh. This
produced good contrast between the stained protein bands and the gel background.
Destain solution was then removed and the gel stored in a sealed plastic box
containing 7% glacial acetic acid preservative.
9.4 Computer packages used in production of this thesis
This thesis has been written using Micosoft Word version 6
Data has been stored on Microsoft Excel version 5 spreadsheets
Statistics have been calculated using Minitab for Windows version 10
Graphs have been produced using Graphpad Prism version 1.03
References were stored using Reference Manager for Windows version 6
Patient data was stored on a central laboratory database in Microsoft Access v 5
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INTRODUCTION
Relapse in Crohn's disease
♦ Clinical relapse may result from biochemical/irnmunological changes within the
intestinal mucosa
♦ Detection of substances in intestinal secretions may reflect early relapse before
clinical signs
♦ Biochemical predictors of relapse may contribute to our knowledge of the
inflammatory mechanism
♦ High concentrations ofpro-inflammatory cytokines IL-1 and IL-8 define patients at
high risk of relapse
Complement C3 in Crohn's disease
♦ Evidence for complement activation in inflamed intestine
♦ Loss ofC3 to the gut increased in active disease
♦ Macrophages synthesize more C3 in response to EL-1
AIMS
♦ To quantify C3 in intestinal secretions from patients with inactive Crohn's disease
♦ To test whether this is related to disease outcome at 1 yr. follow-up
PATIENTS AND METHODS




Disease duration (months) 95 (1-374)
Resections 1 (0-4)
brackets indicate median (range)
• Disease assessed as inactive byWGLF IgG <10 pg/ml
• In most cases CDAI <150
The whole gut lavage procedure
• Bowel cleansing with PEG provides source of intestinal secretions
• Patients drink PEG at a rate of 250 ml/15 min. until clear effluent is passed per-
rectum
• Previous studies have demonstrated that when clear fluid is passed, a gut perfusion is
established
with steady state loss of substances to the gut
• Clear WGLF is processed with protease inhibitors before storage at -70°C
Analytical methods
• Total IgG in WGLF assayed by in-house sandwich ELISA
WGLF IgG correlates well with CDAI >150
• New competition ELISA to quantify C3(c)
Reference range for WGLF C3 (43 non-inflammatory intestinal disease patients)
0.3-0.8 pg/ml.
Limit of detection 0.3 pg/ml
Clinical outcome
Patients were followed-up for one year after gut lavage
and catagorised as follows:
TABLE 2
Relapse A change in symptoms requiring oral steroid therapy
Remission No change in symptoms
Steroid dependent Requiring oral steroids at follow-up and 9/12 months
Immunosupressive Require Azothioprine or
6-Mercaptopurine
Resection Refractory disease requiring surgery
RESULTS
TABLE 3
Outcome classified byWGLF C3
Relapse Remission Steroids Immunosup Resection
C3 <0.9 pg/ml 2 8 5 1 3
C3 >0.8 pg/ml 8 5 2 2 3
figures denote number ofpatients (excluding 4 lost to follow-up)
Immunosup = taking immunosuppresents
• A greater proportion ofpatients who relapsed had normal levels ofWGLF C3
compared with steroid free remission group (P =0.07 %2 test)
• Patients relapsing at follow-up as opposed to those remaining in steroid free
remission can be analysed on the basis ofWGLF C3 using Kaplan-Meier survival
analysis (one relapse patient with low C3 omitted as time to relapse not known)
• Curves were compared by the log rank test. The result of this: %2 4.2, P= 0.042 is
that for patients with inactive Crohn's disease, normal levels ofWGLF C3 give a
relative risk of relapse of 4.4
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• This finding was the exact opposite to that expected i.e. that as WGLF C3 is raised
in active Crohn's disease, slight increases in WGLF C3 might indicate early stages of
mucosal inflammation.
Possible explanations
1) Those patients who relapse might show increased mucosal C3 but, if this was
consumed (tissue deposition) it may be undetected hi WGLF. Mucosal C3 consumption
may be involved in the inflammatory process.
Previous studies show that complement deposition in the intestine ofpatients with
Crohn's disease is related to the degree of inflammation. Patients with inactive disease
should all show low level complement deposition.
• In my study, detection ofgreaterWGLF C3 in active disease does not indicate a
reduction in mucosal C3 consumption, it may simply reflect increased leakage of
plasma proteins.
• It would be of interest to compare mucosal mRNA for C3 in those patients who
relapsed and those remaining in remission
2) Complement could play a protective role in the regulation ofmucosal immune
responses. This may be especially important in Crohn's disease where there is an
imbalance towards inflammatory responses.
• Studies have shown that complement may facilitate uptake of apoptotic cells by
macrophages. If this occurs in the gut, it may potentially reduce dangerous tissue
deposition of apoptotic immune cells.
The role of complement in removal of apoptotic cells from the intestinal mucosa
presents a new area ofpotential study.
This demonstrates how an unexpected scientific finding can open new avenues of
investigation.
